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1General introduction 
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The liver is the largest internal organ in the human body. In physiological circums-
tances, the liver receives 25-30% of the cardiac output. As a result, normal blood flow 
through the liver is approximately 1,600 ml per minute of which 80% is supplied by the 
portal vein and the remaining part by the hepatic artery. This dual blood supply is uni-
que and enables the liver to play a crucial role in connecting the digestive system with 
the circulation. This is reflected by the fact that one of the main functions of the liver 
is to absorb, process, store and distribute metabolites. In addition, the liver is vital for 
detoxification and elimination of toxic substances. Finally, several proteins, including 
coagulation factors and albumin, are synthesized in the liver. Blood flows from the gas-
trointestinal organs to the liver through the superior mesenteric vein and the splenic 
vein, which unite in the portal vein. Within the liver parenchyma, terminal portal venu-
les drain into sinusoids. Eventually, blood leaves the liver through one of three hepatic 
veins, which on their turn drain into the inferior vena cava (1, 2).
LIVER FIBROSIS
Damage to the liver can result in the development of liver fibrosis, this process is called 
liver fibrogenesis. Liver fibrogenesis is characterized by the deposition of extracellular 
matrix components within the liver parenchyma. It is the result of a complex interplay 
of chronic injury, environmental risk factors and genetic susceptibility. Possible causes 
of chronic liver injury include, but are not limited to, alcohol abuse, viral hepatitis, ge-
netic disorders, immune disorders, toxic-metabolic insults, and obesity or presence of 
the metabolic syndrome. When these damaging factors persist, fibrogenesis proceeds 
and can ultimately result in liver cirrhosis, a condition in which the liver parenchyma is 
severely damaged. Cirrhosis on its turn can result in the development of hepatocellular 
carcinoma and liver failure, both life-threatening conditions (1, 2). 
Advanced liver fibrosis and cirrhosis affects hundreds of millions of people and 
comprises a major cause of morbidity and mortality, with a worldwide annual mortality 
due to liver cirrhosis and primary liver cancer of approximately 1.7 million (3, 4). In the 
United States, chronic liver disease and cirrhosis are the eleventh leading cause of mor-
tality (5).  Nowadays, non-alcoholic fatty liver disease (NAFLD) is the most common cause 
of liver disease worldwide. It is estimated that 30% of the current United States popu-
lation is affected by NAFLD, which corresponds to 75 million to 100 million individuals. 
Nonalcoholic steatohepatitis (NASH), the progressive subtype of NAFLD, is present in 
25-30% of this group (Figure 1.1). Presence of characteristics of the metabolic syndrome, 
i.e. central obesity, dyslipidemia, hypertension, and insulin resistance, is associated with 
an increased risk of NASH and more progressive disease. In patients with NASH, cardio-
vascular disease and malignancy are the most common causes of death (6). During their 
lifetime, 20% of patients with NASH will develop cirrhosis. As a result, NASH will become 
the most common indication for liver transplantation between 2020 and 2030 (7, 8). 
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Figure 1.1 Non-alcoholic fatty liver disease (NAFLD) is present in approximately 30% of the current Western 
population. Non-alcoholic steatohepatitis (NASH), the progressive subtype of NAFLD, is encountered in 25-
30% of these individuals. NASH is characterized by steatosis associated with hepatic injury. Presence of cha-
racteristics of the metabolic syndrome, including insulin resistance, central obesity and dyslipidemia, is as-
sociated with a higher risk of NASH and more progressive disease. Ultimately, 20% of individuals with NASH 
will develop cirrhosis. In addition, approximately 4% of persons with NAFLD will progress towards cirrhosis. 
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Traditionally, liver biopsy is considered the gold standard for the diagnosis 
of liver fibrosis, as it assesses the nature and severity of fibrosis, its distribution within 
the liver and other associated lesions. However, limitations of biopsy include sampling 
error and interobserver variation. In addition, because of its invasive nature, liver bi-
opsy is associated with a risk of complications, including serious bleeding and even 
mortality (9-13). Therefore, performing a liver biopsy in healthy individuals is unethical. 
As a result, studying the prevalence of, and risk factors associated with liver fibrosis in 
the general population using liver biopsy is not feasible. Recently, several non-invasive 
alternatives for assessing presence and amount of liver fibrosis have been evaluated. 
These include serum biomarkers and imaging modalities measuring liver stiffness. 
Nowadays, the most widely used and best-validated method to non-invasively assess 
liver fibrosis is transient elastography (Fibroscan®, EchosensTM, France) (14-16). Transient 
elastography is an effective, fast, easy to learn, reproducible and safe method to assess 
liver fibrosis and cirrhosis (16-19). Studies in patients with chronic liver disease have 
shown that transient elastography can also be used to predict liver decompensation, 
portal-hypertension related complications, and survival (20, 21). 
12      Chapter 1
1
Genetics in liver disease
Liver fibrosis is considered a multifactorial disease, in which the interaction between 
chronic liver injury, genetic susceptibility, and environmental risk factors results in fibro-
genesis. Until 2000, genetic analysis focused on the identification of mutations under-
lying monogenic diseases, such as Wilson disease, in a single patient or small group of 
individuals. In that year, the human genome project was presented, paving the way for 
studies aiming to entangle the association between genetic information and complex 
human traits and diseases, such as liver fibrosis (22). The International HapMap project 
and 1000 genomes project have provided an additional important contribution to under-
standing the role of genetics in many diseases and traits by characterizing the human 
genome (23, 24). These, and technical advancements have enabled studying common 
variants in the human genome. These common variants, also known as single nucleotide 
polymorphisms (SNPs), account for most of the genetic variability between individuals, 
together with microsatellites. SNPs can affect the development of disease by influencing 
the function, availability, or transcription of a protein (25). Genome-wide association stu-
dies (GWAS) aim at hypothesis-free testing of hundreds of thousands of SNPs throughout 
the genome to assess their role in complex disorders. This technique has been applied to 
various complex liver diseases, including viral hepatitis, gall stones, cholestatic liver disea-
ses, alcoholic liver disease, and NAFLD (26-36). In addition, several SNPs have been identi-
fied that predispose to liver fibrosis in at-risk populations (27, 30, 31, 34, 37-39). However, 
the role of these SNPs in the general population remains to be elucidated. As a result, it is 
not known whether these genetic variants alter the effect of chronic liver injuries on liver 
fibrogenesis or whether they affect fibrosis development independently of other factors.
THROMBOPHILIA IN LIVER FIBROGENESIS
Increasing evidence suggests a role for hypercoagulability in the development and pro-
gression of liver fibrosis. Presence of prothrombotic risk factors, including the factor V 
Leiden mutation and prothrombin G2021A variant, has been shown to be associated 
with occurrence of more advanced fibrosis and/or cirrhosis in patients with chronic li-
ver injury, while comparable liver injury in patients with haemophilia resulted in a lower 
rate of fibrogenesis (40-48). Until now, no studies have been performed assessing the 
role of prothrombotic risk factors in liver fibrogenesis in the general population.
The exact mechanism by which hypercoagulability influences liver fibrogene-
sis has not yet been fully elucidated. Two alternative hypotheses have been postulated, 
in which thrombin seems to be the key driver of fibrogenesis. The first theory compris-
es the formation of small occlusive thrombi following inflammation-induced throm-
bin production. The development of these thrombi will result in consequently tissue 
ischemia, parenchymal extinction and development of fibrosis and cirrhosis (49, 50). 
The second hypothesis states that thrombin causes direct activation of hepatic stellate 
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cells by binding the protease-activated receptor 1. As stellate cells are responsible for 
the production of extracellular matrix components, activation of these cells will cause 
fibrogenesis (2, 51-54).
In several animal and laboratory studies, administration of low molecular 
weight heparin or vitamin K antagonists had an antifibrotic effect (55-59). This benefi-
cial effect of anticoagulant medication has also been demonstrated in humans. Admin-
istration of unfractionated or low molecular weight heparin in addition to regular treat-
ment resulted in decreased collagen levels and proliferation in patients with chronic 
hepatitis B (60). Administration of low molecular weight heparin was also beneficial in 
a randomized controlled trial in patients with advanced cirrhosis. Enoxaparin adminis-
tration for 48 weeks in a high prophylactic dose (4,000 IU/day) resulted in a significantly 
lower incidence of portal vein thrombosis (PVT) during treatment and during 2 years 
of follow-up. Even more notable was the observation that treatment with enoxaparin 
reduced the incidence of liver decompensation and improved survival without increas-
ing the number and severity of bleeding complications (61). 
VASCULAR LIVER DISEASES
Venous thrombosis is defined as venous occlusion caused by a blood clot. The inci-
dence of venous thrombosis is age-dependent and ranges from 1 per 10,000 cases per 
year in young adults to 1 in 100 cases per year in the very old. In most cases, venous 
thrombosis develops in the deep veins of the lower extremities. However, in rare cases, 
thrombosis occurs in other veins, including the splanchnic veins (62). Splanchnic vein 
thrombosis (SVT) encompasses PVT, mesenteric vein thrombosis, as well as hepatic 
vein thrombosis, which is responsible for the vast majority of cases with Budd-Chiari 
syndrome (BCS). 
Budd-Chiari syndrome
BCS is a rare variant of venous thrombosis, which is defined as occlusion of the hepatic 
venous outflow tract. This occlusion can occur in the outflow tract from the level of the 
small hepatic veins until the right atrium. Outflow obstruction caused by heart failure 
or sinusoidal obstruction syndrome is considered a different entity. Most often, BCS is 
caused by thrombosis of the hepatic veins, but other causes, including extravenous 
compression or invasion by a tumor or abscess are also described. Obstruction of the 
hepatic venous outflow tract can result in portal hypertension and ischemia of hepa-
tocytes due to venous congestion. Clinical presentation of BCS is highly variable. Pa-
tients with BCS can be asymptomatic, have symptoms as abdominal pain, fever, ascites, 
hepatomegaly and jaundice, or can even present with fulminant liver failure (63, 64). 
With the current treatment algorithm, including a step up approach of anticoagulation, 
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recanalization, transjugular intrahepatic portosystemic shunt (TIPS) insertion and liver 
transplantation, survival in patients with BCS is 88% after 1 year and 72% after 5 years 
(65).
Portal vein thrombosis
PVT is characterized by obstruction of the portal vein or its branches. Although the 
prevalence of PVT was reported to be 1% in a large autopsy study, PVT is considered 
a rare subtype of venous thrombosis, like BCS (66). In clinical practice, PVT is classified 
as either acute or chronic depending on the amount of time between origin and diag-
nosis. In acute PVT, patients can be asymptomatic or present with various symptoms, 
including abdominal pain, nausea, fever and ileus. If acute PVT is not recognized and 
the thrombus persists, collaterals will form to restore blood flow from upstream of the 
thrombus to downstream of the thrombus. This network of collaterals is called portal 
cavernoma, which is a hallmark of chronic PVT.  In addition to cavernoma development, 
compensatory dilation of other veins and the hepatic artery will occur. Despite these 
changes, portal hypertension is inevitable. Therefore, complications of portal hyper-
tension, including gastrointestinal bleeding and splenomegaly, are the most important 
clinical features of chronic PVT (64, 67). In addition, gastrointestinal ischemia is consi-
dered a concerning complication of PVT. Ischemia can result in intestinal infarction, a 
condition that requires immediate surgical treatment. However, data on gastrointesti-
nal ischemia in PVT is scarce. It has been suggested that extension of thrombus from 
the portal vein into the superior mesenteric vein and/or splenic vein is associated with 
an increased risk of ischemia and infarction (68). Available studies report a prevalence 
ranging between 2% and 32% in patients with acute PVT. In chronic PVT, little is known 
about the occurrence and impact of gastrointestinal ischemia (69-74). 
Etiology of splanchnic vein thrombosis
Local risk factors are important in the etiology of PVT. This is reflected by the fact that 
PVT is most often seen in patients with liver cirrhosis or hepatobiliairy malignancies. 
In BCS, local risk factors are of far less importance in the Western world. Nonetheless, 
there is considerable overlap in the etiology of BCS and non-cirrhotic, non-malignant 
PVT. Systemic, prothrombotic risk factors are pivotal in the etiology of both disorders, 
as they account for approximately 75-85% of the etiology of SVT (74, 75). These pro-
thrombotic risk factors can be divided into genetic and acquired risk factors. As a mul-
tifactorial etiology is present in 46% of patients with BCS and 48% of those with PVT, 
a complete hematological work-up, assessing both genetic and acquired risk factors, 
should be performed in all patients with SVT (74-76).  Genetic risk factors of SVT include 
the factor V Leiden mutation, prothrombin G20210A gene variant, protein C, protein S 
and antithrombin deficiency, all known risk factors of common venous thrombosis. Re-
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cently, several genetic risk factors of common venous thrombosis were identified that 
have not yet been tested in the etiology of SVT (77-80). Myeloproliferative neoplasms 
(MPNs) – i.e. polycythemia vera, essential thrombocytosis and primary myelofibrosis – 
are the most important acquired risk factor for SVT with a prevalence of 20-50% (74, 75, 
81). Diagnosing MPN in patients with SVT is often challenging as portal hypertension, 
resulting from obstruction of the portal or hepatic vein, can mask the blood cell chan-
ges associated with MPN due to splenomegaly and hemodilution (82).  The JAK2V617F 
mutation is an easily detectable and highly specific marker for presence of (occult) 
MPN, testing for this mutation is therefore recommended in all patients with SVT (64, 
67, 83). However, the JAK2V617F mutation is not present in all patients with MPN. In 
some patients, an additional MPL mutation is identified (84, 85). Recently, new somatic 
mutations in CALR were detected in patients with MPN lacking JAK2V617F and MPL mu-
tations (86, 87). The prevalence and role of these CALR mutations in patients with SVT 
remains to be elucidated.
 
AIMS AND OUTLINE OF THE THESIS 
The aims of this thesis were:
1. to determine the prevalence of and risk factors associated with liver fibrosis in the 
general population
2. to explore the association between thrombophilia and liver fibrosis in the general 
population
3. to assess the role of new genetic risk factors in SVT and to study the occurrence and 
characteristics of gastrointestinal ischemia in portal vein thrombosis 
To address these aims, the current thesis is divided in three parts. As previously descri-
bed, relatively little is known about the occurrence of and factors associated with liver 
fibrosis in the general population, as previous studies focused mainly on fibrosis in risk 
groups, such as patients with alcohol abuse and/or chronic viral hepatitis. Therefore, 
the first part of this thesis addresses the prevalence of and risk factors associated with 
liver fibrosis in the general population. The studies described in this part are conduc-
ted within the Rotterdam Study, a large, ongoing, prospective population-based cohort 
study among subjects aged 45 years and over. Chapter 2 describes the prevalence of li-
ver fibrosis, assessed non-invasively using transient elastography, in participants of the 
Rotterdam Study. In addition, this chapter focuses on the risk factors associated with 
liver fibrosis in this population-based cohort. In chapter 3, we assess the association 
between common genetic variants associated with liver fibrosis in at-risk populations 
and liver fibrogenesis in the general population. The association between interferon 
gamma receptor 2 gene variants and liver fibrosis is discussed into more detail in this 
chapter. 
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Part II of this thesis focuses on the role of thrombophilia in liver fibrogene-
sis.  In chapter 4, we aim to describe the role of anticoagulation in liver disease. In the 
first part of this chapter, the use of anticoagulation in the treatment of vascular liver 
diseases is addressed. The second part evaluates the potential role of anticoagulation 
in the prevention of liver fibrogenesis. In the next two chapters of this thesis, the role 
of thrombophilia in liver fibrogenesis in the general population is further explored. In 
chapter 5, we assess the role of the factor V Leiden mutation, prothrombin G20210A 
gene variant and blood group type non-O – well-known genetic prothrombotic risk 
factors – in liver fibrogenesis in participants of the Rotterdam Study. As von Willebrand 
factor (VWF) is a key player in hemostasis and VWF levels are known to be elevated and 
associated with long-term outcome in patients with cirrhosis, we assess the association 
between VWF levels and liver fibrosis in the general population in chapter 6. 
The third part of this thesis aims to provide more insight in the etiology and 
ischemic complications of vascular liver diseases. Diagnosing MPNs, the most import-
ant acquired risk factor for SVT, in clinical practice is often challenging, especially in 
patients without the JAK2V617F mutation, as mentioned before. Therefore, we describe 
in chapter 7 the role of somatic Calreticulin mutations, recently identified mutations 
found in patients with MPN lacking JAK2V617F and MPL, in patients with SVT. In chapter 
8, we describe the role of genetic variations associated with common venous thrombo-
sis in the etiology of SVT. Gastrointestinal ischemia is one of the most feared complica-
tions of PVT, but data on its prevalence and clinical presentation are scarce. Therefore, 
we explore the occurrence and characteristics of    gastrointestinal ischemia in patients 
with PVT in chapter 9. Finally, in chapter 10, the main findings and conclusions of our 
studies will be summarized and discussed.
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2ABSTRACT
Background and aims
Since little is known about the prevalence of and factors associated with liver fibrosis 
in the general population, we aimed to investigate this in a large, well-characterized 
cohort, by means of transient elastography (TE). 
Methods
This study was part of the Rotterdam Study, a population-based study among individ-
uals ≥45 years. All participants underwent abdominal ultrasound and TE. Liver stiffness 
measurement (LSM) ≥8.0 kPa was used as cut-off suggesting clinically relevant fibrosis. 
Results
Of 3041 participants (age 66.0±7.6 years) with reliable LSM, 169 (5.6%) participants 
had LSM ≥8.0 kPa. Age (OR 2.40, 95%CI 1.72-3.36,p<0.001), ALT (OR 1.24, 95%CI 1.12-
1.38,p<0.001), smoking (OR 1.77, 95%CI 1.16-2.70, p=0.008), spleen size (OR 1.23, 95%CI 
1.09-1.40,p=0.001), HBsAg or anti-HCV positivity (OR 5.38, 95%CI 1.60-18.0,p=0.006), 
and combined presence of diabetes mellitus (DM) and steatosis (OR 5.20, 95%CI 3.01-
8.98, p<0.001 for combined presence) were associated with LSM ≥ 8.0 kPa in multivari-
able analyses. The adjusted predicted probability of LSM ≥8.0 kPa increased per age 
decade, with probabilities ranging from 1.4% (0.9-3.6) in participants aged 50-60 years 
to 9.9% (6.8-14.5) in participants >80 years. Participants with both DM and steatosis 
had the highest probabilities of LSM ≥8.0 kPa (overall probability 17.2% (12.5-23.4), this 
probability did not increase with age (p=0.8). 
Conclusions
In this large population-based study of older adults, LSM ≥8.0 kPa, suggestive of clin-
ically relevant fibrosis, was present in 5.6% and was strongly associated with steatosis 
and DM. In the context of an aging population and an increased prevalence of diabetes 
mellitus and obesity, this study illustrates that liver fibrosis may become a more promi-
nent public health issue in the nearby future.
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Advanced liver fibrosis and cirrhosis affects hundreds of millions of people and compri-
ses a major cause of morbidity and mortality, with a worldwide mortality rate due to 
liver cirrhosis and primary liver cancer of over 1.5 million per year (1, 2). In the United 
States, chronic liver disease and cirrhosis are the eleventh leading cause of mortality 
(3). In the past few decades, non-alcoholic fatty liver disease (NAFLD) has become one 
of the major causes of liver disease (4). In previous European population-based cohort 
studies, the reported prevalence of steatosis, assessed by abdominal ultrasound, ran-
ged from 25-35% (5-8). In patients with diabetes mellitus (DM) the prevalence of NAFLD 
was shown to be as high as 40-70% (9, 10). Considering population ageing and the 
current epidemic in obesity and type II DM in developed countries, the burden of chro-
nic liver diseases – in particular non-alcoholic steatohepatitis (NASH) – is projected to 
increase substantially in the next decades (11-13). 
To date, limited studies have been performed focusing on the prevalence of, 
and risk factors for liver fibrosis in the general population, as data are mainly derived 
from autopsy studies or biopsy studies in selected populations. In theory, one way to 
investigate the prevalence of liver fibrosis and cirrhosis in the general population would 
be to perform a liver biopsy in a large population of healthy volunteers. However, an 
important disadvantage of liver biopsies is the invasive nature of the procedure, and 
healthy volunteers are rarely representative of the general population at risk. In recent 
years, non-invasive techniques have been developed to circumvent the need for liver bi-
opsy. One of these techniques is transient elastography (TE), which is strongly associated 
with histological stages of liver fibrosis (14-19). Previous studies examining factors asso-
ciated with elevated liver stiffness measurements (LSM) in community-based popula-
tions were performed in volunteers attending a free medical check-up and in a Chinese 
population-based cohort study (20, 21). Until now, these factors have not been studied 
in a large random sample of a general Caucasian population. Therefore, the aim of our 
study was to investigate the distribution of and factors associated with clinically relevant 
liver fibrosis, as measured by TE, in a large population-based cohort of Caucasians. 
SUBJECTS AND METHODS
Study population
The Rotterdam Study is a large prospective population-based cohort study conducted 
among adults aged 45 years and above living in Ommoord, a district of Rotterdam, The 
Netherlands. The rationale and study design have been described previously (22). The 
medical ethics committee at the Erasmus University of Rotterdam approved the study, 
and written informed consent was obtained from all participants.
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center between January 2011 and September 2013 were included in the current study. 
Each participant completed an extensive interview and clinical examination that in-
cluded abdominal ultrasonography, TE, a fasting blood collection, and an anthropo-
metric assessment. 
Interview 
The interview preceded the clinical examination and was designed to obtain data con-
cerning demographics, medical history, comorbid conditions, current and past smo-
king behaviour, current alcohol consumption (drinks/week), and drug use. Detailed in-
formation on dispensed drug prescriptions was obtained from automated pharmacies, 
where nearly all participants are registered. 
Biochemistry
Fasting blood samples were collected on the morning of ultrasound examination and 
LSM. Blood lipids, platelet count, glucose and alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), gamma-glutamyltransferase (GGT), alkaline phosphatase 
(ALP), and total bilirubin were measured using automatic enzymatic procedures (Roche 
Diagnostics GmbH, Mannheim, DE). Insulin, hepatitis B surface antigen (HBsAg) and 
anti-hepatitis C virus (anti-HCV) were measured by an automatic immunoassay (Roche 
Diagnostics GmbH, Mannheim, DE). According to local cut-off criteria, the upper limit of 
normal (ULN) of ALT was defined as 40 U/L for men and 30 U/L for women.
Abdominal ultrasonography 
Abdominal ultrasonography was performed by a certified and experienced technician 
on Hitachi HI VISION 900. Images were stored digitally and re-evaluated by a single 
hepatologist with more than ten years of experience in ultrasonography (JS). The diag-
nosis of steatosis was determined by the ultrasound technician according to the proto-
col by Hamaguchi et al (23). Severity of fatty liver was classified as ‘no fatty liver’ (score 
0-1), ‘mild fatty liver’ (score 2-3), or ‘moderate to severe fatty liver’ (score 4-6). NAFLD 
was defined as steatosis in absence of any of the following possible secondary causes 
of steatosis: 1) excessive alcohol consumption (>14 drinks/week), 2) positive HBsAg or 
anti-HCV tests, and 3) use of pharmacological agents associated with steatosis (i.e. ami-
odarone, corticosteroids, methotrexate, and tamoxifen). In addition, spleen size, pres-
ence of collaterals, and Doppler examination of the hepatic veins, hepatic artery and 
portal vein were evaluated during ultrasound examination. Splenomegaly was defined 
as a spleen size >12.0 cm. 
30      Chapter 2
2Transient elastography 
LSM (Fibroscan®, EchoSens™, Paris, France) was performed by a single operator, who 
carried out more than 1000 examinations before start of the study. LSM was performed 
on the right lobe of the liver, through the intercostal spaces, with the participant lying 
flat on his/her back with the right arm laying in maximal abduction. Either M- or XL-
probe was applied, according to instructions by the manufacturer. Participants with 
intracardiac devices and participants with physical disabilities, making TE impossible, 
were excluded from the study. Because of necessary maintenance of probes (for cal-
ibration), TE was not performed on four days during the study period. Failure was re-
corded when no LSM was obtained after at least 10 shots. Reliability of LSM was catego-
rized according to the criteria by Boursier et al (24). LSM was considered ‘poorly reliable’ 
if interquartile range (IQR)/median LSM >0.30 with median LSM ≥7.1 kPa. These ‘poorly 
reliable’ LSM were excluded from our analyses. LSM ≥8.0 kPa and >13.0 kPa were taken 
as cut-offs suggesting clinically relevant liver fibrosis and cirrhosis, respectively. These 
cut-off levels were deliberately chosen, for they are known to yield high positive pre-
dictive values for presence of clinically relevant fibrosis and cirrhosis in previous studies 
(16, 21, 25).  
Covariables
Anthropometric measurements were performed by well-trained research assistants. 
Body Mass Index (BMI) was calculated as weight (kg)/height (m2). Waist circumference 
was measured in centimetres. The average of two blood pressure measurements, ob-
tained at a single visit in upright position after a minimum of 5 minutes rest, was used 
for analysis. Metabolic syndrome was defined, according to Adult Treatment Panel III 
criteria (26), as the presence of at least 3 of the following 5 traits: 1) abdominal obesity, 
defined as a waist circumference in men >102 cm (40 inch) and in women >88 cm (35 
inch), 2) serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated 
triglycerides, 3) serum HDL cholesterol (HDL-C) <40 mg/dL (1.0 mmol/L) in men and 
<50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C, 4) blood pres-
sure ≥130/85 mmHg or drug treatment for elevated blood pressure, 5) fasting plasma 
glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose. 
Hypertension was defined as blood pressure ≥140/90 mmHg or drug treatment for 
elevated blood pressure. DM was defined as FPG ≥126 mg/dL (7.0 mmol/L) or drug 
treatment for elevated blood glucose. The insulin resistance index was calculated using 
the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR): fasting glucose 
(mmol/L) x fasting insulin (mU/L) / 22.5 (27).  
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Baseline data were done using descriptive statistics. Chi-square tests and Student’s t-
tests (means) or Wilcoxon rank sum tests (medians) were used to assess the significance 
of differences in distributions of categorical data and continuous data respectively. 
To examine associations between traits and LSM as continuous (log-transformed) de-
pendent variable or LSM ≥8.0 kPa, we performed linear or logistic regression analyses, 
respectively. Since there is some discordancy regarding the cut-off level of LSM for pre-
sence of advanced liver fibrosis using XL-probe, we performed additional sensitivity 
analyses and we tested our model applying a one point lower cut-off for XL probe (15). 
In addition we tested our model applying a cut-off of 9.5kPa for advanced fibrosis, a 
cut-off that has been proposed in studies including subjects with viral hepatitis (25). 
Interaction terms between age, sex and other covariables were tested in linear and lo-
gistic multivariable regression models. A combined interaction term of DM and steato-
sis with age was constructed by dividing the total cohort into 4 groups: 1) participants 
without DM and steatosis, 2) participants with DM and without steatosis 3) participants 
with steatosis and without DM and 4) those with both DM and steatosis. We calculated 
predicted probabilities of having LSM ≥8.0 kPa by using all covariables of our multivari-
able logistic regression model, i.e. age, sex, spleen size, ALT, BMI, alcohol consumption/
week, smoking behaviour, presence of HBsAg and/or anti-HCV, the presence of DM 
and/or steatosis, and the combined interaction term. Probabilities were expressed as 
median (IQR) percentage. Linear regression analyses was used to assess the significance 
of differences in predicted probabilities between subgroups of our cohort. A p-value of 
<0.05 was considered statistically significant. Statistical analyses were performed using 
SPSS 21.0 (SPSS Inc., Chicago, IL, USA).
RESULTS 
Study population 
Of 3439 participants aged 51 or above who visited the research center between Janu-
ary 2011 and September 2013, a total of 3342 participants underwent TE (Figure 2.1). 
Due to LSM failure, an additional 162 participants (4.8%) were excluded. LSM was reli-
able in 3041 participants. Baseline characteristics of the study population are shown 
in Table 2.1. Fifty-five percent of 3041 participants were women, mean age of the par-
ticipants was 66.0 ± 7.6 years and mean BMI was 27.3 ± 4.0 kg/m2. Participants were 
predominantly of Caucasian ethnicity (95.1%). Median LSM was 4.7 kPa (3.8-5.8) and 
1080 participants (35.5%) had presence of steatosis on abdominal ultrasound. LSM ≥8.0 
kPa, suggesting presence of clinically relevant fibrosis, was detected in 169 participants 
(5.6%). Twenty-two participants had positive viral serology (7 were HBsAg positive and 
16 were anti-HCV positive; one participant was both HBsAg and anti-HCV positive); only 
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Normal liver enzymes were present in 2216 (76.0%) of all participants. Of these 2216 
participants, 81 (3.7%) had LSM ≥8.0 kPa. 
RS Participants
n=3439
Intracardiac device n=27
Physical disability n=3
Maintenance of fibroscan n=67
LSM failure
n=162; 4.8%
Unreliable LSM
n=139; 4.4%
TE performed
n=3342
LSM
n=3180
Reliable LSM
n=3041
Figure 1. 
Figure 2.1 Flow chart of the study. In total, 3041 participants had a reliable liver stiffness measurement.
Factors associated with liver stiffness
The distribution of LSM values in our cohort of 3041 participants is illustrated in Figure 
2.2. Results of linear univariable analyses are illustrated in Supplementary Table 2.1. In 
linear multivariable regression analysis, log-transformed LSM was associated with hi-
gher age, male sex, presence of diabetes mellitus, larger spleen size, higher ALT, presen-
ce of positive viral serology for hepatitis B and/or C and presence of steatosis (Table 2.2). 
Greater HOMA-IR, indicative of more insulin resistance, was associated with higher LSM 
when we replaced presence of diabetes mellitus with HOMA-IR in the model (β=0.003, 
95%CI 0.001-0.004, p<0.001). Replacing BMI with waist circumference in the model did 
not alter the association with LSM (β-0.001, 95%CI -0.001-<0.001, p=0.08). No interac-
tion between age, sex and other covariables was observed for the association with LSM.
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Characteristic Total <8.0 kPa ≥8.0 kPa p-value*
n=3041 n=2872 n=169 (5.6%)
Age (years) 66.0 ± 7.6 65.8 ± 7.5 68.7 ± 8.9 <0.001
Female 55.0 56.1 37.9 <0.001
Caucasian 95.1 95.0 96.9 0.3
BMI (kg/m2) 27.3 ± 4.0 27.2 ± 3.9 28.9 ± 5.2 <0.001
Normal; BMI < 25 28.5 28.9 22.2
Overweight; 25 ≤ BMI < 30 49.2 49.7 40.1
Obese; BMI ≥ 30 22.3 21.4 37.7
Waist circumference (cm) 93.7 ± 12.2 93.3 ± 12.0 99.7 ± 14.2 <0.001
Alcohol consumption (drinks/week) 3.8 (0.4-8.3) 3.8 (0.4-8.3) 3.8 (0.4-8.8) 0.4
Presence of HBsAg and/or anti-HCV 0.8 0.7 2.5 0.03
Smoking 0.002
Never 35.1 35.9 22.2
Former 51.8 51.2 61.1
Current 13.1 12.9 16.7
Hypertension¥ 62.4 61.5 76.7 <0.001
Diabetes Mellitus† 11.1 9.8 33.7 <0.001
Metabolic syndrome 44.0 42.9 61.9 <0.001
Waist circumference >88cm (♀) or >102 
cm (♂)
44.6 43.9 56.9 0.001
Triglycerides >150 mg/dL or drug treat-
ment for elevated triglycerides 
37.2 36.8 44.3 0.05
HDL-C <40 mg/dL(♂) or <50 mg/dL(♀) 
or drug treatment for low HDL-C 
33.5 33.0 42.5 0.01
BP ≥130/85 mmHg or drug treatment 
for elevated BP¥  
77.7 77.2 86.0 0.01
FPG >100 mg/dL or drug treatment for 
elevated blood glucose 
44.7 43.2 69.9 <0.001
Ultrasound characteristics
Steatosis 35.5 34.1 59.2 <0.001
Spleen size (cm)‡ 9.8 ± 1.3 9.8 ± 1.3 10.4 ± 1.5 <0.001
Portal vein flow velocity (cm/s)§ 22.0 ± 4.7 22.0 ± 4.7 22.2 ± 5.4 0.6
Laboratory data
ALT (U/L) 18 (14-24) 18 (14-24) 22 (16-30) <0.001
AST (U/L) 24 (21-28) 24 (21-28) 27 (23-36) <0.001
Bilirubin (umol/L) 8 (6-11) 8 (6-11) 9 (6-12) 0.07
ALP (U/L) 67 (56-78) 67 (56-78) 70 (56-87) 0.08
GGT (U/L) 24 (17-35) 24 (17-34) 38 (25-67) <0.001
HOMA-IR 2.6 (1.7-3.9) 2.5 (1.7-3.8) 3.9 (2.5-6.3) <0.001
Platelets (*109/L) 263 (224-306) 263 (226-307) 242 (205-288) <0.001
Transient elastography
LSM (kPa) 4.7 (3.8-5.8) 4.6 (3.8-5.6) 9.1 (8.6-10.4) <0.001
IQR/M 0.19 (0.12-0.27) 0.19 (0.12-0.27) 0.17 (0.12-0.24) 0.02
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Figure 2.2 Distribution of reliable liver stiffness measurements in 3041 participants.
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Table 2.1 Continued
Data are represented as mean ± standard deviation, median (25th-75th percentile) or percentage.
*  Based on T-test, Wilcoxon rank sum test,  Chi-square test or Fisher’s exact test. 
¥  BP measurement and data on drug treatment for elevated BP was available for 2611participants.
†  Data on presence of diabetes mellitus was obtained in 3001 participants
‡  Spleen size measurement was available for 2587 participants
§  Portal blood flow velocity was available for 2887 participants. 
Abbreviations: kPa, kilopascal; BMI, Body Mass Index; FPG, fasting plasma glucose; HDL-C, high-density li-
poprotein cholesterol; BP, blood pressure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
ALP, alkaline phosphatise; GGT, gamma glutamyl transferase; HOMA-IR, Homeostasis Model Assessment of 
Insulin Resistance; LSM, liver stiffness measurement; IQR/M, interquartile range/ median LSM. 
Using linear regression analysis in 1565 participants without apparent liver dis-
ease, excluding participants with positive HBsAg, anti-HCV, steatosis, excessive alcohol 
intake, and ALT above the upper limit of normal, only higher age (β=0.029 per 10 years, 
95%CI 0.020-0.037, p<0.001) and male sex (β=0.066, 95%CI 0.049-0.082, p<0.001) re-
mained associated with log LSM. In these participants, the 5th and 95th percentile values 
of LSM were 2.8 kPa and 7.3 kPa respectively. Age (β=0.021 per 10 years, 95%CI 0.013-
0.030, p<0.001) and male sex (β=0.067, 95%CI 0.051-0.082, p<0.001) remained associat-
ed with higher log LSM after excluding an additional 51 cases with LSM ≥8.0 kPa. 
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2Factors associated with and predicted probability of clinically relevant fibrosis
Of 3041 participants, 169 (5.6%) had LSM ≥8.0 kPa, suggesting clinically relevant fibro-
sis, and 19 (0.6%) had LSM >13.0 kPa, suggesting presence of advanced fibrosis or cir-
rhosis. General characteristics of participants according to a LSM cut-off of 8.0 kPa are 
shown in Table 2.1. One participant with LSM ≥8.0 kPa had positive serum anti-HCV 
and 3 participants had positive serum HBsAg. Results of logistic univariable analyses 
are illustrated in Supplementary Table 2.2. Factors associated with LSM ≥8.0 kPa in mul-
tivariable logistic regression analysis are shown in Table 2.3. Severity of steatosis was 
not associated with elevated LSM, applying different cut-offs (p=0.31 for ≥ 8.0 kPa, and 
p=0.79 for ≥ 9.5 kPa). Thirteen of 19 (68%) participants with LSM >13.0 kPa were female, 
mean age of this group was 70.0 ± 11.8 years and mean BMI 28.7 ± 6.4 kg/m2. Two of 
these participants drank more than 14 alcoholic beverages per week, 11 (57.9%) parti-
cipants had steatosis on ultrasonography, and 7 (38.9%) had diabetes mellitus. Spleno-
megaly was present in 5 of 19 participants with LSM >13.0 kPa. None of the participants 
with LSM >13.0 kPa had positive viral serology for hepatitis B or C.  
We performed several sensitivity analyses to determine the robustness of our 
findings. Consistency was shown, when a one point lower cut-off for elevated LSM was 
applied for use of the XL probe or when 9.5kPa was used as a cut-off for clinically rel-
evant liver fibrosis. When participants with ALT >2x the ULN were excluded from the 
analyses, as severe inflammation of the liver may have influenced the positive predic-
tive value of presence of liver fibrosis, the prevalence of LSM ≥8.0 kPa was 5.2% and 
the same factors, with sex instead of spleen size, remained associated with elevated 
log-transformed LSM. 
Table 2.2 Factors associated with (log-transformed) LSM in linear multivariable regression analysis 
(n=3041)
Variable β (95%CI) p-value
Age, per 10 years 0.029 (0.022-0.036) <0.001
Sex, male 0.055 (0.042-0.067) <0.001
Diabetes Mellitus 0.041 (0.023-0.059) <0.001
Spleen size, cm 0.012 (0.007-0.016) <0.001
ALT, per 10 U/L 0.014 (0.009-0.018) <0.001
BMI, kg/m2 -0.001 (-0.002-0.001) 0.28
Steatosis 0.024 (0.012-0.037) <0.001
Alcohol consumption, drinks/week <0.001 (-0.001-0.001) 0.50
Current or former smoking 0.002 (-0.009-0.013) 0.74
HBsAg or anti-HCV positive 0.090 (0.025-0.156) 0.007
Abbreviations: LSM, liver stiffness measurement; ALT, alanine aminotransferase; BMI, Body Mass Index; HB-
sAg, hepatitis B surface antigen; HCV, hepatitis C virus
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2We calculated predicted probabilities of having LSM ≥8.0 kPa, taken into ac-
count all factors associated with LSM ≥8.0 kPa in our multivariable model. These pre-
dicted probabilities increased incrementally with age (Figure 2.3). The adjusted prob-
ability of having LSM ≥8.0 kPa was 1.4% (0.9-3.6) for participants of 50-60 years of age, 
3.4% (2.1-6.0) for those aged 60-70 years, 5.5% (3.6-8.5) for participants aged 70-80 
years, and 9.9% (6.8-14.5) for participants aged >80 years. 
Since the association between age and LSM ≥8.0 kPa was significantly influ-
enced by the presence of DM and/or steatosis (p for combined interaction term=0.04), 
we also calculated predicted probabilities of having LSM ≥8.0 kPa per age decade for 
participants with and without DM and/or steatosis (Figure 2.4). These probabilities in-
creased per age decade for participants without DM or steatosis (n=1814) (1.1% (0.8-
1.6) in participants aged 50-60 years versus 10.5% (6.6-14.6) in participants >80 years, 
p=4.0*10-162). Probabilities also increased with increasing age for participants with ste-
atosis, but without DM (n=853) (5.1% (3.6-7.0) versus 8.8 (5.0-11.0), p=0.001). For partic-
ipants with only DM (n=118), probabilities did not increase with age (p=0.76). Partici-
pants with both DM and steatosis had the highest probabilities of having LSM ≥8.0 kPa 
for all age decades. For these 216 participants the overall probability of LSM ≥8.0 kPa 
was 17.2% (12.5-23.4). These probabilities did not increase with age (14.3 (12.1-18.4) 
versus 17.0 (12.3-24.1) versus 20.1 (13.5-23.9) versus 16.3 (12.5-23.8) respectively per 
increasing age decade, overall p=0.76).  
Table 2.3 Factors associated with LSM ≥8.0 kPa (n=169) in logistic multivariable regression analysis
Variable OR (95%CI) p-value
Age for no DM, no steatosis, per 10 years 2.40 (1.72-3.36) <0.001
Sex, male 1.35 (0.91-2.02) 0.14
Spleen size, cm 1.23 (1.09-1.40) 0.001
ALT, per 10 U/L 1.24 (1.12-1.38) <0.001
BMI, kg/m2 1.00 (0.95-1.06) 0.97
Alcohol consumption, drinks/week 1.00 (0.98-1.03) 0.76
Current or former smoking 1.77 (1.16-2.70) 0.008
HBsAg or anti-HCV positive 5.38 (1.60-18.0) 0.006
Interaction 
For age 66.0 years*
No DM, no steatosis 1 (ref ) ref
Steatosis, no DM 1.99 (1.28-3.10) 0.002
DM, no steatosis 3.22 (1.39-7.42) 0.006
DM and steatosis 5.20 (3.01-8.98) <0.001
*  66.0 years was the mean age in the total population
Abbreviations: LSM, liver stiffness measurement; kPa, kilopascal; DM, diabetes mellitus; ALT, alanine amino-
transferase; BMI, Body Mass Index; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; ref, reference 
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Figure 2.3 Predicted probabilities (%) of having LSM ≥ 8.0 kPa increase with age. Probabilities are adjusted 
for age, sex, BMI, current or former smoking, presence of diabetes mellitus and/or steatosis, ALT, presence 
of HBsAg and/or anti-HCV, weekly alcohol consumption, spleen size, and the interaction between age and 
presence of DM and/or steatosis.
2
We also observed a second interaction in our analyses: the association be-
tween current or former smoking and LSM ≥8.0 kPa was significantly influenced by sex 
(p for interaction term=0.024). Of 1902 previously or currently smoking participants, 
males had a median predicted probability of having LSM ≥8.0 kPa of 6.2% (3.6-10.2) 
compared to a probability of 3.7% (2.1-6.8) in female smokers (p<0.001). These prob-
abilities were 2.8% (1.6-5.0) and 2.4% (1.3-3.8) respectively for males and females who 
had never smoked (p<0.001).
Liver stiffness in participants with NAFLD
A sub analysis was performed to investigate factors associated with LSM in participants 
with NAFLD. Of 3041 participants, 532 participants were excluded due to presence of 
secondary causes associated with steatosis (excessive alcohol consumption (n=449), 
positive anti-HCV (n=16), positive HBsAg (n=7), pharmacological agents associated with 
steatosis (n=69)). Eight hundred twenty-two (32.8%) participants had NAFLD. Mean age 
of participants with NAFLD was 66.0 ± 7.2 years, mean BMI was 29.8 ± 4.0 kg/m2, and me-
dian LSM was 4.9 kPa (4.0-6.1). Sixty-nine (8.4%) participants of this subgroup had LSM 
≥8.0 kPa. In multivariable linear regression analysis, higher age (β=0.027 per 10 years, 
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Figure 2.4 Predicted probabilities (%) of having LSM ≥ 8.0 kPa per age decade for participants with and wit-
hout diabetes mellitus and/or steatosis. Probabilities are adjusted for age, sex, BMI, current or former smo-
king, presence of diabetes mellitus and/or steatosis, ALT, presence of HBsAg and/or anti-HCV, weekly alcohol 
consumption, spleen size, and the interaction between age and presence of DM and/or steatosis.
2
95%CI 0.012-0.042, p<0.001), presence of diabetes mellitus (β=0.038, 95%CI 0.010-
0.065, p=0.007), male sex (β=0.044, 95%CI 0.019-0.068, p=0.001), higher ALT (β=0.023 
per 10 U/L, 95%CI 0.014-0.032, p<0.001), and larger spleen size (β=0.014, 95%CI 0.006-
0.023, p=0.001) were associated with higher log LSM. Replacing presence of diabetes 
mellitus by HOMA-IR did not alter results. Presence of diabetes mellitus (OR 2.96, 95%CI 
1.60-5.47, p=0.001), higher ALT (OR 1.43 per 10 U/L, 95% CI 1.19-1.72, p<0.001), and 
increasing weekly alcohol consumption (OR 1.09, 95%CI 1.01-1.18, p=0.023) were as-
sociated with having LSM ≥8.0 kPa in participants with NAFLD in multivariable logistic 
regression analysis.
DISCUSSION
To date, this is the largest study to investigate factors associated with and distribution 
of liver fibrosis, assessed by TE, in a general Caucasian population of older individuals. 
In this cross-sectional study the prevalence of LSM ≥8.0 kPa, suggestive of clinically re-
levant liver fibrosis, was 5.6%. Higher age, presence of DM and/or steatosis, higher ALT, 
larger spleen size, current or former smoking, and positive viral serology for hepatitis B 
and/or C were independently associated with LSM ≥8.0 kPa. 
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2Only few community-based studies have assessed liver fibrosis in adults by 
means of TE. In a study by Roulot et al, in which reliable LSM was obtained in 1190 sub-
jects older than 45 years attending a free medical check-up, prevalence of LSM ≥8.0 kPa 
was 7.5% and risk factors of LSM ≥8.0 kPa were rather consistent with our findings and in-
cluded age, elevated liver enzymes and factors associated with the metabolic syndrome 
(21). We were able to include ultrasonographic findings in our analyses, and found that 
both steatosis and spleen size were significantly associated with greater liver stiffness. 
Although the prevalence of LSM ≥8.0 kPa in our cohorts is nearly comparable, our study 
population may have included a less selected population, but had a higher mean age, 
greater prevalence of metabolic syndrome and included more women than the popu-
lation described by Roulot et al. A cross-sectional community-based study by Wong et 
al. assessed the prevalence of NAFLD and LSM ≥9.6 kPa in Hong Kong Chinese subjects 
by using MRI and TE (20). LSM ≥9.6 kPa was present in 2.0% of the total cohort of 759 
subjects without a hepatitis B or C infection and in 3.7% of subjects with NAFLD. These 
percentages were comparable with our results (data not shown), even though the preva-
lence of steatosis and metabolic syndrome and the mean age of our cohort were higher. 
In the present study, higher age was associated with continuous LSM or ele-
vated LSM in both linear and logistic regression analysis, respectively. An association 
of age with LSM has been corroborated in some previous studies, but not in others 
(21, 28-32). Indeed, the incidence of liver diseases increases with advancing age, which 
may in part explain a higher prevalence of LSM ≥8.0 kPa at higher age (33). However, 
we demonstrated that higher age remained associated with higher LSM after exclusion 
of subjects with positive viral serology for hepatitis B and/or C, steatosis, ALT above 
the upper limit of normal and LSM ≥8.0 kPa. Elastic properties of the normal liver may 
change as a result of ageing for several reasons. Firstly, age-related changes in histolog-
ical architecture of the liver may cause increased liver stiffness. With ageing there is a 
decline in hepatic blood flow, hepatic volume, and number and volume of individual 
hepatocytes (34, 35). Hepatocytes in aged livers show increased polyploidy (36). Sec-
ondly, livers of older individuals may be stiffer as a result of accumulation of collagen. It 
is hypothesized that older individuals have reduced collagenolytic activity (37). In addi-
tion, cellular senescence, caused by telomere dysfunction, and increased mitochondrial 
damage and oxidative stress, may increase susceptibility of the older liver to liver dam-
age and may reduce the capacity of the liver to regenerate (33). 
A compelling observation in our study was that the association of age with 
LSM ≥8.0 kPa was positively influenced by presence of steatosis and/or DM. The pre-
dicted probabilities of LSM ≥8.0 kPa increased with age for participants without DM. 
For participants with DM on the other hand, the probability of having clinically relevant 
fibrosis was already as high as 8.2-14.0% for participants aged 50-60 years, depending 
on the concurrent presence of steatosis, and these probabilities did not increase with 
age. These findings underline the significant role of these – potentially modifiable – risk 
factors in liver fibrosis and stress the importance of early targeting insulin resistance 
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2and/or DM. We observed that the presence of steatosis and/or DM did not influence 
the probability of LSM ≥8.0 kPa in octo- and nonagenarians, which can be the result 
of a survival effect, but it may also suggest that both steatosis and insulin resistance 
or DM play a less important role in liver fibrosis at very old age. However, this remains 
speculative as some selection bias may exist. In addition, this study was cross-sectional 
by design and we were therefore unable to determine the role of duration of presence 
of DM or steatosis on probability of high LSM in the very old. 
Furthermore, a strong association between increased liver stiffness and pres-
ence of DM and/or greater insulin resistance was not only observed in the study popu-
lation as a whole, but also in a subgroup of subjects with ultrasonographically defined 
NAFLD. The prevalence of LSM ≥8.0 kPa in participants with NAFLD was as high as 8.4%. 
These findings suggest that NAFLD may be an important determinant of clinically rel-
evant fibrosis in a population that has a very low prevalence of viral hepatitis. Since 
NAFLD will become more prevalent considering population ageing and the current 
increasing prevalence of DM and obesity, and because the presence of NASH is asso-
ciated with an increased overall, cardiovascular, and liver related mortality, NAFLD will 
become a more urgent public health issue in the next few decades (38-41). 
In contrary to the observations by Roulot et al, we found that previous or cur-
rent smoking was significantly associated with elevated liver stiffness (21). Smoking 
may cause liver injury through various mechanisms, including (in)direct toxic effects, 
immunological effects through pro-inflammatory cytokine release, and oncogenic ef-
fects through free radical damage (42). The harmful effects of smoking on the liver have 
been investigated in some experimental studies with rats and in smaller clinical studies 
including patients with various liver diseases, however, epidemiological evidence of an 
independent association is limited (43-50). Although a synergism between alcohol con-
sumption and smoking is well-known, smoking was shown to increase the risk of liver 
cirrhosis independent of alcohol consumption in a previous population-based cohort 
study, consistent with our study (45). 
The strengths of this study encompass the large number of participants that 
were included and extensive data that were available for characterization of metabol-
ic and environmental traits. In addition, abdominal ultrasound was performed in all 
participants. Our study also has some limitations. For diagnosing liver fibrosis, biop-
sy remains the gold standard. However, performing a biopsy in all participants of this 
population-based cohort would have been unethical. Therefore, we used TE to obtain 
LSM for all participants. Although limited research is available addressing the positive 
predictive value to rule in advanced fibrosis and cirrhosis in subjects of the general 
population, TE is considered to be a reproducible and effective non-invasive alternative 
to assess liver fibrosis in patients with chronic liver diseases (25, 51). In addition, TE has 
also been shown to be able to predict portal hypertension-related complications, de-
compensation and survival in patients with chronic liver disease (52, 53). There is some 
debate regarding which criteria to apply to determine reliability of TE. Applying the 
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2other reliability criteria – success rate ≥ 60%, ≥ 10 valid measurements, and IQR/median 
LSM ≤0.3 – to our cohort resulted in comparable results. Unfortunately, we did not have 
access to histology to corroborate our results. However, we expect the cut-off of 8.0 kPa 
for clinically relevant fibrosis to be feasible, since Roulot et al could determine a cause 
of liver disease in all subjects with LSM ≥8.0 kPa in whom a biopsy was performed (21). 
XL-probe may have a lower cut-off value for advanced liver fibrosis and different cut-
offs have been applied for advanced fibrosis in patients with chronic liver diseases de-
pending on etiology (15, 25). Consistency of results was found when different cut-offs 
were used in our study. Steatosis was diagnosed by means of ultrasonography, which 
may identify a degree of steatosis greater than 30%. Nevertheless, abdominal ultraso-
nography has an acceptable sensitivity of 80-100% for detecting steatosis, and its ac-
curacy for diagnosis of steatosis meets other imaging modalities (54-56). Finally, there 
are controversial data about the influence of liver steatosis on LSM values in chronic 
hepatitis C patients (57-60). In patients with NAFLD most studies have shown no or 
an inverse relationship between degree of steatosis and LSM (16, 19, 61). Petta et al. 
demonstrated an association between severity of steatosis and LSM in NAFLD patients 
without significant fibrosis at biopsy. In this study, a cut-off of 7.9 kPa – similar to the 
cut-off used in the present study – was identified as the best LSM cut-off for discrimi-
nating significant fibrosis in presence of severe steatosis (≥66%) or severe bright liver 
echo pattern (62). We demonstrated no association between severity of steatosis and 
elevated liver stiffness in participants with steatosis. However, we cannot completely 
rule out the possibility that steatosis on itself may have affected LSM, independent of 
fibrosis stage, due to the lack of biopsies in this general population.
In summary, prevalence of LSM higher than 8.0kPa, suggestive of clinically rel-
evant liver fibrosis, was 5.6% in this older adult population-based cohort. Factors asso-
ciated with clinically relevant fibrosis were higher age, presence of DM and/or steatosis, 
higher ALT, greater spleen size, current or former smoking, and positive viral serology 
for hepatitis B and/or C. Presence of DM, especially in concurrent presence of steatosis, 
resulted in increased probabilities of having clinically relevant fibrosis. In the context of 
an ageing population and increasing prevalence of obesity, DM and NAFLD, this study 
illustrates that liver fibrosis and its complications may become a more prominent pub-
lic health issue in the nearby future.
42      Chapter 2
2REFERENCES
1. http://apps.who.int/gho/data/node.main.887?lang=en. In.
2. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 
2008;12:733-746, vii.
3. Heron M. Deaths: leading causes for 2010. Natl Vital Stat Rep 2013;62:1-96.
4. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease 
in Europe: a review of available epidemiological data. J Hepatol 2013;58:593-608.
5. Bedogni G, Miglioli L, Masutti F, Castiglione A, Croce LS, Tiribelli C, Bellentani S. Incidence and nat-
ural course of fatty liver in the general population: the Dionysos study. Hepatology 2007;46:1387-
1391.
6. Caballeria L, Pera G, Auladell MA, Toran P, Munoz L, Miranda D, Aluma A, et al. Prevalence and factors 
associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur 
J Gastroenterol Hepatol 2010;22:24-32.
7. Haring R, Wallaschofski H, Nauck M, Dorr M, Baumeister SE, Volzke H. Ultrasonographic hepatic ste-
atosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase 
levels. Hepatology 2009;50:1403-1411.
8. Koehler EM, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH, Janssen HL. Prevalence 
and risk factors of non-alcoholic fatty liver disease in the elderly: Results from the Rotterdam study. 
J Hepatol 2012;57:1305-1311.
9. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, et al. Prevalence of and risk 
factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the 
Edinburgh Type 2 Diabetes Study. Diabetes Care 2011;34:1139-1144.
10. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, et al. Prevalence of nonal-
coholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic 
patients. Diabetes Care 2007;30:1212-1218.
11. Floreani A. Liver diseases in the elderly: an update. Dig Dis 2007;25:138-143.
12. From the Centers for Disease Control and Prevention. Public health and aging: trends in aging--Unit-
ed States and worldwide. JAMA 2003;289:1371-1373.
13. Frith J, Jones D, Newton JL. Chronic liver disease in an ageing population. Age Ageing 2009;38:11-
18.
14. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenter-
ology 2012;142:1293-1302 e1294.
15. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, Beaton M, et al. Fea-
sibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in 
overweight and obese patients. Hepatology 2012;55:199-208.
16. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, et al. Diagnosis of fibro-
sis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 
2010;51:454-462.
17. Verveer C, Zondervan PE, ten Kate FJ, Hansen BE, Janssen HL, de Knegt RJ. Evaluation of transient 
elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. 
Liver Int 2012;32:622-628.
Diabetes mellitus, steatosis and liver stiffness      43 
218. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance 
of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 
2008;134:960-974.
19. Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y, et al. Noninvasive assessment 
of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NA-
FLD). Dig Liver Dis 2008;40:371-378.
20. Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, Yeung DK, et al. Prevalence of non-alcoho-
lic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-
magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409-415.
21. Roulot D, Costes JL, Buyck JF, Warzocha U, Gambier N, Czernichow S, Le Clesiau H, et al. Transient 
elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population 
aged over 45 years. Gut 2011;60:977-984.
22. Hofman A, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A, Ikram MA, Klaver CC, et al. 
The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol 2013;28:889-926.
23. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, et al. The severity of ultrasono-
graphic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat 
accumulation. Am J Gastroenterol 2007;102:2708-2715.
24. Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, Fouchard-Hubert I, et al. De-
termination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 
2013;57:1182-1191.
25. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J 
Hepatol 2008;48:835-847.
26. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, et al. Diagno-
sis and management of the metabolic syndrome - An American Heart Association/National Heart, 
Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model as-
sessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concen-
trations in man. Diabetologia 1985;28:412-419.
28. Roulot D, Czernichow S, Le Clesiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in 
apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008;48:606-
613.
29. Colombo S, Belloli L, Zaccanelli M, Badia E, Jamoletti C, Buonocore M, Del Poggio P. Normal liver 
stiffness and its determinants in healthy blood donors. Dig Liver Dis 2011;43:231-236.
30. Salles N, Dussarat P, Foucher J, Villars S, de Ledinghen V. Non-invasive evaluation of liver fibrosis 
by transient elastography and biochemical markers in elderly inpatients. Gastroenterol Clin Biol 
2009;33:126-132.
31. Das K, Sarkar R, Ahmed SM, Mridha AR, Mukherjee PS, Dhali GK, Santra A, et al. “Normal” liver stiff-
ness measure (LSM) values are higher in both lean and obese individuals: a population-based study 
from a developing country. Hepatology 2012;55:584-593.
32. Sirli R, Sporea I, Tudora A, Deleanu A, Popescu A. Transient Elastographic Evaluation of Subjects Wit-
hout Known Hepatic Pathology: Does Age Change the Liver Stiffness? Journal of Gastrointestinal 
and Liver Diseases 2009;18:57-60.
44      Chapter 2
233. Hoare M, Das T, Alexander G. Ageing, telomeres, senescence, and liver injury. Journal of Hepatology 
2010;53:950-961.
34. Wynne HA, James OF. The ageing liver. Age Ageing 1990;19:1-3.
35. Schmucker DL, Sanchez H. Liver regeneration and aging: a current perspective. Curr Gerontol Geri-
atr Res 2011;2011:526379.
36. Schmucker DL. Hepatocyte fine structure during maturation and senescence. J Electron Microsc 
Tech 1990;14:106-125.
37. Gagliano N, Arosio B, Grizzi F, Masson S, Tagliabue J, Dioguardi N, Vergani C, et al. Reduced col-
lagenolytic activity of matrix metalloproteinases and development of liver fibrosis in the aging rat. 
Mech Ageing Dev 2002;123:413-425.
38. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of 
nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-
121.
39. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term 
follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873.
40. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic 
fatty liver disease. J Hepatol 2008;49:608-612.
41. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver 
disease. N Engl J Med 2010;363:1341-1350.
42. El-Zayadi AR. Heavy smoking and liver. World Journal of Gastroenterology 2006;12:6098-6101.
43. Azzalini L, Ferrer E, Ramalho LN, Moreno M, Dominguez M, Colmenero J, Peinado VI, et al. Ciga-
rette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology 2010;51:1567-
1576.
44. Bolukbas FFO, Kabasakal L, Bolukbas C, Uysal MK, Peker O, Ovunc O. Hepatocyte damage caused by 
nicotine alone and in combination with alcohol. Gastroenterology 1998;114:A1318-A1319.
45. Dam MK, Flensborg-Madsen T, Eliasen M, Becker U, Tolstrup JS. Smoking and risk of liver cirrhosis: a 
population-based cohort study. Scandinavian Journal of Gastroenterology 2013;48:585-591.
46. Dev A, Patel K, Conrad A, Blatt LM, McHutchison JG. Relationship of smoking and fibrosis in patients 
with chronic hepatitis C. Clinical Gastroenterology and Hepatology 2006;4:797-801.
47. Hezode C, Lonjon I, Roudot-Thoraval F, Mavier JP, Pawlotsky JM, Zafrani ES, Dhumeaux D. Impact of 
smoking on histological liver lesions in chronic hepatitis C. Gut 2003;52:126-129.
48. Pessione F, Ramond MJ, Njapoum C, Duchatelle V, Degott C, Erlinger S, Rueff B, et al. Cigarette smok-
ing and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001;34:121-125.
49. Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, Damicis A, Arico S, et al. The Effect of Drinking 
Coffee and Smoking Cigarettes on the Risk of Cirrhosis Associated with Alcohol-Consumption - a 
Case-Control Study. European Journal of Epidemiology 1994;10:657-664.
50. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, Liaw YF. Prospective study of hepatocellular 
carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. American Journal of 
Epidemiology 1997;145:1039-1047.
51. Rockey DC. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastog-
raphy. Gastroenterology 2008;134:8-14.
Diabetes mellitus, steatosis and liver stiffness      45 
252. Robic MA, Procopet B, Metivier S, Peron JM, Selves J, Vinel JP, Bureau C. Liver stiffness accurately 
predicts portal hypertension related complications in patients with chronic liver disease: a prospec-
tive study. J Hepatol 2011;55:1017-1024.
53. Vergniol J, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W, Couzigou P, et al. Noninva-
sive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients With Chronic Hepatitis 
C. Gastroenterology 2011;140:1970-U1197.
54. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenter-
ol 2006;40 Suppl 1:S34-38.
55. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcohol-
ic steatohepatitis: present and future. Hepatology 2007;46:582-589.
56. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy 
and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 
2011;54:1082-1090.
57. Boursier J, de Ledinghen V, Sturm N, Amrani L, Bacq Y, Sandrini J, Le Bail B, et al. Precise evaluation of 
liver histology by computerized morphometry shows that steatosis influences liver stiffness mea-
sured by transient elastography in chronic hepatitis C. J Gastroenterol 2014;49:527-537.
58. Lupsor M, Badea R, Stefanescu H, Grigorescu M, Sparchez Z, Serban A, Branda H, et al. Analysis of 
histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort 
of 324 patients. J Gastrointestin Liver Dis 2008;17:155-163.
59. Macaluso FS, Maida M, Camma C, Cabibbo G, Cabibi D, Alduino R, Di Marco V, et al. Steatosis affects 
the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 
chronic hepatitis C. J Hepatol 2014;61:523-529.
60. Sanchez-Conde M, Montes Ramirez ML, Bellon Cano JM, Caminoa A, Alvarez Rodriguez F, Gonzalez 
Garcia J, Miralles Martin P, et al. Impact of liver steatosis on the correlation between liver stiffness 
and fibrosis measured by transient elastography in patients coinfected with human immunodefi-
ciency virus and hepatitis C virus. J Viral Hepat 2011;18:e278-283.
61. Gaia S, Carenzi S, Barilli AL, Bugianesi E, Smedile A, Brunello F, Marzano A, et al. Reliability of tran-
sient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral 
hepatitis. J Hepatol 2011;54:64-71.
62. Petta S, Maida M, Macaluso FS, Marco VD, Camma C, Cabibi D, Craxi A. The severity of steatosis 
influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Hepatology 
2015.
Author names in bold designate shared co-first authorship
46      Chapter 2
2Supplementary table 2.1 Factors associated with (log-transformed) LSM in linear univariable regression 
analyses (n=3041)
Variable β (95%CI) p-value
Age, per 10 years 0.028 (0.022-0.035) <0.001
Sex, male 0.075 (0.065-0.085) <0.001
Diabetes Mellitus 0.083 (0.067-0.099) <0.001
Spleen size, cm 0.024 (0.020-0.028) <0.001
ALT, per 10 U/L 0.019 (0.015-0.023) <0.001
BMI, kg/m2 0.004 (0.003-0.005) <0.001
Hypertension 0.033 (0.021-0.044) <0.001
Steatosis 0.046 (0.035-0.056) <0.001
Waist circumference, cm 0.002 (0.002-0.003) <0.001
Alcohol consumption, drinks/week 0.001 (<0.001-0.002) 0.004
Current or former smoking 0.012 (0.001-0.023) 0.030
Platelets (*109/L) <0.001 (<0.001-<0.001) <0.001
Bilirubin, umol/L 0.001 (<0.001-0.001) 0.037
HBsAg or anti-HCV positive 0.089 (0.029-0.149) 0.004
Abbreviations: LSM, liver stiffness measurement; ALT, alanine aminotransferase; BMI, Body Mass Index; HB-
sAg, hepatitis B surface antigen; HCV, hepatitis C virus
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2Supplementary table 2.2 Factors associated with LSM ≥8.0 kPa (n=169) in logistic univariable regression 
analyses
Variable OR (95%CI) p-value
Age, per 10 years 1.57 (1.30-1.90) <0.001
Sex, male 2.09 (1.52-2.88) <0.001
Diabetes Mellitus 4.68 (3.32-6.61) <0.001
Spleen size, cm 1.39 (1.25-1.55) <0.001
ALT, per 10 U/L 1.28 (1.17-1.40) <0.001
BMI, kg/m2 1.10 (1.06-1.14) <0.001
Hypertension 2.06 (1.40-3.03) <0.001
Steatosis 2.80 (2.04-3.84) <0.001
Waist circumference, cm 1.04 (1.03-1.05) <0.001
Alcohol consumption, drinks/week 1.01 (0.99-1.03) 0.19
Current or former smoking 1.96 (1.34-2.86) 0.001
Platelets (*109/L) 0.995 (0.99-1.00) <0.001
Bilirubin, umol/L 1.02 (1.00-1.03) 0.047
HBsAg or anti-HCV positive 3.85 (1.29-11.5) 0.016
Abbreviations: LSM, liver stiffness measurement; ALT, alanine aminotransferase; BMI, Body Mass Index; HB-
sAg, hepatitis B surface antigen; HCV, hepatitis C virus
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3ABSTRACT
Background and aims
Increasing evidence suggests that genetic factors play a role in the development of 
liver fibrosis. The association between several single nucleotide polymorphisms (SNPs) 
and liver fibrosis is well-established in patients with viral hepatitis or non-alcoholic fatty 
liver disease. The aim of this study was to investigate the association between these 
candidate SNPs and liver fibrosis in the general population, using liver stiffness (LS) as 
a proxy.
Methods
This research is part of the Rotterdam study, a large population-based cohort of sub-
jects aged ≥ 55 years. In all patients, LS was measured using transient elastography. 
We investigated SNPs in 13 loci known to be associated with fibrosis and/or cirrhosis in 
at-risk populations. 
Results
In 1059 participants, two linked SNPs in the interferon gamma receptor 2 (IFNGR2) gene 
were independently associated with liver fibrosis in multivariable analysis (p=0.04 for 
rs9976971 and p=0.01 for rs2284553). A third variant in the IFNGR2 gene, rs9808753, 
showed a trend towards a significant association with fibrosis (p=0.08). The associa-
tion between these three IFNGR2 SNPs and fibrosis was significantly modified by body 
mass index (BMI). For participants with the IFNGR2 AA genotypes, LS was higher as BMI 
increased. Subgroup analysis in participants with steatosis also showed an association 
between the IFNGR2 SNPs and fibrosis. 
Conclusions
In this large population-based cohort, IFNGR2 gene variants were independently asso-
ciated with liver fibrosis. These results suggest that the IFNGR2 SNPs do not only play 
a role in liver fibrogenesis in at-risk populations, but in the general population as well.
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3INTRODUCTION
Liver fibrosis is known to develop from many types of chronic liver injuries. Persistence 
of hepatic injuries leads to progression of liver fibrosis into cirrhosis and hepatocellular 
carcinoma, conditions associated with high morbidity and mortality.(1, 2) In addition 
to chronic liver injuries, other factors are known to influence the development of liver 
fibrosis; among these are genetic variations.(3)
Single nucleotide polymorphisms (SNPs) are variations in an individual’s DNA 
that consist of a single nucleotide which differs from the one in the majority of the pop-
ulation. Together with microsatellites, SNPs account for most of the genetic variability 
between individuals.(4) As of July 2013, more than 62 million SNPs have been described 
in humans.(5) SNPs can affect the function, availability or transcription of a protein and 
can therefore also affect the development of disease.(4)
Genome wide association studies have identified several SNPs associated with 
liver fibrosis in at-risk populations.(6, 7) In addition, SNPs in or near the interleukin 28B 
(IL28B) gene and patatin-like phospholipase domain-containing protein 3 (PNPLA3) 
gene were shown to be associated with liver fibrosis in patients with chronic hepatitis 
C and non-alcoholic fatty liver disease respectively in genetic association studies.(8, 9) 
Furthermore, SNPs in the interferon gamma receptor 2 (IFNGR2) gene, known to have 
antifibrogenic activity, have also been studied in order to determine their association 
with liver fibrogenesis in at-risk populations. SNPs in this gene were found to be associ-
ated with progression of liver fibrosis in patients with chronic hepatitis C.(10) 
Until now, all studies on the role of genetic variants in liver fibrogenesis have 
focused on associations in at-risk populations, such as individuals with chronic viral 
hepatitis or fatty liver disease. As far as we are aware, no studies have been performed 
to investigate whether these associations between genetic variants and liver fibrosis 
are also present in the general population. As a result, we do not know whether the 
genetic variants discovered in at-risk populations alter the effect of chronic liver inju-
ries on liver fibrogenesis or whether they affect fibrosis development independently of 
other factors. Therefore, the aim of our study was to determine the association between 
candidate genetic variants identified in at-risk populations and liver fibrosis, assessed 
using transient elastography (TE), in a large population-based cohort.
MATERIALS AND METHODS
Study population and design
This study was part of the Rotterdam study, a large ongoing prospective population-
based cohort study in the Netherlands, which started in 1990.(11) All inhabitants of 
Ommoord, a suburb in the city of Rotterdam, aged 55 years and over were asked to 
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3participate in this study. As of 2000, a new cohort was added to the initial study popula-
tion. This second cohort consisted of participants who had turned 55 years of age since 
the start of the study or who had moved into the study district. Participants visit the 
designated research center every 3-4 years. Each assessment cycle consists of a home 
interview and a range of physical examinations at the research center. For more details, 
the reader is referred to previous publications.(11) As of 2009, each examination cycle 
includes an abdominal ultrasound and TE measurement.
The Rotterdam study has been approved by the Medical Ethics Committee 
of the Erasmus University Medical Center and written informed consent has been ob-
tained from all participants.(11)
Assessment of liver fibrosis and steatosis
Liver fibrosis was assessed non-invasively by measuring liver stiffness (LS) using TE (Fi-
broscan®, Echosens™). LS measurements were considered reliable if 10 valid measu-
rements were obtained with a success rate of at least 60% and an interquartile range 
of less than 30% of the median LS value. All LS measurements were performed by a 
single experienced ultrasonographer using either an M or XL-probe according to the 
manufacturer’s recommendations. TE is contraindicated in patients with an intracardiac 
device and was therefore not performed in these participants. A liver stiffness cut-off 
value of 8.0 kPa was used as suggestive of clinically relevant fibrosis.(12, 13)
Abdominal ultrasound (Hitachi HI VISION 900) was used to assess the presence 
of steatosis, to measure spleen size and to examine the hepatic parenchyma. Images 
were re-evaluated by an expert hepatologist with vast experience in ultrasound. The 
presence of steatosis was always reassessed by the expert hepatologist.
Biochemistry and assessment of covariables
During the assessment cycle, fasting venous blood samples were collected and stored 
at -80˚C. Alanine aminotransferase (ALT) and glucose levels were determined using au-
tomated procedures (Roche Diagnostics GmbH, Mannheim, Germany). Levels of hepa-
titis B surface antigen (HBsAg) and anti-hepatitis C virus (HCV) antibodies were measu-
red to determine the presence of viral hepatitis. Insulin, HBsAg and anti-HCV antibodies 
were measured using immunoassays (Roche Diagnostics GmbH, Mannheim, Germany). 
The extent of insulin resistance was determined using the Homeostasis Model Assess-
ment of Insulin Resistance (HOMA-IR) defined as fasting glucose (mmol/L) x fasting in-
sulin (mU/L) ÷ 22.5.(14)
During the home interview, extensive data was obtained on demographics, 
medical history, comorbidity, alcohol consumption, smoking behavior, and drug use. 
Excessive alcohol consumption was defined as an intake of more than 14 units of al-
cohol per week. Trained research nurses performed anthropometric measurements at 
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3the research center, from which body mass index (BMI) was calculated as weight (kg) ÷ 
height squared (m)2. 
Genotyping
DNA was isolated from whole blood samples and extracted according to standard au-
tomated procedures.(15) Genotyping in the Rotterdam study cohort was performed in 
batches in the Erasmus University Medical Center, Rotterdam, The Netherlands using 
the Infinium II HumanHap 550K Genotyping Bead-Chip® version 3 (Illumina Inc., San 
Diego, CA, USA). Sample-specific quality control included filters for low call rate, hetero-
zygosity and sex mismatch. SNP-specific quality control measures comprised filters for 
call rate, minor allele frequency and Hardy-Weinberg equilibrium (HWE). The Markov 
Chain Haplotyping package (16) was used for imputation with the cohort of the 1000 
Genomes Project (17) as reference population. A detailed description of these methods 
has been published elsewhere.(18-21) 
We analyzed SNPs that have been associated with liver fibrosis in large at-risk 
populations (Table 3.1).(6-10) Additionally, all SNPs of the cirrhosis risk score were ana-
lyzed for a possible association with LS in our cohort. This previously published cirrhosis 
risk score was constructed in a group of Caucasian patients with chronic hepatitis C to 
estimate the risk of development of cirrhosis.(22) One of the imputed SNPs, rs2290351, 
is in full linkage disequilibrium with a genotyped SNP, rs4932145. Therefore, we have 
chosen to use this genotyped SNP as proxy for rs2290351 in our analyses.
Statistical analysis
Baseline characteristics are expressed as numbers with proportions for categorical 
variables and as median with interquartile range or mean with standard deviation for 
continuous variables. Genotypes were coded as 0,1 or 2 based on the number of effect 
alleles. The fractional allele count (imputed dosage of the effect allele) was used in case 
of imputation. All SNPs were analyzed in an additive genetic model. LS measurements 
were not normally distributed and therefore logarithmically transformed prior to the 
analyses. We performed linear regression analysis to examine associations between 
SNPs and LS measurements, adjusting for age, sex, presence of steatosis, type of elas-
tography probe used, spleen size, ALT, BMI, alcoholic intake, presence of viral hepatitis 
and HOMA-IR. Effect modification was tested for age, sex, BMI, alcoholic intake and ste-
atosis by adding interaction terms to the regression models. Logistic regression analysis 
was used to assess the association between the PNPLA3 SNP and presence of steatosis. 
This was a candidate gene study, investigating SNPs with a well-established 
association with fibrosis in at-risk populations. All observed univariable associations 
were tested for independency by adjusting for possible confounders in multivariable 
models. Therefore, a p-value of <0.05 was considered statistically significant. Statistical 
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3analyses were performed using SPSS 21 (SPSS Inc., Chicago, IL, USA). The STREGA rec-
ommendations were applied for reporting this study.(23)
Genetic risk scores were constructed using the SNP with the strongest associa-
tion of every locus, i.e. adding only one SNP per gene to the risk score. The SNPs includ-
ed in this score are listed in supplementary Table 3.1. For every participant, the weight-
ed sum of the total number of fibrosis risk alleles was calculated. Weighting was based 
on effect estimates obtained from previous studies.(6, 7, 10, 22, 24, 25) This method 
has been described in more detail elsewhere.(26) For every participant, the genetic risk 
score was subsequently calculated by dividing the sum of weighted fibrosis risk alleles 
by the total number of SNPs included in the score. Two genetic risk scores were calcu-
lated. The first consisted of all SNPs, except those included in the cirrhosis risk score. In 
the second genetic risk score, all SNPs were included. Next to these genetic risk scores 
we also calculated the cirrhosis risk score for every participant using the method as 
described by Huang et al.(22)  
Table 3.1 Single nucleotide polymorphisms associated with fibrosis in at-risk populations. 
SNP id Chromosome 
(forward strand)
Gene Minor allele MAF
rs738409 22:44324727 PNPLA3 G 0.22
rs12979860 19:39738787 IL28B T 0.32
rs12980275 19:39731783 IL28B G 0.31
rs8099917 19:39743165 IL28B G 0.17
rs9976971 21:34768097 IFNGR2 A 0.42
rs2284553 21:34776695 IFNGR2 A 0.39
rs9808753 21:34787312 IFNGR2 G 0.16
rs17882748 21:34775721 IFNGR2 C 0.48
rs62522600 8:103841709 AZIN1 A 0.05
rs4986791 9:120475602 TLR4 T 0.06
rs886277 11:2439767 TRPM5 C 0.37
rs2290351 15:90374781 AP3S2 A 0.25
rs4290029 1:224400640 None C 0.14
rs17740066 3:121100283 STXBP5L  A 0.10
rs2878771 12:50352393 AQP2 C 0.19
rs2229738 11:68562328 CPT1A T 0.09
rs1140409 17:62496670 DDX5 C 0.09
rs343062 7:35549066 None T 0.36
Abbreviations: SNP, Single nucleotide polymorphisms; PNPLA3, patatin-like phospholipase domain-con-
taining protein 3; IL28B, interleukin 28B; IFNGR2, interferon gamma receptor 2; AZIN1, antizyme inhibitor 
1; TLR4, toll-like receptor 4; TRPM5, transient receptor potential cation channel, subfamily M, member 5; 
AP3S2, adaptor-related protein complex 3, sigma 2 subunit; STXBP5L, syntaxin binding protein-5-like; AQP2, 
aquaporin 2; CPT1A, carnitine palmitoyltransferase 1A; DDX5, DEAD (Asp-Glu-Ala-Asp) box helicase 5, MAF, 
Minor allele frequency in individuals from European descent (EUR) in the 1000 Genomes project (http://
browser.1000genomes.org).
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3RESULTS
Study population
Of the 1324 participants in which reliable LS measurements were available, genetic 
data was obtained for 1059 participants, comprising the study population. The base-
line characteristics of this study population are presented in Table 3.2. Mean age was 
74.2 ± 5.6 years and 50.2% of participants were male. Almost all participants were of 
Caucasian origin (99.6%). Median LS was 5.1 kPa (interquartile range 4.1-6.3). In 101 
participants (9.5%) a liver stiffness ≥ 8.0 kPa was present. Two participants appeared 
infected with the hepatitis B virus (0.2%) and 9 participants with the hepatitis C virus 
(0.9%). Steatosis was diagnosed in 338 participants (31.9%).
Table 3.2 Baseline characteristics of the study population.
Characteristic n=1059
Age (years) 74.2 ± 5.6
Male sex 532 (50.2%)
Caucasian * 999 (99.6%)  
BMI (kg/m2) 26.7 ± 3.6
BMI (kg/m2) categories
Normal weight (<25) 361 (34.1%)
Overweight (25-30) 521 (49.2%)
Obese (≥30) 177 (16.7%)
HOMA-IR 2.5 (1.7-3.6)
Alcoholic intake >14 IU/week † 121 (11.6%) 
Chronic viral hepatitis ‡
B 2 (0.2%)
C 9 (0.9%) 
Spleen size (cm) 9.6 ± 1.3
ALT (u/mL) 18.0 (14.0-23.0)
Steatosis 338 (31.9%)
Fibroscan probe 
M 531 (50.1%)
XL 528 (49.9%)
LSM (kPa) 5.1 (4.1-6.3)
Values are mean ± standard deviation, number (proportion) or median (interquartile range)
* Data on ethnicity was missing for 56 participants. 
† Data on alcoholic intake was missing for 12 participants. 
‡ Data on presence of viral hepatitis was missing for 14 participants.
Abbreviations: BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance; ALT, 
alanine aminotransferase; LSM, liver stiffness measurement; kPa, kilopascal. 
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3Genotyping
Two SNPs in the IFNGR2 gene, rs9976971 and rs2284553, were in strong linkage dise-
quilibrium (R2=0.80, D’=0.96). Quality of imputation was high, with R2-values ranging 
from 0.94 to 1.0 (Supplementary Table 3.2). All SNPs were in HWE, except for rs17740066 
(DDX5, X2=16.36, p<0.001), which was therefore excluded from all analyses. Frequencies 
and call rates of the different SNPs in our cohort are shown in supplementary Table 3.3.
Associations between SNPs and liver fibrosis
Associations between liver fibrosis and the different SNPs are listed in Table 3.3. Two 
linked SNPs in the IFNGR2 gene, rs9976971 and rs2284553, were associated with incre-
ased fibrosis in our cohort (β=0.016, p=0.018 for rs9976971 and β=0.017, p=0.011 for 
rs2284553) (Figure 3.1). 
The association between IFNGR2 SNPs rs9976971 and rs2284553 and fibrosis re-
mained significant in a multivariable model (β=0.013, p=0.044 for rs9976971; β=0.017, 
p=0.010 for rs2284553) (see Table 3.4). Other factors independently associated with 
liver fibrosis in these models were age, sex, HOMA-IR, spleen size and ALT. Moreover, 
rs9808753 (IFNGR2 SNP 3) showed a trend towards a significant association with fibrosis 
in multivariable analysis (β=0.016, p=0.081). 
There was no association between fibrosis and SNPs near IL28B (p-values 
>0.17) or PNPLA3 (p=0.19 in adjusted analysis). 
Table 3.3 Univariable regression models with logarithmically transformed liver stiffness as outcome 
(n=1059). Betas represent the increase in logarithmically transformed liver stiffness per fibrosis risk allele. 
SNP id Fibrosis risk allele/frequency Beta (SE) p-value
rs738409 G/0.24 -0.006 (0.008) 0.44
rs12979860 C/0.68 -0.009 (0.007) 0.21
rs12980275 A/0.70 -0.005 (0.007) 0.47
rs8099917 T/0.80 -0.011 (0.008) 0.17
rs9976971 A/0.43 0.016 (0.007) 0.018
rs2284553 A/0.40 0.017 (0.007) 0.011
rs9808753 A/0.86 0.012 (0.009) 0.21
rs17882748 C/0.45 -0.007 (0.007) 0.33
rs62522600 G/0.93 -0.008 (0.013) 0.55
rs4986791 C/0.95 -0.016 (0.015) 0.26
rs886277 C/0.41 -0.001 (0.007) 0.94
rs4932145 A/0.23 -0.009 (0.008) 0.26
rs4290029 G/0.85 0.003 (0.009) 0.75
rs2878771 G/0.84 0.003 (0.010) 0.78
rs2229738 C/0.97 0.011 (0.018) 0.53
rs1140409 C/0.06 0.004 (0.014) 0.77
rs343062 T/0.40 0.003 (0.006) 0.69
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Figure 3.1 Association between single nucleotide polymorphisms (SNP) in the interferon gamma receptor 2 
gene and liver stiffness measurements. Panel (A) represents rs9976971, panel (B) rs2284553 and panel (C) de-
picts rs9808753. For all three SNPs, liver stiffness increases with the addition of an A allele. Error bars represent 
the geometric means of liver stiffness values for each genotype per SNP and their 95% confidence interval.
3
Subgroup analyses 
We performed a sensitivity analysis by excluding all participants infected with hepatitis 
B or C (n=11) as well as those who had an alcohol intake of 14 or more international 
units per week (n=121). In the remaining subgroup of 928 participants (one participant 
had both viral hepatitis and a high alcohol intake), the association between the IFNGR2 
SNPs and liver fibrosis was comparable with that observed in the total cohort (β=0.019, 
p=0.008 for rs9976971 and β=0.022, p=0.002 for rs2284553 respectively in univaria-
ble analysis). In adjusted analysis, we also observed a significant association between 
rs9976971, rs2284553 and liver fibrosis (β=0.015, p=0.03 and β=0.020, p=0.004 respecti-
vely). Results for the other SNPs were comparable to those obtained in the total cohort.
The association between the IFNGR2 SNPs and fibrosis was also present in a 
subgroup of participants with steatosis. In this group of 338 participants, rs9976971, 
rs2284553 and rs9808753 were all significantly associated with liver fibrosis (p=0.046, 
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30.044 and 0.022 respectively). In a multivariable model, only rs9808753 remained inde-
pendently associated with fibrosis in this subgroup (β=0.045, p=0.010).
Modification of the association between IFNGR2 SNPs and liver fibrosis
BMI significantly influenced the association between the IFNGR2 SNP rs2284553 and 
fibrosis, with higher LS measurements found in participants with an increasing BMI 
(p-value for the interaction term was 0.036). Similar results were obtained for the in-
teraction term between BMI and IFNGR2 SNPs rs9976971 and rs9808753 (p=0.050 for 
rs9976971 and p=0.044 for rs9808753). Associations between the IFNGR2 SNPs, BMI 
and liver fibrosis are shown in Figure 3.2. We explored this interaction further by di-
viding BMI into 3 groups: normal weight (BMI 0-25), overweight (BMI 25-30) and obese 
(BMI≥30). Interaction terms of BMI with all three IFNGR2 SNPs and fibrosis as dependent 
variable were significant in ordinal regression analyses (p=0.037 for rs2284553, p=0.037 
for rs9976971 and p=0.023 for rs9808753). In obese participants, the association be-
tween rs9976971 or rs2284553 and fibrosis was stronger than that observed in the total 
cohort (β=0.055, p=0.002 for rs9976971 and β=0.056, p=0.002 for rs2284553).The same 
applied to overweight participants for the association between SNP rs9808753 and fi-
brosis (β=0.034, p=0.01). 
The association between rs9808753 and liver fibrosis was also significantly 
modified by the presence of steatosis. The association between the A allele of rs9808753 
and fibrosis was stronger in participants with steatosis than in those without steatosis 
(p-value for the interaction term was 0.003). There were no interactions between the 
IFNGR2 SNPs and age, sex or alcohol intake. 
Table 3.4 Multivariable analyses in 2 separate models for the association between single nucleotide poly-
morphisms in the interferon gamma receptor 2 gene and liver fibrosis (n=1059). 
rs9976971 rs2284553
Variable Beta p-value Variable Beta p-value
Sex, male 0.063 <0.001 Sex, male 0.063 <0.001
Age, years 0.007 <0.001 Age, years 0.007 <0.001
HOMA-IR 0.004 0.004 HOMA-IR 0.004 0.005
FS-probe, M 0.011 0.27 FS-probe, M 0.011 0.27
Steatosis 0.023 0.050 Steatosis 0.023 0.050
Spleen size, cm 0.012 0.002 Spleen size, cm 0.012 0.002
ALT, u/mL 0.003 <0.001 ALT, u/mL 0.003 <0.001
Body mass index <0.001 0.88 Body mass index <0.001 0.88
Alcohol intake, IU per week -0.001 0.37 Alcohol intake, IU per week -0.001 0.34
Viral hepatitis B or C 0.041 0.39 Viral hepatitis B or C 0.040 0.40
rs9976971 0.013 0.044 rs2284553 0.017 0.010
Abbreviations: HOMA-IR, homeostasis model assessment of insulin resistance; FS, Fibroscan®; ALT, alanine 
aminotransferase. 
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Figure 3.2 Predicted liver stiffness measurements with body mass index (BMI) for all genotypes of the inter-
feron gamma receptor 2 single nucleotide polymorphisms (SNPs). Panel (A) represents rs9976971, panel (B) 
rs2284553 and panel (C) depicts rs9808753.  Predicted liver stiffness increases for genotypes AA with incre-
asing BMI for all SNPs. Models are adjusted for age, sex, presence of steatosis, type of Fibroscan probe used, 
alanine aminotransferase, homeostasis model assessment of insulin resistance, spleen size, units of alcoholic 
intake per week and presence of viral hepatitis B or C.
3
Genetic risk scores
The first composed genetic risk score, consisting of a group of SNPs representing all 
loci except for those included in the previously reported cirrhosis risk score (see Sup-
plementary Table 3.1), was not associated with liver fibrosis in a univariable model 
(β=0.038, p=0.14). However, we found it to be independently associated with fibrosis in 
a multivariable model (β=0.051, p=0.047). No association between the second genetic 
risk score, including SNPs representing all loci, and liver fibrosis was observed (β=0.051 
and p=0.18 in a multivariable model). 
The cirrhosis risk score was not associated with liver fibrosis in our cohort 
(p=0.26). When we compared participants with LS values suggestive of significant fi-
brosis or cirrhosis (LS≥9.5 kPa) with participants with LS values suggestive of no or mini-
mal fibrosis (LS<7.1 kPa) only, again no relationship between the cirrhosis risk score and 
liver fibrosis was observed (p=0.66).
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3PNPLA3 in steatosis
We observed an association between the PNPLA3 SNP and steatosis in our cohort (OR 
1.58, 95%CI 1.27-1.97, p<0.001 for addition of an 148M allele). PNPLA3 was indepen-
dently associated with steatosis after adjustment for age, sex, BMI, HOMA-IR, serum 
triglyceride levels and high density lipoprotein cholesterol (HDL-C) levels (additive OR 
1.87, 95%CI 1.43-2.45, p<0.001).
DISCUSSION
This study shows that SNPs in the IFNGR2 gene are independently associated with liver 
fibrosis, as assessed by TE, in a population-based cohort of elderly participants. After 
exclusion of participants who had viral hepatitis and those who had an excessive alco-
hol intake – both well-known causes of liver fibrosis – the association between these 
SNPs and liver fibrosis was still present. The association between the IFNGR2 SNPs and 
fibrosis was also confirmed in a subgroup of participants with steatosis.
The SNPs investigated in this study have all been reported in previous studies. 
In such studies, an association with liver fibrosis in at-risk populations was detected 
for all of the loci included in our analyses.(6-10, 22) Since we discovered that SNPs in 
the IFNGR2 gene are also associated with liver fibrosis in the general population, this 
implies that these SNPs affect fibrosis development independently of chronic liver inju-
ries, which is a novel finding.  
The gene variants that were associated with liver fibrosis in our cohort were 
situated in the IFNGR2 gene. Interferon gamma, the type II interferon, has been shown 
to influence liver fibrogenesis. The precise mechanism of this effect has not been fully 
elucidated but interferon gamma has been shown not only to inhibit collagen synthe-
sis in hepatic stellate cells but also to induce progression of the stage of liver fibrosis 
in patients with chronic hepatitis C.(27, 28) Of the two known interferon gamma re-
ceptors, type 1 and 2, IFNGR2 seems to be the most important for interferon gamma 
to exert its effect.(29) In a recent study, an association between variants in the IFNGR2 
gene and liver fibrosis was described for the first time in a large cohort of patients with 
chronic hepatitis C.(10) In this study, two highly linked SNPs, rs9976971 and rs2284553, 
were significantly associated with liver fibrosis. Since we also found these two linked 
SNPs to be independently associated with liver fibrosis in our cohort of healthy partic-
ipants, as well as in a subgroup of participants with steatosis, interferon gamma seems 
to promote fibrogenesis independently of any interaction with viral replication. Studies 
to further elucidate the biological mechanism by which the IFNGR2 SNPs influence liver 
fibrogenesis are warranted. Once the mechanism by which IFNGR2 exert its effect on 
fibrogenesis is known, treatment options targeting this pathway could be developed.
An interesting finding of our study was that the effect of the IFNGR2 gene variants 
on liver fibrosis was significantly altered by BMI: in obese participants, LS was consider-
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3ably higher for the AA genotypes of SNP rs2284553, rs9976971 and rs9808753 than for the 
other genotypes. A possible explanation is related to the fact that obesity is characterized 
by a state of chronic inflammation in which adipose tissue is infiltrated by macrophages 
and starts producing cytokines.(30, 31) It is certainly possible that this pro-inflammatory 
state reinforced the effect of interferon gamma on liver fibrogenesis in those obese indi-
viduals in our cohort who had the fibrosis-prone genotypes of the IFNGR2 SNPs.
None of the SNPs in other fibrosis loci were associated with liver fibrosis in 
our cohort. A possible explanation for this finding is that these loci have an effect in 
at-risk populations only. To further clarify this, validation of our results in other popula-
tion-based cohort studies is required.
A strength of our study is that it was conducted in a large, well-described, ho-
mogeneous cohort of elderly, Caucasian citizens living in a suburb of Rotterdam. This 
suburb was chosen because it is a representative subset of the Dutch population and 
because it has an extensive network of health care providers and pharmacists.
In this study, liver fibrosis was assessed using TE. Liver biopsy remains the gold 
standard for detecting liver fibrosis. However, this study was conducted in the general 
population and performing a biopsy in these healthy participants would have been 
unethical. TE was therefore used as a non-invasive alternative for assessing the degree 
of liver fibrosis. TE has several advantages. It is non-invasive, assesses an area approx-
imately 100 times greater than a liver biopsy specimen, has good reproducibility, and 
is as effective as other non-invasive tests that assess liver fibrosis.(32-34) TE is therefore 
an ideal method for population-based studies. In two recent studies, TE was also able to 
predict 5-year survival and was as effective as the hepatic venous pressure gradient in 
predicting portal hypertension-related complications and decompensation in patients 
with chronic liver disease.(35, 36) The fact that we used LS as a continuous variable in 
our analyses – rather than categorizing LS measurements into Metavir fibrosis stages - 
enabled us to assess trends in the effects of gene variants on liver fibrosis. 
To assess the combined effect of the fibrosis-associated loci, we created ge-
netic risk scores based on those SNPs that had the highest associations with fibrosis. 
Weighting of these scores was based on effect estimates obtained in previous studies. 
In these studies, effect estimates of the fibrosis risk associated with specific alleles were 
determined only in at-risk populations, such as individuals with viral hepatitis or non-al-
coholic liver disease. Since these populations differ substantially from the individuals in 
our cohort, these effect estimates are suboptimal for application in our study. However, 
since no effect estimates are currently available from cohorts similar to ours, we were 
therefore forced to use the effect estimates determined in at-risk populations. 
The association between IFNGR2 SNPs and liver fibrosis was previously report-
ed in patients with chronic hepatitis C.(10) Nonetheless, it is desirable to validate our 
findings in a cohort of healthy participants. However, to the best of our knowledge, no 
such cohort is yet available. Therefore, studies in population-based cohorts assessing 
both genetics and liver fibrosis are warranted.
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3In conclusion, this is the first study that shows an association between SNPs 
and liver fibrosis in the general population. Our findings suggest that gene variants in 
the IFNGR2 gene influence liver fibrogenesis, irrespective of other causal factors of liver 
fibrosis. This association was even stronger in obese individuals. These results could 
have implications for the development and tailoring of interferon-gamma based thera-
py for the treatment of liver fibrosis. Influencing the interferon-gamma pathway could 
be a treatment option in liver fibrosis, regardless of its etiology. 
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3Supplementary table 3.1 Single nucleotide polymorphisms (SNP) included in the genetic risk scores. The top 
SNP of each locus was included in the genetic risk scores.
First genetic risk score Second genetic risk score
rs738409 rs738409
rs12980275 rs12980275
rs2284553 rs2284553
rs2229738 rs2229738
rs343062 rs343062
rs1140409 rs1140409
rs62522600
rs4986791
rs886277
rs4932145
rs4290029
rs2878771
Supplementary table 3.2 Quality of imputation of the single nucleotide polymorphisms.
SNP Imputation quality (R2) RS-I Imputation quality (R2) RS-II
rs738409 0.993 0.994
rs12979860 0.977 0.981
rs17882748 0.939 0.939
rs62522600 0.996 0.996
rs4290029 0.986 0.984
rs2878771 0.974 0.973
rs2229738 0.950 0.950
rs343062 0.995 0.996
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3Supplementary table 3.3 Frequencies of genotypes and call rates for all genotyped single nucleotide poly-
morphisms in the study cohort (n=1059).
SNP Genotypes Frequency, n(%) Call rate (%)
rs12980275 GG 103 (9.9%) 97.8
GA 425 (41.0%)
AA 508 (49.0%)
rs8099917 GG 40 (3.9%) 97.4
GT 339 (32.9%)
TT 652 (63.2%)
rs9976971 GG 325 (31.4%) 97.8
GA 522 (50.4%)
AA 189 (18.2%)
rs2284553 GG 373 (36.0%) 97.9
GA 502 (48.4%)
AA 162 (15.6%)
rs9808753 GG 19 (1.8%) 97.9
GA 250 (24.1%)
AA 768 (74.1%)
rs4986791 TT 3 (0.3%) 97.9
TC 102 (9.8%)
CC 932 (89.9%)
rs886277 TT 345 (33.3%) 97.7
TC 524 (50.6%)
CC 166 (16.0%)
rs4932145 GG 615 (59.3%) 97.9
GA 362 (34.9%)
AA 60 (5.8%)
rs17740066* GG 862 (83.3%) 97.7
GA 153 (14.8%)
AA 20 (1.9%)
rs1140409 AA 913 (88.9%) 97.0
AC 112 (10.9%)
CC 2 (0.2%)
*  rs17740066 was out of Hardy-Weinberg equilibrium and therefore excluded from all analyses
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4ABSTRACT
Anticoagulant therapy is a cornerstone in the treatment of different liver diseases. In 
Budd-Chiari syndrome (BCS), survival rates have increased considerably after the intro-
duction of a treatment strategy in which anticoagulation is treatment of first choice. In 
all patients diagnosed with acute portal vein thrombosis (PVT) anticoagulant therapy 
for at least 3 months is indicated. Anticoagulation should also be considered in patients 
with chronic PVT and a concurrent prothrombotic risk factor. Current evidence suggests 
that patients with PVT in cirrhosis will benefit from treatment with anticoagulation as 
well. In severe chronic liver disease the levels of both pro- and anticoagulant factors are 
decreased, resetting the coagulant balance in an individual patient and making it more 
prone to deviate to a hypo- or hypercoagulable state. An increased activity of the co-
agulation cascade is not solely a feature of chronic liver disease; it influences the devel-
opment of liver fibrosis as well. Several studies in animals and humans have shown that 
anticoagulation could prevent or improve fibrogenesis and even disease progression 
in cirrhosis. Anticoagulation is therefore a promising anti-fibrotic treatment modality.
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4INTRODUCTION
Haemostasis depends on the complex interaction of several variables including coa-
gulation factors, tissue factor and platelets. The liver produces most of the pro- and 
anticoagulant factors and is therefore essential in coagulation. 
For decades, chronic liver disease has been considered an acquired bleeding 
disorder caused by decreased levels of procoagulant factors. Prolonged activated par-
tial thromboplastin time (APTT) and prothrombin time/international normalized ratio 
(PT/INR) in these patients supported this hypothesis. However, a growing body of evi-
dence suggests this describes only part of the actual situation. 
Already in 1981 was observed that bleeding after liver biopsy was poorly 
correlated with the PT (1). Abnormal coagulation tests were also not able to predict 
bleeding risk after invasive procedures (1, 2). In patients with chronic liver disease the 
administration of factor VIIa improves the PT, but fails to control variceal bleeding or 
bleeding during liver transplantation (3, 4). Moreover, patients with chronic liver dis-
ease are at an increased risk of developing venous thromboembolism and portal vein 
thrombosis, proving that, despite the increased coagulation times, the suggested state 
of auto-anticoagulation in these patients is a myth (5, 6). Patients with cirrhosis have 
elevated levels of factor VIII and von Willebrand factor and decreased levels of protein 
C and antithrombin, resetting the balance between pro- and anticoagulant factors to a 
new, more fragile, equilibrium (7, 8). This delicate balance can be disturbed more eas-
ily, resulting in hypo- or hypercoagulation. The conventional coagulation tests, PT/INR 
and APTT, do not accurately reflect the coagulation status in patients with cirrhosis. 
These tests determine whether a patient is deficient in procoagulant factors, but reveal 
nothing about the status of the anticoagulant factors or the increase in procoagulant 
factors (9). As a result, these tests can not be used to reliable predict the bleeding risk 
in these patients. 
The coagulant imbalance in chronic liver disease can be detected with a 
thrombin-generation assay in the presence/absence of thrombomodulin, an activator 
of protein C (7). Since this laboratory test is not easy to perform, an alternative test 
using snake venom has been developed (10). In cirrhosis these tests show that the re-
duction of procoagulant factors is compensated for by a concomitant decrease in anti-
coagulant factors resulting in normal to even increased thrombin generation in these 
patients, provided there is an adequate amount of thrombocytes (11). In advancing 
stages of cirrhosis the resistance to trombomodulin increases, resulting in an increasing 
hypercoagulable state (12, 13). 
Disturbances in the coagulation cascade are also observed in vascular liver dis-
eases, providing the rationale for anticoagulant therapy in these disorders. This review 
will focus on the various applications of anticoagulant therapy in liver disease. 
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4THE ROLE OF ANTICOAGULATION IN THE TREATMENT OF 
VASCULAR LIVER DISEASES
Vascular liver diseases encompass a range of mostly rare disorders. In some of them 
anticoagulant therapy is indicated. In this review the role of anticoagulant therapy in 
BCS, PVT, idiopathic noncirrhotic portal hypertension (INCPH) and sinusoidal obstruc-
tion syndrome (SOS) will be discussed. 
Budd-Chiari syndrome
BCS is a rare disorder caused by an obstruction of the hepatic venous outflow tract. The 
location of the obstruction can be situated from the level of the small hepatic veins to 
the terminal portion of the inferior vena cava (14). In the majority of patients with BCS 
an underlying prothrombotic risk factor is present. A large European multicentre cohort 
study showed that 84% of the patients had at least 1 thrombotic risk factor; 46% of the 
total cohort had even more than 1 risk factor for thrombosis (15). It is recommended to 
test for risk factors of thrombosis, including myeloproliferative disorders, in all patients 
diagnosed with BCS (16). 
The current recommendations for management of BCS are based on cohort 
studies and expert opinions. No prospective randomized trials have been performed in 
patients with BCS due to the rarity of this disorder. BCS is however one of the most life 
threatening forms of thrombosis and anticoagulation should therefore be recommend-
ed to all BCS patients and initiated immediately to prevent progression of thrombosis 
and, if possible, to achieve recanalization (14, 16, 17). 
Table 4.1 Survival rates in patients with Budd-Chiari syndrome after anticoagulant treatment
References Patients 
included
Treatment 
strategy
Time of 
diagnosis
Survival rates
1 
ye
ar
2 
ye
ar
s
3 
ye
ar
s
5 
ye
ar
s
10
 y
ea
rs
Zeitoun et al. (18) 120 AC and/or shunt Before 1985 62 50 47
After 1985 88 75 63
Langlet et al. (19) 69 AC and/or shunt 91 82 74
Darwish Murad et al. (20) 237 AC and/or shunt/ TIPS/ LTx 82 69 62
Plessier et al. (21) 51 AC and RC/TIPS/ LTx if necessary 96 89 89
Darwish Murad et al. (15) 163 AC and RC/shunt/ TIPS/
LTx if necessary
87 82
Note: Only studies with an inclusion of 50 or more patients are described here
AC, anticoagulant treatment; shunt, surgical shunt; TIPS, transjugular intrahepatic portosystemic shunt; LTx, 
liver transplantation; RC, recanalization
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4After the introduction of a more thorough screening for prothrombotic risk 
factors and an earlier initiation of anticoagulant therapy in 1985, an improvement in 
survival was observed (see Table 4.1) (18). A survival rate of 82% at 5 years was observed 
in BCS patients treated with anticoagulation. Surgical portosystemic shunting did not 
significantly influence this survival rate (19). BCS patients with a good prognosis have 
an improved survival on anticoagulation therapy (relative risk 0.14), in contrary to pa-
tients with an intermediate (relative risk 0.88) or poor prognosis (relative risk 1.3) (20). 
Treatment according to a regimen of step-wise therapeutic procedures with increasing 
invasiveness has improved survival rates. An overall 5-year survival rate of 89% was re-
ported for a treatment regimen starting with low molecular weight heparin (LMWH) 
followed by vitamin K antagonists (VKA) targeting at an INR of 2 to 3. Additional steps 
in the management of BCS were percutaneous recanalization of the hepatic veins or 
inferior vena cava; transjugular intrahepatic portosystemic shunt (TIPS) insertion and 
liver transplantation if all previous treatments were unsuccessful (21). An international 
prospective multicentre study demonstrated an overall survival of 87% at 1 year with 
this step-up treatment regimen (15). 
In patients with BCS special features must be taken into account. The incidence 
of heparin-induced thrombocytopenia in BCS patients with a myeloproliferative disor-
der is high, with a reported incidence up to 14%, so monitoring platelet count during 
heparin treatment of these patients is advised (22-24). The most important compli-
cation of anticoagulant therapy is obviously the occurrence of bleeding events. The 
incidence of major bleeding episodes was reported to be 22.8 per 100 patient years 
(95% confidence interval (CI) 14.3-31.3), which is higher in comparison with the bleed-
ing incidence in anticoagulated patients with a venous thromboembolism. Esophageal 
varices and invasive therapeutic procedures were the most important determinants of 
major bleeding occurrence (25). 
Treatment with thrombolysis has only been studied in small samples. Due to 
major bleeding complications and limited recanalization rates thrombolysis by itself 
should be used with caution in patients with BCS. Local thrombolysis is sometimes 
used together with stenting of short segment stenosis in the hepatic veins (26, 27). 
Portal vein thrombosis
PVT is defined as the development of a thrombus in the portal vein and/or its branches. 
In a large autopsy study the estimated population prevalence of PVT was 1%. In most 
of the cases PVT was associated with cirrhosis or malignancy (28). PVT can be classified 
as acute or chronic, according to the duration of symptoms (29). In more than half of 
the patients diagnosed with PVT one or more general prothrombotic conditions are 
present. In addition, local factors, such as cirrhosis and malignancy, contribute to the de-
velopment of PVT (30). Screening for these disorders and risk factors is therefore recom-
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4mended in patients with PVT (16). The management of patients with PVT depends on 
the stage at which the thrombosis is detected and whether cirrhosis is present (14, 16). 
Non-cirrhotic non-malignant portal vein thrombosis
Acute portal vein thrombosis
In acute PVT therapy aiming at recanalization of the obstructed veins and prevention of 
further development of the thrombus is indicated to prevent portal hypertension and 
intestinal infarction due to thrombosis of the mesenteric veins (14, 16). An international 
prospective study in 102 patients with acute PVT showed recanalization of the por-
tal vein in 39% of patients treated with anticoagulant therapy. The inability to achieve 
recanalization was independently associated with the presence of ascites and an oc-
cluded splenic vein. The occurrence of bleeding, further development of the throm-
bus and death was rare (30). International consensus guidelines advise to start LMWH 
without delay in patients diagnosed with acute PVT. If the patient is stable, therapy can 
be switched to oral anticoagulation with VKA targeting at an INR between 2 and 3 (16, 
17). The optimal duration of anticoagulant treatment has not yet been established. An 
international expert panel has recommended to anticoagulate all patients with acute 
PVT for at least 3 months. If persistent prothrombotic risk factors can not be corrected 
otherwise, anticoagulation should be continued lifelong to prevent recurrent throm-
botic events (14).
Management of acute PVT with thrombolysis has only been studied in small 
cohorts. The results of these studies vary considerably, with recanalization rates ran-
ging from 15-60%. Major bleeding is a frequently observed complication of thromboly-
sis, with incidences up to 60% (27, 31, 32). Thrombolysis should therefore only be used 
with great caution.
Chronic portal vein thrombosis
Despite the development of collaterals, complications of portal hypertension will occur 
in case of a persisting thrombus in the portal venous system (33, 34). 
Patients with chronic PVT may well have prothrombotic risk factors, making 
them prone for recurrent thrombotic events (33, 34). An autopsy study showed that 
patients with PVT had an increased risk of other venous thromboembolisms (odds ratio 
2.9, 95% CI 2.2-3.7), suggesting the presence of a hypercoagulable state in patients with 
idiopathic PVT (35). Therefore, anticoagulant therapy has been suggested as treatment 
option in patients with chronic PVT to prevent further development of portal hyper-
tension and/or recurrent thrombosis. On the other hand anticoagulation may increase 
the risk of bleeding form gastro-esophageal varices, which is one of the most feared 
complications of PVT. Screening for varices in all patients with chronic PVT must be 
performed and it is recommended to treat patients with PVT-induced varices endo-
scopically according to the guidelines for cirrhotic patients (14, 16). 
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4No controlled prospective trials assessing the role of anticoagulant therapy in 
patients with chronic PVT are available. Only few studies describe anticoagulation as 
treatment modality in these patients. Current evidence shows a reduced recurrence 
rate of thrombotic events in the portal venous system and an improved survival in 
patients treated with anticoagulant therapy, including those with previous variceal 
bleeding. Reported one- and five-year survival rates are 82% and 78% respectively (36). 
Bleeding rates were not increased in anticoagulated patients (34).  Given the scarcity of 
evidence, international guidelines advise to consider long-term anticoagulant therapy 
only in patients with chronic PVT with a prothrombotic risk factor. Prophylaxis of bleed-
ing should be initiated before starting anticoagulant therapy in patients with gastroin-
testinal varices (14, 16, 17).  
Portal vein thrombosis in cirrhosis
PVT is frequently observed in patients with end stage liver disease (28). The incidence of 
PVT increases with the severity of cirrhosis and reduction of portal flow (37). In patients 
with liver cirrhosis a prevalence ranging from 8% up to 14% at the time of liver transplan-
tation has been reported (6, 38, 39). Furthermore, in cirrhotic patients with PVT higher 
prevalences of prothrombotic factors are observed in comparison with cirrhotic patients 
without PVT (6, 40). Complete and incomplete recanalization can be achieved with anti-
coagulant therapy in a significant amount of cases (42-86%) without the occurrence of 
significant bleeding events (38, 41, 42). In a recently published study, early initiation of 
anticoagulant therapy was the only parameter independently associated with recanali-
zation. After discontinuation of anticoagulant therapy a recurrent thrombotic event was 
observed in 39% of patients with initial complete recanalization (42). In a prospective 
case-control study 33 cirrhotic patients with PVT were treated with LMWH. In 6 patients 
a TIPS was additionally inserted. Complete recanalization was observed in 36% of treated 
patients; in total 63% of patients showed some form of recanalization in comparison with 
1/21 among controls. Thrombus extension occurred significantly more often in patients 
not treated with anticoagulation (p<0.001). One major bleed was observed during anti-
coagulant therapy. The rate of variceal bleedings was lower in the treatment group (43). 
Special caution should be taken in patients on the waiting list for liver trans-
plantation. In patients with a complete PVT at the time of liver transplantation, survival 
is significantly decreased. Screening for PVT and anticoagulant treatment of patients 
listed for liver transplantation may be beneficial, given the significantly higher recanal-
ization rates in anticoagulated patients in comparison with listed patients who were 
untreated, making the transplantation procedure technically more feasible (38).
Current guidelines advise to decide on a case-by-case basis which patients 
should be treated with anticoagulation. Given the recently emerged evidence, we be-
lieve that anticoagulant therapy could have a more prominent role in the treatment of 
PVT in patients with liver cirrhosis. However, in patients with severe decompensated 
cirrhosis caution should be taken in administering anticoagulant therapy.
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4Idiopathic noncirrhotic portal hypertension
INCPH is characterised by the presence of portal hypertension in the absence of liver 
cirrhosis and known causes of noncirrhotic portal hypertension (44). The etiology of 
INCPH is diverse and differs between ethnic groups, but thrombotic events in the mi-
crocirculation of the liver may well play an important role (45). Particularly in Western 
patients thrombophilia is considered an important risk factor in the etiology of this 
disease. PVT is a frequently encountered entity in patients with INCPH, especially in 
those with a concomitant human immunodeficiency virus (HIV) infection (44, 46, 47). 
Based on the current knowledge it is advised to treat INCPH with anticoagulant therapy 
in case of prothrombotic disorders and/or development of PVT (44, 46, 48-50). Further 
studies are nonetheless required to determine the effect of anticoagulant therapy on 
mortality in patients with INCPH.
Sinusoidal obstruction syndrome
SOS (previously known as veno-occlusive disease) is a disorder most commonly caused 
by toxicity from chemotherapeutic regimens used in the work-up for stem cell trans-
plantation. This syndrome is characterized by sinusoidal non-thrombotic circulatory 
obstruction (16). A meta-analysis of 12 studies showed that primary prophylaxis with 
heparin was associated with a non-significant trend towards a decreased risk of SOS in 
patients undergoing hematopoietic stem cell transplantation (pooled RR 0.9; 95% CI 
0.62-1.29). Methodological flaws and heterogeneity between studies made it nonethe-
less impossible for the authors to draw solid conclusions from the pooled analysis (51). 
Defibrotide, an anticoagulant with a relatively low risk of bleeding, was evaluated as 
treatment modality in patients with SOS in four studies (52-55). The day 100 survival of 
patients treated with defibrotide ranged from 32-65%. No bleeding episodes were ob-
served in these studies (52-55). Future studies in this area are required to determine the 
role of anticoagulation as prophylaxis and treatment modality in patients with SOS (16). 
ANTICOAGULANT THERAPY TO PREVENT FIBROGENESIS AND 
DISEASE PROGRESSION
Hypercoagulability is not only a feature of chronic liver disease, it also seems to play 
an important role in the development of fibrosis. In an autopsy study, the extent of mi-
crothrombi in branches of the hepatic and portal vein correlated with fibrosis and cir-
rhosis progression (56). In the current literature, two hypotheses are described explain-
ing how coagulation can influence liver fibrogenesis (see Figure 4.1). The first involves 
microthrombi caused by inflammation resulting in tissue ischemia with parenchymal 
extinction and fibrous septa as a consequence. The other hypothesis states that throm-
bin, produced upon activation of the coagulation cascade due to inflammation, directly 
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Figure 4.1 Schematic overview of two hypotheses describing the role of the coagulation cascade in hepatic 
fibrogenesis
4
activates hepatic stellate cells (HSC) by binding the thrombin receptor (protease acti-
vated receptor (PAR)) resulting in fibrogenesis (57). Evidence for this second, not organ 
specific, hypothesis is reported in several studies. In rodents, PAR1-antagonism or PAR-1 
knockout inhibited HSC activation and reduced fibrogenesis (58, 59). In patients with 
hepatitis C virus (HCV) infection PAR-1 gene polymorphisms influenced the progres-
sion of liver fibrosis (60). 
The association between coagulation and fibrogenesis has been supported by 
multiple clinical studies. In patients with HCV and haemophilia liver fibrosis progressed 
slower in comparison with HCV infected patients without haemophilia (61, 62). The risk 
of fast development of fibrosis was significantly increased in HCV patients who are car-
riers of the factor V Leiden mutation or prothrombin G20210A mutation (63, 64). The 
presence of other procoagulant factors has also been associated with more advanced 
fibrosis and/or cirrhosis (65-68). 
The important role of coagulation in the development of liver fibrosis, irre-
spective of etiologic pathology, suggests that prevention of fibrogenesis and possibly 
even improvement of already developed fibrosis could be achieved by inhibiting co-
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4agulation. This may be important, especially given the lack of anti-fibrotic therapy in 
current clinical practice. In several animal and laboratory studies the effect of different 
kinds of coagulation inhibiting medication on fibrogenesis was studied (see Table 4.2). 
Reduction of liver fibrosis, prevention of fibrogenesis and improvement of hepatic re-
generation was seen after administration of LMWH in rodents (69-71). An antifibrotic 
effect was also achieved by thrombin antagonism and Warfarin, a VKA (72, 73).
In humans, treatment with unfractionated heparin or LMWH for 3 weeks in 
addition to regular treatment in patients with chronic hepatitis B decreased collagen 
levels and proliferation significantly (74). 
Recently, a landmark study has been published. In this trial 70 patients with 
cirrhosis were randomized between treatment with Enoxaparin in a prophylactic dose 
for 48 weeks and no treatment. In the treated group a lower incidence of PVT was ob-
served during treatment and during 2-years of follow-up (p=0.025 and p=0.001 respec-
tively). Liver decompensation occurred significantly less frequent in the treated group 
(p<0.001). After discontinuation of Enoxaparin the incidence of decompensation was 
comparable between the two groups. The probability of survival was higher in the 
treated group (p=0.02). Enoxaparin was well tolerated; only one patient had to discon-
tinue treatment due to thrombocytopenia. The bleeding incidence did not differ be-
tween the two groups. The authors explain these results by suggesting that Enoxaparin 
might be able to improve portal hypertension induced intestinal microthrombosis, re-
ducing bacterial translocation and liver decompensation as a consequence (75). Larger, 
double-blind, multicentre trials with concurrent evaluation of portal hypertension are 
required to confirm these findings.
Table 4.2 Anticoagulant medication improves fibrogenesis in animals and humans
Drug name Class of drugs References
Animal models
SSR182289 Thrombin antagonists Duplantier (72)
Enoxaparin LWMH Abdel-Salam (69); Assy (71)
Nadroparin LWMH Abdel-Salam (69)
Dalteparin LMWH Abe (70)
Warfarin VKA Anstee (73)
Humans
Unfractionated heparin Heparins Shi (74)
Parnaparin LMWH Shi (74)
Enoxaparin LWMH Villa (75)
LMWH, low molecular weight heparin; VKA, vitamin K antagonists
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5ABSTRACT 
Background and aims
The coagulation system is known to be involved in fibrogenesis in patients with liver 
disease. We investigated whether common genetic prothrombotic risk factors are as-
sociated with an increased risk of fibrosis in the general population.
Methods
This investigation was part of the Rotterdam Study, an ongoing, population-based co-
hort study. Liver stiffness (LS) was measured using transient elastography (Fibroscan®) 
and associated with single nucleotide polymorphisms determining blood group type 
and presence of the Factor V Leiden (FVL) mutation or Prothrombin G20210A gene vari-
ant. 
Results
Reliable LS measurements and genetic data were obtained from 1055 Caucasian par-
ticipants. LS ≥8.0 kPa, suggestive of clinically relevant fibrosis, was observed in 101 sub-
jects (9.6%). Presence of FVL or prothrombin G20210A was independently associated 
with an increased risk of LS ≥8.0 kPa (OR 2.09, 95%CI 1.07-4.07, p=0.03). Combination of 
blood group type non-O and the FVL mutation or prothrombin G20210A variant result-
ed in an even higher risk of LS ≥8.0 kPa (OR 3.36, 95%CI 1.50-7.56, p=0.003). Presence 
of the FVL mutation or prothrombin G20210A variant in participants with blood group 
non-O was associated with a predicted probability of 14.3% (7.7-23.8) of LS ≥8.0 kPa. 
Conclusions
Participants carrying the FVL mutation or prothrombin G20210A variant have an in-
creased risk of clinically relevant liver fibrosis, which is even higher in blood group type 
non-O carriers. The fact that genetic prothrombotic risk factors are associated with an 
increased risk of liver fibrosis suggests that coagulation plays an important role in fibro-
genesis in the general population.
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Liver fibrosis develops as the result of a complex interplay between chronic liver injury, 
genetic susceptibility and environmental risk factors. Hypercoagulability is considered 
to be one of the factors influencing liver fibrosis development and progression in liver 
disease [1]. The exact mechanism of this influence has not yet been fully elucidated, 
but thrombin seems to play a key role. Thrombin could cause liver fibrosis by directly 
activating hepatic stellate cells by binding the protease-activated receptor 1 [2-5]. An 
alternative hypothesis describes that thrombin production causes the formation of oc-
clusive thrombi which eventually results in tissue ischemia, parenchymal extinction 
and ultimately liver fibrosis and cirrhosis [6, 7].
The Factor V Leiden (FVL) mutation, prothrombin G20210A gene variant and 
ABO blood group type non-O are well-known genetic prothrombotic risk factors. Pres-
ence of these risk factors is associated with a two- to five-fold increased risk of venous 
thrombosis [8-11]. In addition, the combined presence of FVL or prothrombin G20210A 
with blood group type non-O is known to result in an additionally increased risk of 
venous thrombosis. In previous studies, patients with both FVL and blood group type 
non-O were reported to have a 4- to 23-fold increased risk of venous thrombosis com-
pared to patients with blood group O and without FVL [12-16]. Combined presence of 
prothrombin G20210A and blood group type non-O was associated with a nine-fold 
increased risk of venous thrombosis compared to controls and a two-fold increased 
risk compared to patients with prothrombin G20210A and blood group type O [15, 17]. 
Several studies have reported an association between presence of FVL, pro-
thrombin G20210A, blood group type non-O and liver fibrogenesis in liver disease. Two 
studies in patients with chronic hepatitis C showed that the rate of fibrosis progression 
and the risk of cirrhosis was increased in patients carrying the FVL mutation [18, 19]. In 
addition, presence of FVL caused a significant acceleration of liver fibrogenesis when 
exposing mice to chronic liver injury [20]. An increased rate of liver fibrosis development 
was also observed in patients with hepatitis C carrying the prothrombin G20210A gene 
variant [21]. Finally, increased severity of liver fibrosis was observed in chronic hepatitis 
C patients with blood group type non-O, the most common prothrombotic genetic risk 
factor [12, 22]. It is unknown whether these prothrombotic risk factors also play a role in 
liver fibrogenesis in the general population. Therefore, the aim of the current study was 
to investigate whether presence of the FVL mutation, prothrombin G20210A gene vari-
ant and/or blood group type non-O is associated with an increased risk of liver fibrosis, 
assessed by using liver stiffness (LS) as proxy, in a population-based study.
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Study population and design
This study was part of the Rotterdam Study, a large ongoing prospective popula-
tion-based cohort study in the Netherlands. The rationale and study design of the Rot-
terdam Study have been described elsewhere [23]. At the start of the Rotterdam Study 
in 1990, all inhabitants of Ommoord, a suburb in the city of Rotterdam, aged 55 years 
and over were asked to participate in this study. In 2000, a new cohort was added to the 
initial study population. This second cohort consisted of participants who had moved 
to Ommoord or who had turned 55 years of age since the start of the study. Partici-
pants are evaluated at the designated research center every 3-4 years. Each assessment 
cycle consists of an extensive home interview and a range of physical examinations, 
including fasting blood collection, at the research center. As of 2009, each examination 
cycle additionally includes an abdominal ultrasound and transient elastography (TE) 
measurement. Abdominal ultrasound and TE were performed after obtaining fasting 
blood samples at the research center. The Rotterdam Study has been approved by the 
Medical Ethics Committee of the Erasmus MC University Medical Center and by the 
Ministry of Health, Welfare and Sport of the Netherlands, implementing the “Wet Bev-
olkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. All participants 
provided written informed consent to participate in the study and permission to obtain 
information from their treating physicians. 
Liver stiffness measurement and abdominal ultrasonography
Liver fibrosis was assessed non-invasively by measuring LS using TE (Fibroscan®, Echo-
sens™). A single, experienced ultrasonographer measured LS. Measurements were per-
formed on the right lobe of the liver, through the intercostal spaces, with the participant 
lying flat on his/her back with the right arm laying in maximal abduction and in between 
breathing movements. The failure rate of TE in our study was 4.3%. LS measurements 
were considered reliable if 10 valid measurements were obtained with a success rate 
of at least 60% and an interquartile range of less than 30% of the median LS. Based on 
these criteria, 21.6% of LS measurements was considered unreliable, which is compa-
rable to other studies [24, 25]. Either an M or XL-probe was used to obtain LS measure-
ments, according to the manufacturer’s recommendations. XL-probe was used to meas-
ure LS in participants with a skin capsule distance larger than 2.5 cm, as assessed by 
abdominal ultrasound. In the remaining patients LS was measured using the M-probe. 
Participants with an intracardiac device were excluded from the current study, since TE 
is contraindicated in these participants. Consistent with others, an LS cut-off value of 8.0 
kPa was used to identify clinically relevant liver fibrosis [26, 27]. In a subgroup analysis, 
LS ≥9.5 kPa was used as cut-off to determine presence of severe fibrosis or cirrhosis [28]. 
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ence of steatosis, to measure spleen size, and to examine the hepatic parenchyma 
amongst others. Images were stored digitally and re-evaluated by an expert hepatol-
ogist with large experience in abdominal ultrasound. The diagnosis of steatosis was 
determined by the ultrasound technician according to the protocol by Hamaguchi et al 
[29]. Presence of steatosis was reassessed by the expert hepatologist in all cases.
Evaluation of the Factor V Leiden mutation, prothrombin G20210A gene 
variant and ABO blood group type
Presence of FVL and prothrombin G20210A was determined by assessing the genotype 
present at rs6025 (GàT) and rs1799963 (GàA) respectively. Participants were classified 
as having either ABO blood group type O or ABO blood group type non-O based on 
the genotype present at rs505922, used as proxy for rs687289 (R2=1.0, D’=1.0) (presence 
of genotype GG at rs687289 corresponds with presence of blood group type O). To de-
termine presence of these single nucleotide polymorphisms (SNPs), DNA was isolated 
from whole blood samples and extracted according to standard automated procedures 
[30]. Genotyping in the Rotterdam study cohort was performed in batches in the Eras-
mus MC University Medical Center, Rotterdam, The Netherlands using the Infinium II 
HumanHap 550K Genotyping Bead-Chip® version 3 (Illumina Inc., San Diego, CA, USA). 
Sample-specific quality control included filters for low call rate, heterozygosity and sex 
mismatch. SNP-specific quality control measures comprised filters for call rate, minor al-
lele frequency and Hardy-Weinberg equilibrium. The Markov Chain Haplotyping pack-
age [31] was applied for imputation using the cohort of the 1000 Genomes Project as 
reference population [32]. A detailed description of these methods has been published 
elsewhere [33-36]. 
Interview, anthropometry and biochemistry
During the home interview, extensive data was obtained on demographics, medical 
history, comorbidity, alcohol consumption, smoking behavior, and drug use. Excessive 
alcohol consumption was defined as an intake of 14 or more international units (IU) of 
alcohol per week for women. For men, an intake of >21 IU per week was considered 
to be excessive. History of venous thromboembolism (VTE) was determined by using 
medical charts. VTE was defined as presence of pulmonary embolism or deep venous 
thrombosis. Trained research nurses performed anthropometric measurements at the 
research center, from which body mass index (BMI) was calculated as weight (kg) divi-
ded by height squared (m)2. 
During the assessment cycle, fasting venous blood samples were collected 
and stored at -80˚C. Alanine aminotransferase (ALT) and glucose levels were deter-
mined using automated procedures (Roche Diagnostics GmbH, Mannheim, Germany). 
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treatment for elevated blood glucose. To determine presence of viral hepatitis, hepatitis 
B surface antigen (HBsAg) and anti-hepatitis C virus (HCV) antibodies were measured 
using immunoassays (Roche Diagnostics GmbH, Mannheim, Germany). 
Statistical analysis
Baseline characteristics are expressed as numbers with proportions for categorical vari-
ables and as median with interquartile range or mean with standard deviation for con-
tinuous variables. Significance of differences in baseline characteristics was assessed 
by using Chi-squared tests (counts), Student t-tests (means) or Mann-Whitney U tests 
(medians) respectively. Logistic regression analysis was used to examine associations 
between presence of FVL, prothrombin G20210A and/or blood group type and LS ≥8.0 
kPa. In multivariable logistic regression analysis, we adjusted for age, sex, and logarith-
mically transformed ALT. In a second multivariable model was adjusted for age, sex, ALT, 
and steatosis. We adjusted for additional possible confounders in a multivariable model 
including age, sex, ALT, steatosis, presence of diabetes mellitus, current or former smok-
ing, and alcohol intake. Finally, we assessed the effect of type of Fibroscan probe used 
by adding this variable to the initial multivariable regression model.
Predicted probabilities of having LS ≥8.0 kPa were calculated for four sub-
groups based on the combination of blood group type O or non-O and presence or 
absence of FVL or prothrombin G20210A. These probabilities were calculated using lo-
gistic regression analysis adjusting for age, sex, and ALT. Probabilities were expressed 
as median percentage with their interquartile range. A p-value of <0.05 was considered 
statistically significant. Statistical analyses were performed using SPSS 21 (IBM SPSS 
Statistics for windows, Version 21.0, Armonk, NY, USA: IBM corp). 
RESULTS
Characteristics of the study population 
Reliable LS measurements were available in 1324 participants. Of these participants, 
269 were excluded, because of lack of informed consent for determining genetic vari-
ants or non-Caucasian ethnicity (n=43). As a result, the total study cohort described in 
this manuscript consisted of 1055 participants. Baseline characteristics of this cohort 
are described in Table 5.1. Mean age of these 1055 participants was 74.2 ± 5.6 years and 
528 (50.0%) of them were male. Six participants (0.6%) had a history of VTE, i.e. five had 
a history of pulmonary embolism and one had experienced a deep venous thrombosis. 
These thrombotic events all occurred between 1996 and 2010. Steatosis was detected 
at abdominal ultrasonography in 337 participants (31.9%) and 56 participants (5.4%) 
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participants (9.6%) had LS ≥8.0 kPa, suggesting presence of clinically relevant liver fi-
brosis. These participants were significantly older, more frequently male, had a higher 
BMI and had more often DM as compared to participants with LS <8.0 kPa (Table 5.1). 
Besides, they were also more frequently current or former smokers, had more often 
steatosis, a larger spleen size and higher ALT than participants with LS <8.0 kPa.
Association of the Factor V Leiden mutation, prothrombin G20210A gene 
variant, blood group type and LS ≥8.0 kPa
There was no linkage disequilibrium between the SNPs determining the FVL mutation 
(rs6025), prothrombin G20210A (rs1799963) and ABO blood group type (rs687289). Qual-
ity of imputation of rs6025 and rs1799963 was high (R2>0.99). The call rate for rs505922, 
used as proxy for rs687289, was 97.8%. All SNPs were in Hardy-Weinberg Equilibrium. 
A heterozygous FVL mutation was present in 49 participants (4.6%) and 20 
participants (1.9%) had a heterozygous prothrombin G20210A gene variant (Table 5.2), 
which is in accordance with the general Dutch population. No homozygotes for FVL or 
prothrombin G20210A were present. One participant had both variants. Blood group 
type non-O was present in 568 participants (55.0%) of our cohort. FVL or prothrombin 
Table 5.1 Baseline characteristics of the study population  
Characteristic Total cohort 
(n=1055)
LS <8.0 kPa 
(n=954)
LS ≥8.0 kPa 
(n=101)
p-value‡
Age (years) 74.2 ± 5.6 73.9 ± 5.3 76.6 ± 7.2 <0.001
Sex, male 528 (50.0%) 464 (48.6%) 64 (63.4%) 0.005
BMI (kg/m2) 26.7 ± 3.6 26.6 ± 3.4 27.7 ± 4.4 0.003
Diabetes mellitus 117 (11.3%) 94 (10.1%) 23 (23.5%) <0.001
Current or former smoking 678 (64.8%) 602 (63.7%) 76 (75.2%) 0.02
Excessive alcohol intake* 56 (5.4%) 53 (5.6%) 3 (3.0%) 0.3
History of venous thromboembolism 6 (0.6%) 6 (0.6%) 0 (0%) 1.0
Viral hepatitis 11 (1.1%) 10 (1.1%) 1 (1.0%) 1.0
Positive HBsAg 2 (0.2%) 1 (0.1%) 1 (1.0%)
Presence of anti-HCV 9 (0.9%) 9 (1.0%) 0 (0%)
Steatosis 337 (31.9%) 288 (30.2%) 49 (48.5%) <0.001
Spleen size (cm)† 9.6 ± 1.3 9.6 ± 1.3 10.2 ± 1.6 <0.001
ALT (U/L) 18 (14-23) 18 (14-22) 20 (16-30) <0.001
Fibroscan probe, M 529 (50.1%) 474 (49.7%) 55 (54.5%) 0.4
Values are represented as count (proportion), mean ± standard deviation, or median (interquartile range)
* Excessive alcohol intake was defined as intake >14 IU per week for women and >21 IU per week for men. 
† Spleen size measurements were missing in 135 participants. 
‡ p-value for the comparison of participants with LS <8.0 kPa versus those with LS ≥8.0 kPa
Abbreviations: BMI, body mass index; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; ALT, alanine 
aminotransferase; LS, liver stiffness. 
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5G20210A was present in 11.9% of participants with LS ≥8.0 kPa versus 5.9% in those 
with LS <8.0 kPa (univariable OR 2.12, 95%CI 1.12-4.01, p=0.02). Prevalence of blood 
group type non-O did not differ between participants with LS ≥8.0 kPa versus those 
without LS ≥8.0 kPa (55.6% versus 54.9% respectively, univariable OR 1.02, 95%CI 0.68-
1.54, p=0.9). None of the six participants with a history of VTE had the FVL mutation or 
prothrombin G20210A gene variant. Three of them (50%) had blood group type non-O. 
All participants with a history of VTE had LS <8.0 kPa. 
In multivariable regression analysis, adjusting for age, sex, and ALT, presence of 
FVL or prothrombin G20210A was independently associated with an increased risk of 
having LS ≥8.0 kPa (OR 2.09, 95%CI 1.07-4.07, p=0.03). In a second multivariable model, 
additionally adjusting for steatosis, comparable results were obtained for the associ-
ation between FVL or prothrombin G20210A and LS ≥8.0 kPa (OR 2.08, 95%CI 1.06-
4.07, p=0.03). Additionally adjusting for presence of diabetes mellitus, current or former 
smoking, and alcohol intake (OR 2.12, 95%CI 1.08-4.18, p=0.03 for FVL or prothrombin 
G20210A) or type of Fibroscan probe (OR 2.11, 95%CI 1.08-4.11, p=0.03 for FVL or pro-
thrombin G20210A) did not change results. 
To test the robustness of our findings, we performed an analysis in a subgroup 
of our cohort consisting of all participants without signs of steatosis, with absence of 
HBsAg and anti-HCV and an alcohol intake ≤14 IU per week for women and ≤21 IU per 
Table 5.2 Association of the Factor V Leiden mutation, prothrombin G20210A gene variant, ABO blood 
group type and presence of LS ≥8.0 kPa
Total cohort 
(n=1055)
LS <8.0 kPa 
(n=954)
LS ≥8.0 kPa 
(n=101)
OR (95%CI)* p-value*
FVL mutation† 49 (4.6%) 41 (4.3%) 8 (7.9%) 2.00 (0.90-4.46) 0.09
Prothrombin G20210A gene variant‡ 20 (1.9%) 16 (1.7%) 4 (4.0%) 2.04 (0.66-6.28) 0.2
FVL mutation or 
Prothrombin G20210A gene variant◊ 
68 (6.4%) 56 (5.9%) 12 (11.9%) 2.09 (1.07-4.07) 0.03
Blood group type non-O¥ 568 (55.0%) 513 (54.9%) 55 (55.6%) 0.92 (0.60-1.40) 0.7
Prevalences are presented as count (percentage).
*  Multivariable logistic regression analyses testing the association between the FVL mutation, prothrombin 
G20210A gene variant, ABO blood group type and LS ≥8.0 kPa. All models are adjusted for age, sex and ALT 
(U/L)
†  Determined by the genotype present at rs6025. Allele frequencies: G=97.7%, T=2.3%. Genotype distribution 
total cohort: GG=95.4%, GT=4.6%, TT=0%
‡  Determined by the genotype present at rs1799963. Allele frequencies: G=99.0%, A=1.0%. Genotype distri-
bution total cohort: GG=98.1%, GA=1.9%, AA=0% 
◊  Either an FVL mutation or Prothrombin G20210A gene variant was found in 67 participants. One additional 
participant had both an FVL mutation or Prothrombin G20210A gene variant
¥  Determined by the genotype present at rs687289. Allele frequencies: G=67.3%, A=32.8%. Genotype distri-
bution total cohort: GG=45.2%, GA=44.3%, AA=10.6% 
Abbrevations: FVL, Factor V Leiden; LS, liver stiffness; OR, odds ratio; ALT, alanine aminotransferase.
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   
     
     
         
   
   
          
        
         
    
Figure 5.1 Association between presence of the FVL mutation or prothrombin G20210A gene variant and LS 
≥8.0 kPa in the total cohort and several subgroups, i.e. participants without well-known risk factors of liver 
injury (without steatosis, with absence of HBsAg and anti-HCV and an alcohol intake ≤14 IU per week for wo-
men and ≤21 IU per week for men), participants with blood group type non-O and participants with blood 
group type O. All logistic regression models are adjusted for age, sex and ALT (U/L).
Abbreviations: FVL, Factor V Leiden; LS, liver stiffness; HBsAg, hepatitis B surface antigen; HCV, hepatitis C 
virus;  IU, international units; ALT, alanine aminotransferase
5
week for men, respectively. In this subgroup of 673 participants, presence of FVL or 
prothrombin G20210A was again independently associated with having LS ≥8.0 kPa in 
a multivariable model, adjusted for age, sex and ALT (OR 2.55, 95%CI 1.03-6.31, p=0.04) 
(Figure 5.1). 
LS ≥9.5 kPa, suggestive of presence of severe fibrosis or cirrhosis, was present 
in 49 participants (4.6%). Seven of these participants (14.3%) had the FVL mutation or 
prothrombin G20210A gene variant compared to 61 (6.1%) participants with LS <9.5 
kPa (OR 2.56, 95%CI 1.12-5.85, p=0.03 in univariable analysis and OR 2.33, 95%CI 0.98-
5.51, p=0.06 in multivariable analysis). Six out of seven participants (86%) with FVL or 
prothrombin G20210A and LS ≥9.5 kPa had blood group type non-O. When performing 
a sensitivity analysis using a LS cut-off of 6.0 kPa, we did not find an association with 
presence of FVL or prothrombin G20210A (p=0.8). 
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prothrombin G20210A gene variant on the risk of having LS ≥8.0 kPa
We subsequently divided our cohort into two groups based on blood group type. Pres-
ence of both blood group type non-O and FVL or prothrombin G20210A was associated 
with an increased risk of having LS ≥8.0 kPa, adjusted for age, sex and ALT (OR 3.36, 
95%CI 1.50-7.56, p=0.003) (Figure 5.1). Participants with blood group type O and pres-
ence of FVL or prothrombin G20210A on the other hand, did not have an increased risk 
of having LS ≥8.0 kPa (OR 1.30, 95%CI 0.36-4.68, p=0.7). 
Predicted probabilities of having LS ≥8.0 kPa were calculated for four sub-
groups based on the combination of blood group type and presence or absence of 
FVL or prothrombin G20210A. These probabilities, adjusted for age, sex, and ALT, were 
comparable for all participants with blood group type O, irrespective of whether FVL or 
prothrombin G20210A was present (4.6% (3.1-7.9) with versus 4.9% (2.9-8.0) without 
FVL or prothrombin G20210A, p=0.8). For participants with blood group type non-O 
on the other hand, the median predicted probability of having LS ≥8.0 kPa was signifi-
cantly higher for those participants with concurrent presence of FVL or prothrombin 
G20210A (14.3% (7.7-23.8)) than for participants with blood group type non-O without 
FVL or prothrombin G20210A (4.0% (2.4-6.6), p=0.008). 
DISCUSSION
In this large population-based study, presence of the FVL mutation or prothrombin 
G20210A gene variant was associated with a twofold increased risk of having clinically 
relevant liver fibrosis, as indicated by presence of LS ≥8.0 kPa. Furthermore, the com-
bined presence of FVL or prothrombin G20210A and blood group type non-O resulted 
in an even higher risk of having liver fibrosis. As a result, participants with both blood 
group type non-O and either FVL or prothrombin G20210A had a predicted probability 
of 14.3% of having clinically relevant liver fibrosis.
An increased risk of liver fibrosis was also observed in the subgroup of partic-
ipants without well-known risk factors for liver injury. This finding indicates the rele-
vance of FVL, prothrombin G20210A and blood group type non-O – common genetic 
prothrombotic risk factors – as risk factors of liver fibrosis, regardless of well-known 
liver-related causes of fibrosis. 
Our results confirm the observations of previous studies showing that the pres-
ence of FVL, prothrombin G20210A or blood group type non-O was associated with an 
increased rate of development or progression of liver fibrosis in patients with chronic 
hepatitis C [18, 19, 21, 22]. Although the combined presence of FVL or prothrombin 
G20210A and blood group type non-O resulted in a strongly increased risk of fibrosis, 
presence of blood group type non-O solely was not associated with fibrosis in our co-
hort. This might be attributed to the fact that the extent of hypercoagulability associat-
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5ed with presence of blood group type non-O is lower compared to that associated with 
FVL or prothrombin G20210A, which may result in less impact on liver fibrogenesis.
The major strength of the current study is that data was derived from a large, 
well-described, prospective, ongoing, population-based cohort. The observed preva-
lences of FVL, prothrombin G20210A and blood group type non-O in our cohort were 
comparable to those of the general Caucasian population (2-8% for FVL and prothrom-
bin G20210A [37-40] and 55% for blood group type non-O [12, 41] respectively). We did 
not demonstrate a significant association between liver fibrosis and either FVL or pro-
thrombin G20210A alone, despite the fact that we were able to include more than 1,000 
participants, as these mutations are not encountered frequently enough to provide suf-
ficient power. Nonetheless, the observed risks of having liver fibrosis were comparable 
for either presence of FVL or prothrombin G20210A alone as well as for the combined 
analyses of presence of FVL or prothrombin G20210A, indicating that each of both mu-
tations increases the risk of liver fibrosis in the general population. 
The prevalence and impact on the risk of venous thrombosis differs for FVL or 
prothrombin G20210A on one hand and blood group type on the other hand. The first 
type of risk factors has a relatively low prevalence with a more profound effect, while the 
latter is widely encountered with an associated less prominent effect on venous throm-
bosis risk. Therefore, after addressing the separate effects of these types of risk factors, 
we also showed that combined presence of FVL or prothrombin G20210A in partici-
pants with blood group type non-O was associated with an additionally increased risk 
of liver fibrosis, as was previously demonstrated for the association between the com-
bination of these genetic risk factors and venous thrombosis [15]. This additionally in-
creased risk is in line with results from previous studies and cannot be explained by the 
effects of these prothrombotic risk factors separately [12-17]. A possible explanation 
for this phenomenon could be that FVL and presence of blood group type non-O both 
cause a decrease in sensitivity for activated protein C (APC), resulting in an additional-
ly increased thrombosis risk if both factors are present [42]. The decreased sensitivity 
for APC in both conditions can be explained by 1) increased levels of factor VIII, which 
reduces APC sensitivity and is observed in participants with blood group type non-O 
[43] and 2) APC resistance, which is a hallmark feature of the FVL mutation [8]. Hence, 
this combined effect on APC sensitivity might cause an additionally increased risk of 
thrombosis [13]. In addition, factor V is required for inactivation of factor VIII by APC 
[44]. In patients with FVL, abnormal factor V will result in less inactivation of factor VIII. 
Combined with the abovementioned increased factor VIII levels associated with blood 
group type non-O, APC sensitivity is further reduced [13]. The additional increase in 
hypercoagulability could explain the enhanced risk of fibrosis in participants with both 
FVL and blood group type non-O. 
The mechanism by which the increased thrombosis risk associated with the 
combined occurrence of the prothrombin G20210A gene variant and blood group type 
non-O could occur is to be explored. Only few studies have reported on the association 
Prothrombotic genetic risk factors and liver fibrosis      99 
5between combined presence of prothrombin G20210A, blood group type non-O and 
an increased risk of thrombosis, with varying results [14, 15, 17, 45]. Our study adds to 
the understanding that the coagulation system is involved in the pathogenesis and 
acceleration of liver fibrogenesis. Based on our findings, screening for presence of FVL, 
prothrombin G20210A and blood group type might be advocated in persons with LS 
measurements suggestive of fibrosis without a clear etiologic explanation for these 
findings. If recognized in time, individuals with thrombophilic risk factors as cause of 
fibrosis might benefit from anticoagulant therapy in the prevention of progression of 
fibrosis towards cirrhosis.
A limitation of this study is that we used transient elastography, as opposed to 
liver biopsy, to assess presence of liver fibrosis in this study. However, given the invasive 
nature of liver biopsies – the gold standard to detect liver fibrosis – it would be unethical 
to perform this in healthy participants. Measuring liver stiffness with TE is an effective, 
non-invasive, reproducible and currently well-established method to assess liver fibro-
sis [28, 46, 47]. Several studies have previously described associations between genetic 
variants and various liver diseases, using transient elastography as phenotype [48-56]. 
We used a cut-off of 8.0 kPa for clinically relevant liver fibrosis, as proposed and validat-
ed in previous community-based studies [26, 27]. Roulot et al. could detect a cause of 
liver disease in all subjects with LS ≥8.0 kPa and, among those in whom liver biopsy was 
performed, almost all showed liver fibrosis or cirrhosis. Therefore, we believe this cut-
off to be suitable for detecting presence of liver fibrosis in healthy participants [26]. In 
addition, a cut-off of 9.5 kPa, suggestive of severe fibrosis or cirrhosis, was used in a sen-
sitivity analysis [57]. We did not find an association with presence of FVL or Prothrombin 
G20210A and LS ≥6.0 kPa. However, this sensitivity analysis has to be interpreted with 
caution since TE is less accurate in quantitating intermediate fibrosis [47]. For this rea-
son, applying a LS cut-off below 8.0 kPa could result in heterogeneous subgroups, as an 
increasing number of participants would be misclassified as having fibrosis. 
In conclusion, our findings suggest that presence of the FVL mutation or pro-
thrombin G20210A gene variant is associated with a twofold increased risk of liver fi-
brosis, as assessed by measuring LS, in the general population. Participants with com-
bined presence of FVL or prothrombin G20210A and blood group type non-O were 
most at risk for fibrosis. Our results suggest that these genetic risk factors may be of 
clinical relevance for the development of liver fibrosis in the general population. 
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6ABSTRACT
Background and aims
Liver fibrosis and its complications are a major health problem. In cirrhosis, von Wil-
lebrand factor (VWF) level is strongly elevated and predictive of clinical outcomes. The 
aim of the current study was to investigate whether VWF levels predict liver fibrosis, 
as measured by liver stiffness (LS), in a population-based cohort and in a subgroup of 
participants with steatosis.
Methods
Participants were recruited from the Rotterdam study, a large ongoing population-
based cohort. LS was measured using transient elastography and hepatic steatosis 
using abdominal ultrasound on average 10.7±0.4 years after determining VWF levels.
Results
In 1,228 participants (age 74.0±5.6, 49.9% male), median VWF level at baseline was 1.11 
(IQR 0.87-1.43) and median LS was 5.1 (4.1-6.3) kPa. VWF levels were positively associat-
ed with LS (p=4.7*10-5). This association persisted after adjustment for factors known to 
influence LS, i.e. age, male sex, presence of diabetes mellitus, steatosis, spleen size, ALT, 
and current or former smoking (p=0.008). VWF levels were also independently associ-
ated with presence of LS ≥9.5 kPa, suggesting severe fibrosis  (p=0.04). In a subgroup 
with steatosis (n=395), VWF was again independently associated with LS (p=0.04). If 
VWF levels were subdivided into quartiles, LS was more severe for similar VWF levels in 
participants with steatosis compared to those without steatosis. 
Conclusions
In this population-based cohort and in a subgroup of participants with steatosis, VWF 
levels at baseline were independently associated with liver fibrosis after 10 years. Our 
data suggests that VWF might be used as marker of preclinical liver fibrosis. 
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6INTRODUCTION
Liver fibrosis is a major health problem as it can ultimately result in the development of 
cirrhosis and liver cancer, which are conditions associated with a worldwide mortality 
of 1.7 million deaths per year (1, 2). Unlike cirrhosis, liver fibrosis can remain undetected 
for long. Indeed, we have previously shown that in a population-based cohort, 5.6% 
had unknowingly clinically significant liver fibrosis. We identified several factors which 
were associated with liver fibrosis in the general population, such as higher age, pres-
ence of diabetes mellitus and/or steatosis (3). However, an increasing body of evidence 
suggests that hypercoagulability should also be considered an important factor in liver 
fibrogenesis (4-13).  
One of the key players in hemostasis is von Willebrand factor (VWF). VWF is 
produced by endothelial cells and is involved in platelet adhesion and thrombus forma-
tion at sites of vascular injury. It binds coagulation factor VIII (FVIII), thereby preventing 
it from clearance (14, 15). High plasma levels of VWF are a known risk factor for arterial 
and venous thromboembolism (16-18). VWF levels in plasma are determined mainly 
by genetic factors, with a reported heritability of 53-75%, of which the ABO gene is the 
most important determinant (19-21). In addition, VWF levels are also determined by 
non-genetic factors, including age and inflammation. 
 In patients with liver cirrhosis, VWF levels are strongly elevated (22). Previous 
studies showed that VWF levels correlate with the hepatic venous pressure gradient 
and can independently predict clinical outcome, including mortality, in cirrhotic pa-
tients (23, 24). However, the cause of these elevated VWF levels is not exactly known. 
In cirrhosis, endothelial dysfunction contributes to an increase in the hepatic vascular 
tone, resulting in portal hypertension (25, 26). Since VWF is produced by endothelial 
cells, the elevation of VWF levels in cirrhosis may be caused by endothelial dysfunction 
(27, 28). 
Recently, a study in patients with chronic hepatitis C showed that VWF levels 
are elevated in patients with liver fibrosis. VWF levels increased incrementally with in-
creasing fibrosis stage (29). It is unknown whether this association between VWF and 
fibrosis is also present in a the general population. Therefore, the aim of the current 
study was to investigate the association between VWF levels and liver fibrosis – as-
sessed non-invasively using liver stiffness (LS) measurements as proxy – after 10 years 
in a large, population-based cohort and in a subgroup of participants with steatosis. 
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Study population and design
This study was part of the Rotterdam study, a large ongoing prospective population-
based cohort study conducted in Rotterdam, The Netherlands (30). For this study, indi-
viduals living in Ommoord, a suburb of the city of Rotterdam, aged 55 years and over 
were asked to participate. This resulted in a response rate of 78%. The initial cohort of 
the Rotterdam Study (RS-I) started in 1990. As of 2000 a new cohort (RS-II), consisting 
of participants who had turned 55 years or had moved into the study district, was ad-
ded to the study population. Participants visit the designated research center every 3-4 
years. Each examination cycle consists of an extensive home interview, fasting blood 
sampling and a variety of physical examinations in the research center. VWF antigen le-
vels were determined in blood samples taken during the third center visit of cohort RS-I 
(1997-1999) and during the first visit of cohort RS-II (2000-2001). Starting from 2009, 
LS measurements and abdominal ultrasound were introduced and performed in each 
examination cycle thereafter. These investigations were performed after obtaining fas-
ting blood samples at the research center. LS measurements and abdominal ultrasound 
were performed during the fifth and third visit of the RS-I and RS-II cohorts respectively 
(2009-2012). Median interval between VWF level determination and LS measurement 
was 10.7 ± 0.4 years (range 8.2-14.8 years).
The Rotterdam Study has been approved by the Medical Ethics Committee of 
the Erasmus Medical Center and by the Ministry of Health, Welfare and Sport of the 
Netherlands, implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies 
Act: Rotterdam Study)”. All participants provided written informed consent to partici-
pate in the study and permission to obtain information from their treating physicians. 
Liver stiffness measurement and abdominal ultrasonography
Presence of liver fibrosis was assessed non-invasively by measuring LS using transient 
elastography (TE) (Fibroscan®; Echosens™). LS was measured by a single, experienced 
ultrasonographer. Measurements were performed with the participant lying flat on his/
her back with the right arm laying in maximal abduction and in between breathing 
movements. The failure rate of TE in the present study was 4.0%. LS measurements 
were considered reliable if 10 valid measurements were obtained with a success rate 
of at least 60% and an interquartile range (IQR) of less than 30% of the median LS 
measurement value. Based on these criteria, the unreliability rate in the present study 
was 22.1%, which is comparable to other studies (31, 32). M or XL-probe was used to 
obtain LS measurements, according to manufacturer’s recommendations. TE was not 
performed in participants with an intracardiac device, as TE is contraindicated in this 
setting. An LS cut-off value of 8.0 kPa was used to identify clinically relevant liver fibrosis 
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6(33, 34). A more conservative LS cut-off of ≥9.5 kPa was used to determine presence of 
severe fibrosis or cirrhosis (35).
Abdominal ultrasonography (Hitachi HI VISION 900) was additionally per-
formed to assess presence of hepatic steatosis, to measure spleen size, and to examine 
the hepatic parenchyma amongst others. Images were stored digitally and re-evalu-
ated by an expert hepatologist with large experience in abdominal ultrasound. The 
diagnosis of steatosis was determined by the ultrasonographer according to the Hama-
guchi et al. scoring system (36). In all cases, presence of steatosis was reassessed by a 
hepatologist with vast experience in ultrasonography. 
Biochemistry and anthropometry
Fasting venous citrate blood samples were collected at the research center and plasma 
was stored at -80 ˚C. VWF antigen was determined by an in-house enzyme linked im-
munosorbent assay (DakoCytomation, Glostrop, Denmark), as discussed in more detail 
elsewhere (37). Alanine aminotransferase (ALT) and glucose levels were determined us-
ing automatic procedures (Roche Diagnostics GmbH, Mannheim, Germany). Diabetes 
mellitus (DM) was defined as fasting plasma glucose ≥7.0 mmol/L or drug treatment 
for elevated blood glucose. Hepatitis B surface antigen (HBsAg) and anti-hepatitis C 
virus (HCV) antibodies were measured using immunoassays (Roche Diagnostics GmbH, 
Mannheim, Germany) to determine presence of viral hepatitis. 
During the home interview, extensive data was obtained on demographics, 
medical history, comorbidity, alcohol consumption, smoking behavior, and drug use. 
Excessive alcohol consumption was defined as an intake of more than 14 units of al-
cohol per week. Trained research nurses performed anthropometric measurements at 
the research center, from which body mass index (BMI) was calculated as weight (kg) 
divided by height (m)2. 
Genetic analysis
DNA was isolated from whole blood samples and extracted according to standard au-
tomated procedures (38). Genotyping was performed in batches using the Illumina Infi-
nium II HumanHap 550K Genotyping Bead-Chip® version 3 (Illumina Inc., San Diego, CA, 
USA). Imputation was performed using the Markov Chain Haplotyping (MaCH) package 
(39), using the cohort of the 1000 Genomes Project as reference population (40). A de-
tailed description of these methods has been published elsewhere (41-44). PLINK was 
used to convert dosage data of two imputed single nucleotide polymorhpisms (SNPs) 
– rs2726953 and rs868875 – to best guess data (45). 
We analyzed ten SNPs known to be associated with VWF levels. These SNPs were 
identified in two large studies (37, 41). There was no linkage disequilibrium between the ten 
SNPs included in our analyses. All SNPs were tested for Hardy-Weinberg equilibrium (46).
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Baseline characteristics are expressed as counts with proportions for categorical varia-
bles and as median with IQR or mean with standard deviation for continuous variables. 
Differences in baseline characteristics were assessed using Chi-squared tests (counts), 
Student t-tests (means) or Mann-Whitney U tests (medians) respectively. VWF levels 
and LS measurements were logarithmically transformed prior to all analyses, as both 
variables were not normally distributed. Linear regression analysis was used to examine 
the association between VWF levels and LS. Associations between VWF levels and LS 
≥8.0 or ≥9.5 kPa were evaluated using logistic regression analyses. In multivariable re-
gression analyses, we adjusted for age, sex, DM, spleen size, ALT, BMI, hepatic steatosis, 
alcohol consumption, current or former smoking, and presence of HBsAg positivity or 
anti-HCV positivity at the moment of LS measurement. 
Genotypes were coded as 0,1 or 2 based on the number of VWF increasing al-
leles. The fractional allele count (imputed dosage of the VWF increasing allele) was used 
in case of imputation. All SNPs were analyzed in an additive genetic regression model. 
Linear and logistic regression analyses, adjusted for age and sex, were used to assess 
the association between the VWF-associated SNPs and continuous LS measurements 
and LS ≥8.0 kPa respectively. 
Statistical analyses were performed using SPSS 21 (IBM SPSS Statistics for win-
dows, Version 21.0, Armonk, NY, USA). 
RESULTS 
Study population
Reliable liver stiffness measurements were available in 1,324 participants. In this group, 
VWF levels were previously determined in 1,228 participants (92.7%). Characteristics of 
this cohort are described in Table 6.1. Mean age at time of LS measurement was 74.0 ± 
5.6 years and 49.9% was male. Median LS was 5.1 (4.1-6.3) kPa and LS ≥8.0 kPa, sugges-
tive of clinically relevant fibrosis, was present in 113 participants (9.2%). Median VWF 
level was 1.11 (IQR 0.87-1.43) IU/mL. VWF levels increased with age (β=0.005, p=6.4*10-
11). Participants with blood group type non-O had significantly higher VWF levels com-
pared to participants with blood group type O (median VWF level 1.25 (0.99-1.58) IU/
mL and 0.93 (0.76-1.14) IU/mL respectively, p<0.001). 
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measurements
VWF levels were significantly associated with increasing LS after 10.7 ± 0.4 years 
(β=0.11 log kPa per log IU/mL, p=4.7*10-5, Figure 6.1). Adjusting for blood group type 
did not alter this association (β=0.11, p=3.6*10-4). In multivariable analysis, adjusted for 
factors known to be associated with LS – age, male sex, presence of diabetes mellitus, 
hepatic steatosis, spleen size, ALT, and current or former smoking – VWF levels were 
still independently associated with LS (β=0.073 (95%CI 0.019-0.127), p=0.008) (Table 
6.2). Increasing VWF levels were also associated with an increased risk of having LS ≥8.0 
kPa, suggestive of clinically relevant liver fibrosis (OR 4.85 per log increase in VWF level, 
95%CI 1.44-16.31, p=0.01). After adjusting for the abovementioned factors in a multiva-
riable model, this association remained, though it did not reach statistical significance 
(OR 3.61, 95%CI 0.86-15.16, p=0.08). When applying a LS cut-off of 9.5 kPa, suggestive 
of presence of severe fibrosis or cirrhosis, we observed an independent association 
Table 6.1 Baseline characteristics of the study cohort at time of LS measurement 
Characteristic Total cohort 
(n=1,228)
Presence of 
steatosis 
(n=395)
Absence of 
steatosis 
(n=833)
p-value§
Age (years) 74.0 ± 5.6 73.1 ± 4.8 74.5 ± 5.9 <0.001
Male sex 613 (49.9) 212 (53.7) 401 (48.1) 0.07
Caucasian ancestry* 1069 (96.6) 343 (96.9) 726 (96.4) 0.7
BMI (kg/m2) 26.7 ± 3.5 28.9 ± 3.4 25.6 ± 3.0 <0.001
Alcohol intake >14 IU/week 143 (11.8) 74 (18.9) 69 (8.4) <0.001
Current or former smoking 782 (64.2) 271 (69.1) 511 (61.9) 0.01
Diabetes mellitus 143 (11.9) 82 (21.2) 61 (7.5) <0.001
Viral hepatitis 13 (1.1) 6 (1.5) 7 (0.9) 0.4
Positive HBsAg 1 (0.1) 0 1 (0.1) 1.0
Presence of anti-HCV 12 (1.0) 6 (1.5) 6 (0.7) 0.2
Spleen size (cm)¥ 9.6 ± 1.3 9.9 ± 1.4 9.5 ± 1.3 <0.001
Liver stiffness measurement (kPa) 5.1 (4.1-6.3) 5.4 (4.4-6.9) 4.9 (4.0-6.1) <0.001
Fibroscan probe, M 608 (49.5) 135 (34.2) 473 (56.8) <0.001
ALT (U/L) 18 (14-23) 21 (16-28) 17 (13-21) <0.001
Blood group type non-O† 552 (55.1) 189 (58.7) 363 (53.5) 0.1
Von Willebrand factor level (IU/mL)‡ 1.11 (0.87-1.43) 1.12 (0.91-1.47) 1.10 (0.86-1.38) 0.1
Values are represented as count (proportion), mean ± standard deviation, or median (interquartile range)
* Data on ethnicity was missing for 121 participants. 
¥ Spleen size measurements were missing in 160 participants. 
† Blood group type was missing in 227 participants.
‡ Von Willebrand factor level was measured 10.7 ± 0.4 years before liver stiffness measurement
§ p-value for the comparison of participants with steatosis versus those without steatosis
Abbreviations: BMI, body mass index; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; ALT, alanine 
aminotransferase. 
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Figure 6.1 Association between von Willebrand factor Antigen levels (IU/mL) and liver stiffness measure-
ments (kPa) after 10.7 ± 0.4 years (n=1,228). Liver stiffness measurements increase significantly with increa-
sing VWF levels at baseline. 
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Table 6.2 Association between von Willebrand factor levels and liver stiffness measurements in linear multi-
variable regression analyses (n=1,228)
Variable β (95%CI) p-value
Age (years) 0.006 (0.004-0.008) <0.001
Male sex 0.062 (0.043-0.081) <0.001
Diabetes Mellitus 0.033 (0.005-0.060) 0.02
Spleen size (cm) 0.015 (0.008-0.022) <0.001
ALT (U/L) 0.002 (0.001-0.003) <0.001
BMI (kg/m2) -0.003 (-0.005-<0.001) 0.07
Steatosis 0.038 (0.017-0.058) <0.001
Alcohol consumption (drinks/week) <0.001 (-0.002-0.001) 0.5
Current or former smoking 0.020 (0.002-0.039) 0.03
HBsAg or anti-HCV positive 0.015 (-0.076-0.105) 0.8
Von Willebrand factor levels (IU/mL) 0.073 (0.019-0.127) 0.008
Abbreviations: ALT, alanine aminotransferase; BMI, Body Mass Index; HBsAg, hepatitis B surface antigen; 
HCV, hepatitis C virus
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with VWF levels in both univariable (OR 7.45, 95%CI 1.37-40.44, p=0.02) and multivari-
able analysis (OR 8.02, 95%CI 1.09-59.28, p=0.04) (Table 6.3). There was no interaction 
between VWF levels and the other covariables included in the multivariable analyses 
for the association with LS.
Data on the VWF-associated SNPs was available in 1033 Caucasian partici-
pants (84.1% of the total cohort), due to lack of informed consent or non-Caucasian 
ethnicity in 195 participants. Genotypes and minor allele frequencies of these 10 SNPs 
are shown in Supplementary Table 6.1. Quality of imputation was high for all SNPs (R2 
≥0.97) except for rs868875, which had moderate imputation quality (R2=0.78). One SNP, 
rs216321, located in the VWF gene, was associated with increased LS in an additive 
linear regression model (β=0.026 log kPa per VWF increasing allele, p=0.02). However, 
after adjustment for multiple testing, this association was not considered statistically 
significant. The other VWF-associated SNPs, including the SNP in the ABO gene, were 
not associated with increasing LS (p-values ≥0.07).
 
Von Willebrand factor levels and liver stiffness measurements in participants 
with steatosis
Steatosis was detected at abdominal ultrasonography in 395 participants (32.2%). Par-
ticipants with steatosis were significantly younger, had a higher BMI, had more often an 
excessive alcohol intake, and were more often current or former smokers compared to 
participants without steatosis (Table 6.1). In addition, DM, a higher spleen size, higher 
LS, use of the XL-probe and higher ALT were more often observed in participants with 
steatosis. VWF levels at baseline did not differ between participants with and without 
Table 6.3 Association between von Willebrand factor level and liver stiffness measurement ≥9.5 kPa in logis-
tic multivariable regression analyses (n=1,228)
Variable OR (95%CI) p-value
Age (years) 1.10 (1.05-1.16) <0.001
Male sex 1.77 (0.87-3.63) 0.1
Diabetes Mellitus 2.03 (0.94-4.35) 0.07
Spleen size (cm) 1.37 (1.10-1.70) 0.005
ALT (U/L) 1.04 (1.02-1.06) <0.001
BMI (kg/m2) 1.01 (0.91-1.12) 0.9
Steatosis 1.19 (0.58-2.41) 0.6
Alcohol consumption (drinks/week) 0.99 (0.94-1.04) 0.8
Current or former smoking 2.12 (0.94-4.79) 0.07
HBsAg or anti-HCV positive 2.61 (0.30-22.69) 0.4
Von Willebrand factor levels (IU/mL) 8.02 (1.09-59.28) 0.04
Abbreviations:  ALT, alanine aminotransferase; BMI, Body Mass Index; HBsAg, hepatitis B surface antigen; 
HCV, hepatitis C virus
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Figure 6.2 Association between von Willebrand factor Antigen level quartiles and liver stiffness measure-
ments (kPa) after 10.7 ± 0.4 years in participants with and without steatosis respectively. Associations were 
adjusted for age and sex. Liver stiffness measurements were significantly higher for participants with steato-
sis for all VWF quartiles. 
VWF quartiles: 1) 0.36-0.87 IU/mL 2) 0.88-1.11 IU/mL 3) 1.12-1.43 IU/mL 4) 1.44-3.03 IU/mL.
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steatosis after 10.7 ± 0.4 years (median VWF level 1.12 (0.91-1.47) IU/mL versus 1.10 
(0.86-1.38) IU/mL respectively, p=0.1). However, presence of steatosis was associated 
with higher VWF levels at baseline after adjustment for age and sex (β=0.021 log IU/mL, 
p=0.03). In the subgroup of participants with steatosis, VWF levels were associated with 
increasing LS in both univariable (β=0.13 log kPa per log IU/mL, p=0.009) and multiva-
riable regression analyses (β=0.11, p=0.04). Participants with steatosis had higher LS 
in comparison with participants without steatosis for similar VWF levels, when divided 
into quartiles (p-values 0.01; 0.03; 0.01 and <0.001 for VWF quartiles 1,2,3, and 4 respec-
tively, adjusted for age and sex) (Figure 6.2). LS ≥8.0 kPa was observed in 55 participants 
(13.9%) with steatosis and 23 participants (5.8%) with steatosis had LS ≥9.5 kPa. We did 
not observe an association between VWF levels and presence of LS ≥8.0 kPa or ≥9.5 kPa 
in the subgroup of participants with steatosis (OR 2.22, 95%CI 0.39-12.49, p=0.4 and OR 
3.48, 95%CI 0.27-45.51, p=0.3 respectively). 
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6DISCUSSION 
In this large, population-based study, VWF levels were associated with liver fibrosis – as-
sessed non-invasively using LS measurements as proxy – after 10 years. In addition, we 
observed an association between VWF levels and LS in a subgroup of participants with 
steatosis. Participants with steatosis had more severe LS values for similar VWF levels 
compared to participants without steatosis. 
In liver cirrhosis, VWF is a predictor of clinically significant portal hyperten-
sion and mortality (23, 24). However, the mechanism resulting in elevated VWF levels 
in cirrhosis remains to be elucidated (22). It has been hypothesized that this elevation 
may be caused by endothelial dysfunction (27, 28), since endothelial dysfunction con-
tributes to the development of portal hypertension (25, 26) and VWF is produced by 
endothelial cells. In addition, the hepatic synthesis of VWF is increased in patients with 
cirrhosis (47). Cirrhosis is known to be associated with a delicate hemostatic balance, 
characterized by a decrease in most procoagulant and anticoagulant factors, but with 
an increase in VWF levels (48). This hemostatic balance may be easily shifted towards 
a hypercoagulable state. Since VWF is an important promoter of hemostasis, increased 
VWF levels in cirrhosis might contribute to this hypercoagulable state. It has been 
demonstrated repeatedly that hypercoagulability is not only a feature of cirrhosis, but 
also a driver of liver fibrogenesis (4-13). Therefore, there might be a role for VWF in pro-
moting liver fibrosis. This is supported by the previous finding that blood group type 
non-O, known to be associated with 25% higher VWF levels compared to blood group 
type O (49, 50), was associated with increased severity of fibrosis in patients with chron-
ic hepatitis C (8). A recent study within the Rotterdam Study cohort on the other hand, 
did not find an association between blood group type solely and presence of clinically 
relevant fibrosis. However, the combined presence of blood group type non-O and the 
factor V Leiden mutation or prothrombin G20210A variant did result in a markedly in-
creased risk of fibrosis in these healthy individuals (7). 
Although it is well-established that VWF levels are elevated in patients with cir-
rhosis, to our knowledge only one recent study has assessed the association between 
VWF levels and liver fibrosis. This study in patients with chronic hepatitis C found that 
VWF levels increase with increasing fibrosis stage. The authors concluded that VWF 
can be used as non-invasive marker to assess presence of significant and advanced 
liver fibrosis and cirrhosis in patients with hepatitis C (29). Our findings in a large pop-
ulation-based cohort of middle-aged and elderly individuals confirm the association 
between VWF levels and liver fibrosis, as VWF levels were positively associated with 
LS measurements after 10 years in the present study. Moreover, VWF levels at base-
line were independently associated with an increased risk of LS ≥9.5 kPa, suggesting 
presence of advanced fibrosis or cirrhosis, 10 years later. In addition, the association 
between VWF and LS was also observed in a subgroup of participants with steatosis, 
suggesting this association is irrespective of the etiology of fibrosis. 
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6We did not find an association between SNPs previously demonstrated to in-
fluence VWF levels and LS. Also the SNP determining blood group type, the most im-
portant genetic determinant of VWF levels (19-21), was not associated with increasing 
LS. In addition, adjusting for blood group type did not alter the association between 
VWF levels and LS. These findings are in line with a previous study within this cohort 
showing a lack of association between blood group type and presence of clinically rel-
evant liver fibrosis (7). Therefore, although the current study shows that VWF levels are 
associated with liver fibrosis after 10 years, the exact mechanism of this relationship 
remains to be clarified by future studies. 
Strengths of the current study are that we were able to include a large cohort 
of participants from an ongoing well-described population-based study. In addition, 
VWF levels, LS measurements and genetic data were available for the vast majority of 
these participants, enabling us not only to investigate the association between VWF 
levels and fibrosis, but also to provide more insight in the association between VWF-as-
sociated SNPs and fibrosis in the same study. A limitation of the current study is that 
we did not use liver biopsy, the gold standard, to assess presence of liver fibrosis. In-
stead, fibrosis was assessed non-invasively in this study, since performing a liver biopsy 
in healthy participants is not feasible. We assessed fibrosis by using TE to measure LS. 
TE is a reproducible, non-invasive, rapid and well-established method to assess liver 
fibrosis (35, 51, 52). TE has been used as phenotype to assess fibrosis in healthy partic-
ipants in several previous studies (3, 7, 33, 34, 53, 54). In the present study, presence of 
steatosis was investigated using abdominal ultrasonography. This method allows for 
accurate identification of steatosis and is the method of choice for screening in popu-
lation-based settings (55).
In conclusion, VWF levels were associated with liver fibrosis after a mean of 
10.7 years in this large population-based cohort and in a subgroup with steatosis. These 
findings suggest that VWF might be used as marker of preclinical liver fibrosis. As VWF is 
able to predict mortality and clinical outcomes in patients with cirrhosis (23, 24), future 
studies should focus on the role of VWF levels in predicting fibrosis progression and 
clinical outcomes in liver fibrosis.
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6Supplementary table 6.1 Genotype and minor allele frequencies of the single nucleotide polymorphisms 
(n=1,033)
SNP Genotypes Frequency, n (%) VWF increasing allele Allele frequency*
rs9390459 AA 169 (16.4) G 0.59
GA 505 (48.9)
GG 359 (34.8)
rs2726953 CC 498 (48.2) T 0.31
CT 430 (41.6)
TT 105 (10.2)
rs687621 TT 466 (45.2) C 0.33
TC 457 (44.2)
CC 109 (10.6)
rs1063857 TT 455 (44.0) C 0.34
TC 445 (43.1)
CC 133 (12.9)
rs4981022 CC 118 (11.4) T 0.67
CT 450 (43.6)
TT 465 (45.0)
rs7978987 GG 438 (42.2) A 0.35
GA 465 (45.0)
AA 130 (12.6)
rs10133762 GG 342 (33.3) T 0.42
GT 497 (48.4)
TT 187 (18.2)
rs868875 GG 42 (4.1) A 0.76
GA 408 (39.5)
AA 583 (56.4)
rs216321 TT 8 (0.8) C 0.92
TC 154 (15.0)
CC 865 (84.2)
rs2283333 TT 11 (1.1) C 0.90
TC 188 (18.2)
CC 834 (80.7)
Abbreviations: SNP, single nucleotide polymorphism; VWF, von Willebrand factor
* Allele frequencies of the von Willebrand factor level increasing allele
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7We studied the role of the recently identified CALR mutations in 141 patients with 
Budd-Chiari Syndrome (BCS) or portal vein thrombosis (PVT) in a large multinational 
cohort. A CALR mutation was present in one of the 141 patients (0.7%). This patient 
was previously diagnosed with primary myelofibrosis. This results in CALR positivity in 
one out of 44 (2.3%) patients with myeloproliferative neoplasm (MPN), and in one of 
11 (9.1%) JAK2V617F negative patients diagnosed with MPN. We suggest that analysis 
of CALR mutations should be performed in JAK2V617F negative BCS and PVT patients. 
BCS and non-malignant, non-cirrhotic PVT are rare vascular liver diseases. The etiology 
of these diseases encompasses both inherited and acquired risk factors, of which MPN 
are the most common with a prevalence ranging between 20-50% (1-3). Detecting pre-
sence of MPN in patients with BCS and PVT is important, given the prognostic and po-
tential therapeutic implications regarding anticoagulant therapy (4, 5). However, diag-
nosing MPN in patients with BCS and PVT is often difficult as portal hypertension caused 
by the obstruction of the hepatic veins and/or portal vein can explain splenomegaly, 
and decreases peripheral blood cell counts through hypersplenism (6). The discovery of 
the JAK2V617F mutation has greatly improved the ability to non-invasively detect MPNs 
in patients with BCS and PVT (7-9). However, in the absence of the JAK2V617F mutation, 
diagnosing MPN can still be challenging and a bone marrow biopsy remains required in 
most patients and may still be inconclusive (4, 10). Recently, exome sequencing resulted 
in the detection of mutations in CALR in patients with essential thrombocythemia (ET) 
or primary myelofibrosis (PMF) lacking JAK2V617F and MPL mutations. CALR mutations 
were present in 67%-88% of these patients (11, 12). Identification of CALR mutations in 
patients with BCS and PVT without the characteristic blood counts could improve the 
ability to diagnose ET and PMF. The aim of our study was to determine the prevalence 
and role of CALR mutations in patients with BCS and non-malignant, non-cirrhotic PVT.
In this case-control study, patients and controls were recruited from the Euro-
pean Network for Vascular Disease of the Liver (EN-Vie) study cohort. This study cohort 
has been described in detail elsewhere (2, 3). For this study, consecutive, incident cases 
of BCS and non-malignant, non-cirrhotic PVT were enrolled between 2003 and 2005 and 
prospectively followed in nine European countries. In addition, healthy, unrelated, pop-
ulation-based controls were included. These controls did not have a history of thrombo-
sis and fulfilled the same age criteria as the included patients (13). Blood samples were 
obtained at diagnosis. DNA was extracted from whole blood according to local standard 
methods. DNA samples were stored in the Erasmus MC University Medical Center in 
Rotterdam at -80°C until analysis. Presence of CALR mutations was determined with a 
PCR fragment analysis examining exon 9. Results of this PCR were analyzed using Gen-
emapper 4.0 as previously described (12). MPNs were diagnosed by performing a bone 
marrow biopsy (in 49% of patients), JAK2V617F mutation detection (in 98% of patients), 
EPO measurements (in 20% of patients), red cell mass measurement (in 11% of patients) 
and/or spontaneous erythroid colony formation (SECF) testing (in 18% of patients).
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7DNA samples were available from 77 patients with BCS, 75 patients with PVT 
and 76 controls. Determination of CALR mutation was successful in 92% of all samples, 
resulting in an inclusion of 70 BCS patients, 71 patients with PVT and 68 controls in 
the current analysis. Baseline characteristics and underlying etiological factors of this 
cohort are shown in Table 7.1. Median age of patients with BCS and PVT was 43.1 (31.0-
53.4) years and 80 (57%) were female. One or more underlying prothrombotic factor(s) 
could be identified in 87% of all patients with BCS and PVT. MPN was present in 44 
patients (31.2%) of whom 26 (37%) patients with BCS and in 18 (26%) patients with 
PVT. The median age of patients with MPN was 44.6 (31.1-51.6) years compared to 
43.1 (30.2-55.0) years in patients without MPN (p=0.95). There was also no difference 
in male/female distribution between the patients with and those without MPN (61% 
and 54% female respectively, p=0.4). Additional prothrombotic risk factors were diag-
nosed in 32 (73%) of all patients with MPN. Thirty-three of the 44 patients with MPN 
had a JAK2V617F mutation (75%). Of the eleven remaining patients with MPN without 
JAK2V617F, three (27%) had polycythemia vera (PV) (diagnosis based on bone marrow 
biopsy findings and SECF), two patients (18%) had ET, two (18%) had PMF, two (18%) 
were unclassifiable and two (18%) had occult MPN, at that time tested by SECF. The di-
agnosis of MPN was based on the above-mentioned criteria and reviewed by a hemato-
logic expert (FWGL). A CALR mutation was present in only one MPN patient (2.3% of all 
patients with MPN). In the 97 BCS and PVT patients without MPN no CALR mutation was 
detected. PMF or ET was present in 17 patients with BCS and PVT in our cohort (39% of 
all patients with MPN). Of these 17 patients, 13 (77%) carried a JAK2V617F, one (6%) had 
a CALR mutation, and 3 (17%) did not have a known MPN-associated mutation. 
The patient with a CALR mutation was a 46-year old female Dutch patient with 
a cardiomyopathy and PMF since 1981, resulting in severe splenomegaly requiring 
splenectomy in 2003. Pathological examination of the spleen showed extensive extra-
medullary hematopoiesis with signs of multiple non-recent splenic infarctions. Post-
operatively, she was diagnosed with PVT including thrombosis of the splenic vein and 
superior mesenteric vein. At that time, a bone marrow biopsy revealed end-stage PMF. 
She did not carry a JAK2V617F mutation. The CALR mutation detected in this patient 
was a type 1 mutation, the most common encountered CALR mutation, characterized 
by a 52-bp deletion in exon 9 (11, 12). At the moment of diagnosis of PVT, platelet count 
in this patient was increased (396*109/L), white blood cell count was 6.3*109/L, and he-
moglobin was 5.8 mmol/L. During follow-up, she presented with several episodes of 
gastrointestinal bleeding twelve months after diagnosis of PVT, caused by peptic ulcers 
under treatment of oral anticoagulants and non-steroidal anti-inflammatory drugs and 
angiodysplasia of the cecum. Fourteen months after diagnosis of PVT, this patient died 
of progressive multi-organ failure after presenting with gastrointestinal bleeding re-
sulting in circulatory collapse.
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7Table 7.1 Baseline characteristics and etiological factors of the study cohort  
BCS
(n=70)
PVT
(n=71)
Age, years 36.4 (26.4-50.7) 49.8 (41.6-57.2)
Female sex 41 (58.6) 39 (54.9)
ALT (U/L) 65 (32-169) 40 (24-61)
Platelets (*109/L) 224 (126-375) 263 (164-403)
White blood cell count (*109/L) 9.7 (6.7-13.6) 9.5 (7.6-12.8)
Hemoglobin (mmol/L) 8.6 (7.5-9.7) 8.2 (7.2-9.3)
Inherited thrombophilia* 15 (21.4) 16 (22.5)
Factor V Leiden mutation 10 (14.3) 4 (5.7)
Prothrombin gene G20210A 2 (2.9) 8 (11.4)
Protein C deficiency 1 (1.5) 1 (1.6)
Protein S deficiency 0 3 (4.9)
Antithrombin deficiency 2 (3.0) 2 (3.3)
Acquired thrombophilia* 54 (77.1) 52 (73.2)
Myeloproliferative neoplasms 26 (37.1) 18 (25.7)
Polycythemia vera 9 (34.6) 3 (16.7)
Essential thrombocytosis 5 (19.2) 7 (38.9)
Primary myelofibrosis 2 (7.7) 3 (16.7)
Unclassifiable 6 (23.1) 4 (22.2)
Occult 4 (15.4) 1 (5.6)
JAK2V617F present 19 (27.1) 14 (19.7)
Antiphospholipid antibody syndrome 21 (30.0) 19 (27.5)
Paroxysmal nocturnal hemoglobinuria 9 (12.9) 0
Hormonal risk factors† 16 (39.0) 18 (46.2)
Non-hematological systemic disorder 8 (11.4) 2 (2.8)
History of thrombosis 14 (20.0) 16 (22.5)
Local risk factor¥ 11 (15.7) 19 (26.8)
Single risk factor 24 (34.3) 23 (32.4)
Multiple risk factors 39 (55.7) 37 (52.1)
No risk factor 7 (10.0) 11 (15.5)
Results are expressed as median (interquartile range) for continuous variables and as count (proportion) for 
categorical variables
* Patients could have more than one etiological factor simultaneously
† Presence of hormonal risk factor was missing in 29 patients with BCS and 32 patients with PVT
¥ Local risk factors were defined as presence of an abdominal trauma, abdominal intervention, and/or intra-
abdominal infection, i.e. pancreatitis, liver abcess, cholangitis, cholecystitis, intra-abdominal abcess, diver-
ticulitis, appendicitis, gastroenteritis, and/or spontaneous bacterial peritonitis with or without sepsis
BCS: Budd-Chiari syndrome; PVT: portal vein thrombosis; ALT, alanine aminotransferase
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7In summary, in this large European cohort of 141 newly diagnosed patients 
with BCS and non-malignant, non-cirrhotic PVT, a somatic CALR mutation was present 
in only one patient with PVT and in none of the patients with BCS. This resulted in a 
prevalence of CALR mutations of 0.7% (one of 141) in the total cohort, 2.3% (one of 
44) in all patients with MPN, and 9.1% (one of 11) in all patients with MPN without 
JAK2V617F.  Importantly, no CALR mutations were detected in patients without MPN 
or controls. 
Recently, the association between MPN and somatic mutations in CALR was 
described for the first time (11, 12). CALR mutations were present only in PMF and ET 
lacking JAK2V617F and MPL mutations. In patients with PMF or ET, the prevalence of 
CALR mutations was reported to be 17-24% (11, 12). In our cohort with only hepatic 
and/or portal vein thrombosis, the observed prevalence of CALR mutations in patients 
with PMF or ET was considerably lower (6%). This might be attributable to the fact that 
patients with a CALR mutation have a lower risk of thrombosis compared to patients 
with a JAK2V617F mutation. This decreased thrombosis risk may in turn result from the 
lower hemoglobin and white blood cell counts observed in patients with a CALR mu-
tation compared to MPN patients without a CALR mutation (11, 12). This finding is in 
line with previous reports that state that CALR-mutant MPN patients do not develop 
thrombosis as often as patients carrying JAK2V617F, resulting in the lower prevalence 
of CALR mutation frequency in our cohort of patients with BCS and PVT as compared 
to this prevalence in cohorts of patients with MPN (14, 15). No CALR mutations were 
observed in the control group in our study, as was expected based on the results of the 
study by Nangalia et al (11). Interestingly, CALR mutations were also absent in patients 
with lymphoid cancers or solid tumors in that study, suggesting that CALR mutations 
might be used as a marker to detect presence of MPN in BCS and PVT. Two other studies 
recently investigated presence of CALR mutations in patients with BCS and PVT, with 
comparable results. Turon et al. found a prevalence of 1.9% CALR mutations in a Spanish 
cohort of patients with BCS and PVT and no CALR mutation was present in a cohort of 
144 patients with abdominal vein thrombosis, also including renal vein, splenic vein 
and mesenteric vein thrombosis (16, 17). In the current study, we included 141 consec-
utive patients with BCS and PVT who were extensively screened for etiological factors 
and prospectively followed in nine European countries. None of the patients included 
in the current study was previously described in the other studies assessing presence 
of CALR mutations in BCS and PVT. 
In conclusion, CALR mutations are rare in patients with BCS and PVT with a 
prevalence of 0.7% in the total cohort and 2.3% in patients with MPN. This low prev-
alence is probably due to the relatively lower risk of thrombosis in CALR-mutant pa-
tients compared to patients with a JAK2V617F mutation. Despite this low prevalence, 
we believe testing for CALR mutations should be considered in patients with BCS and 
PVT who are JAK2V617F negative, as diagnosing MPN is often difficult in these patients 
due to masked blood cell counts because of portal hypertension, occult gastrointesti-
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7nal bleeds and/or hypersplenism. Screening for somatic CALR mutations is an easy to 
perform diagnostic method that could aid in diagnosing MPN with limited burden for 
the patient.
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8ABSTRACT
Background and aims
The etiology of portal vein thrombosis (PVT) and Budd-Chiari syndrome (BCS) shows 
overlap with that of venous thromboembolism (VTE). The aim of this study was to as-
sess the role of candidate single nucleotide polymorphisms (SNPs), which were recently 
identified to increase the risk of VTE, as potential risk factors for PVT and BCS. 
Methods
Patients were recruited from the European Network for Vascular Disease of the Liver 
(EN-Vie) study cohort. Genotyping of six SNPs – in ABO, STXBP5, VWF, CYP4V2, GP6, and 
SERPINC1 – was performed using a Taqman assay. Results were validated in a clinical 
tertiary referral population in three countries. 
Results
In this study, 77 patients with PVT, 77 patients with BCS and 81 healthy controls were 
included. Blood group type non-O, determined by the SNP in ABO, was independently 
associated with an increased risk of PVT compared to both controls (OR 3.1 (95%CI 1.4-
6.9), p=0.005) and BCS (OR 3.0 (95%CI 1.4-6.5), p=0.006). No association between blood 
group non-O and risk of BCS was observed (OR 0.8 (95%CI 0.5-1.8),p=0.8). The associati-
on between blood group non-O and PVT was not observed in the validation cohort (OR 
1.36 (95%CI 0.77-2.39), p=0.3). None of the other VTE-associated SNPs was associated 
with an increased risk of PVT or BCS.
Conclusions
None of the six genetic variants associated with VTE was consistently identified as risk 
factor for PVT or BCS. These findings support the site-specificity of venous thrombosis 
and suggest that other risk factors are of greater importance in splanchnic vein throm-
bosis.
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Budd-Chiari syndrome (BCS) and non-malignant, non-cirrhotic portal vein thrombosis 
(PVT) are rare vascular liver diseases, also known as splanchnic vein thrombosis (SVT), 
characterized by obstruction of the hepatic venous outflow tract and the portal vein, 
respectively (1, 2). In the pathogenesis of both BCS and PVT, prothrombotic disorders 
play a pivotal role. These prothrombotic disorders can be subdivided into genetic and 
acquired risk factors. Together, these risk factors account for approximately 75-85% of 
the etiology of SVT. As a result, 15-25% of the etiology of these disorders is currently 
still unknown (3, 4). Among the previously identified prothrombotic risk factors, con-
siderable overlap exists between the etiology of SVT and the more common forms of 
venous thromboembolism (VTE) as deep venous thrombosis (DVT) and pulmonary em-
bolism (PE). The factor V Leiden mutation, prothrombin G20210A gene variant, protein 
C deficiency, protein S deficiency and antithrombin deficiency – all well-known genetic 
prothrombotic risk factors – play an important role in the pathogenesis of both VTE and 
SVT (3-10).
In 1969, a relationship between ABO blood group type and risk of VTE was de-
scribed for the first time. Individuals with blood group type non-O, which is associated 
with higher levels of von Willebrand factor (VWF) and coagulation factor VIII, had a two- 
to fourfold increased risk of VTE compared to blood group type O (11-13). Combining 
this increased VTE risk with a blood group type non-O prevalence of 55% in Caucasians 
makes blood group non-O to be one of the most important genetic risk factors for VTE 
(14-17). 
A recent large meta-analysis of five genome-wide association studies iden-
tified eight genes in which single nucleotide polymorphisms (SNPs) were associated 
with VWF levels (18). One of the described SNPs was located in the ABO gene, already 
known to be associated with VTE (12, 14, 15, 17). In a large case-control study, SNPs in 
two of the seven other genes associated with VWF and FVIII levels, STXBP5  and VWF, 
were found to be associated with an increased risk of VTE as well (19). 
Besides that, three SNPs in the CYP4V2, GP6, and SERPINC1 gene were strongly 
associated with DVT in a combined analysis of three large case-control study cohorts 
(20). A meta-analysis of five case-control studies confirmed the role of these three SNPs 
as risk factors of VTE among Caucasians (21). 
All these genetic risk factors for VTE – located in the ABO, STXBP5, VWF, CYP4V2, 
GP6, and SERPINC1 gene – have not been tested in patients with SVT yet. Based on the 
fact that other procoagulant factors are shared by both disorders, we hypothesized that 
these genetic factors would also be important risk factors for SVT. Therefore, the aim 
of the current study was to elucidate whether these novel candidate SNPs are also risk 
factors for SVT in the largest study population of patients with BCS and PVT to date. 
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Study cohort
For the current study, patients and controls were recruited from the European Network 
for Vascular Disease of the Liver (EN-Vie) study cohort. This cohort consists of consecu-
tive patients with newly diagnosed non-cirrhotic, non-malignant PVT and BCS. These 
patients were enrolled between October 2003 and October 2005 and prospectively 
followed in academic and large regional hospitals in nine European countries. More 
details regarding the EN-Vie study cohort can be found elsewhere (3, 4). BCS was di-
agnosed by radiological imaging and defined as a hepatic venous outflow obstruction 
and its manifestations, regardless of the cause and level of obstruction, ranging from 
the small hepatic veins to the entrance of the inferior vena cava into the right atrium. 
PVT was defined as radiological evidence of solid material in the portal vein lumen or its 
left or right branch. PVT patients with concomitant cirrhosis or abdominal malignancies 
were excluded. Patients underwent a systematic etiological work-up per protocol. At 
the moment of diagnosis and at several time-points during follow-up, extensive data 
was obtained on clinical symptoms, etiological factors, laboratory parameters, and ra-
diological findings. Risk factors for VTE were investigated as reported previously (22, 
23). 
The EN-Vie study was approved by all national, and if necessary, local ethical 
committees. All patients and controls agreed to participate in the study by providing 
written informed consent. 
Healthy controls
The control group consists of healthy, unrelated individuals, who were recruited during 
the EN-Vie study. These controls were usually friends or acquaintances of the patients of 
the same sex, age, local and ethnic background. Controls were only considered eligible 
if they did not have a history of thrombosis and were not using anticoagulation. 
Genotyping
According to the study protocol, blood samples were drawn from patients and controls 
for storage of DNA and plasma. DNA was extracted from whole blood according to local 
standard methods. All EN-Vie samples were stored at the Erasmus MC University Medi-
cal Center in Rotterdam, the Netherlands at -80°C until analysis. In the current study, 
we included all patients and controls of the EN-Vie study cohort of whom an adequate 
amount of DNA was available at the moment of genotyping. Competitive allele-specific 
PCR assays (KASPTM, LGC genomics, Hoddesdon, Herts, UK) were used to genotype the 
SNPs. We analyzed six SNPs that were previously identified as risk factors of venous 
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8thrombosis (Table 8.1). There was no linkage disequilibrium between these six SNPs 
(19-21, 24). Genotyping was performed centrally at LGC genomics. 
Validation cohort
To validate our findings, we included a cohort of patients diagnosed with BCS or non-
cirrhotic, non-malignant PVT as of November 2005, i.e. after the end of inclusion of the 
EN-Vie cohort. This validation cohort consists of consecutive patients seen during regu-
lar hospital care in the 1) Erasmus MC University Medical Center, Rotterdam, the Nether-
lands, 2) Hopital Beaujon, Clichy, France and the 3) Hospital Clinic, Barcelona, Spain. The 
etiological work-up was left to the discretion of the treating physician. Baseline charac-
teristics and etiological factors were obtained from medical charts of these patients. 
Blood group type was retrieved from medical charts or in some cases by contacting 
the patient or blood transfusion center locally (France). All patients provided written 
informed consent. For the current study, only patients aged ≥16 years were included. 
Statistical analysis
Baseline characteristics are expressed as counts with proportions for categorical vari-
ables and as medians with interquartile range (IQR) for continuous variables. Compar-
ison between categorical variables was performed using Pearson Chi-square tests or 
Fisher’s Exact tests. Continuous variables were compared with student t-tests (means) 
or Mann-Whitney U tests (medians). Call rates and Hardy-Weinberg equilibrium were 
tested for all SNPs (25). Associations between each of the SNPs and presence of PVT 
or BCS were assessed by using an additive genetic binary logistic regression model 
(linear OR per addition of an extra effect allele). The total number of risk-increasing al-
leles carried was calculated and subsequently compared for patients with BCS, PVT and 
controls using a binary logistic regression model adjusting for age and sex. A domi-
nant genetic model (non-GG vs GG at rs687289) was applied to assess the association 
Table 8.1 Single nucleotide polymorphisms associated with venous thromboembolism
SNP Chromosome 
(forward strand)
Gene Minor allele MAF Risk allele
rs687289 9:136137106 ABO A 0.37 A
rs1039084 6:147635413 STXBP5 A 0.47 A
rs1063857 12:6153514 VWF C 0.38 C
rs13146272 4:187120211 CYP4V2 C 0.34 A
rs1613662 19:55536595 GP6 G 0.15 A
rs2227589 1:173886216 SERPINC1 T 0.09 T
Abbreviations: SNP, Single nucleotide polymorphism; MAF, Minor allele frequency in individuals from Euro-
pean descent (EUR) in the 1000 Genomes project (http://browser.1000genomes.org).
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8between blood group type and presence of BCS or PVT in the EN-Vie study group. In 
multivariable regression analyses, models were adjusted for age, sex, and inherited 
thrombophilia, i.e. presence of the factor V Leiden mutation, prothrombin G20210A 
variant, and/or deficiency for protein C, protein S and antithrombin. In addition, models 
were adjusted for presence of myeloproliferative neoplasms (MPN) in a second multi-
variable model. To address potential gene-gene and gene-environmental interactions, 
multivariable logistic regression analyses were also performed taking into account 
possible interactions between blood group type and either presence of other genetic 
risk factors for venous thrombosis or presence of MPN. In the validation cohort, binary 
logistic regression analyses, adjusting for age, sex, and inherited thrombophilia, were 
used to assess the association between blood group type and presence of PVT or BCS. 
Statistical tests were two-sided and a p-value <0.05 was considered to be statistically 
significant. Statistical analyses were performed using SPSS 21 (IBM SPSS Statistics for 
Windows, Version 21.0. Armonk, NY, USA). 
Table 8.2 Baseline characteristics of the EN-Vie study cohort 
EN-Vie study cohort
PVT (n=77) BCS (n=77) p-value
Age, years 50.1 (41.9-57.3) 37.1 (26.5-51.1) <0.001
Female sex 43 (55.8) 46 (59.7) 0.63
ALT (U/L) 43 (24-67) 64 (32-165) 0.03
Platelets (*109/L) 258 (174-401) 223 (123-378) 0.19
Hemoglobin (mmol/L) 8.2 (7.2-9.3) 8.5 (7.5-9.8) 0.21
Bilirubin (umol/L) 16.0 (11.3-24.4) 31.0 (17.1-47.9) 0.027
Inherited thrombophilia 17 (22.1) 16 (20.8) 0.84
Protein C deficiency 1 (1.5) 1 (1.4) 1.0
Protein S deficiency 4 (6.0) 0 0.05
Antithrombin deficiency 2 (3.0) 2 (2.7) 1.0
Factor V Leiden mutation 4 (5.3) 11 (14.3) 0.061
Prothrombin gene G20210A 8 (10.5) 2 (2.6) 0.056
Acquired thrombophilia 58 (75.3) 61 (79.2) 0.56
Myeloproliferative neoplasms 20 (26.3) 29 (37.7) 0.13
JAK2V617F positive 15 (20.3) 21 (27.3) 0.31
Antiphospholipid antibodies 21 (28.0) 23 (29.9) 0.80
Paroxysmal nocturnal hemoglobinuria 0 11 (14.3) 0.001
Local risk factor 21 (27.3) 11 (14.3) 0.047
No risk factor 11 (14.3) 7 (9.1) 0.32
Categorical variables are represented as counts (percentage). Continuous variables are expressed as median 
(interquartile range).
Abbreviations: PVT, portal vein thrombosis; BCS, Budd-Chiari syndrome.
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Patient characteristics
For the current study, DNA samples were available from 79 patients with BCS, 80 pa-
tients with PVT, and 81 controls of the EN-Vie study cohort. Of these, 77 patients with 
BCS, 77 patients with PVT and 81 controls were successfully genotyped and included 
in the current study cohort (overall genotyping success rate 97.9%). Baseline characte-
ristics of the patients with BCS and PVT are described in Table 8.2. Median age of the 
patients was 43.7 (31.0-54.4) years and 42.2% was male. Inherited thrombophilia was 
observed in 22.1% of patients with PVT and in 20.8% of patients with BCS, while an 
acquired prothrombotic risk factor was present in 75.3% and 79.2%, respectively. MPN 
was diagnosed in 26.3% of patients with PVT and in 37.7% of patients with BCS (p=0.1). 
In 85.7% of patients with PVT and 90.9% of patients with BCS, at least one pro-thrombo-
tic risk factor could be detected. In the control group, the Factor V Leiden mutation and 
the prothrombin G20210A variant were present in 3.8% and 2.5%, respectively. 
Genetic variations in splanchnic vein thrombosis
Frequencies of genotypes and call rates of the six SNPs are shown in supplementary 
Table 8.1. All SNPs were in Hardy-Weinberg equilibrium. 
Associations between the six SNPs, previously identified as risk factors of VTE, 
and presence of PVT of BCS in the EN-Vie study cohort, are described in Table 8.3. Only 
the SNP in the ABO gene, rs687289, was associated with an increased risk of PVT com-
Table 8.3 Associations between venous-thromboembolism associated SNPs and PVT or BCS in the EN-Vie 
study cohort (n=154 patients and n=81 controls)
EN-Vie study cohort
PVT (n=77) BCS (n=77)
Risk allele Gene OR (95%CI)* p-value* OR (95%CI)† p-value†
rs687289 A ABO 1.86 (1.09-3.18) 0.023 0.88 (0.53-1.46) 0.63
rs1039084 A STXBP5 0.65 (0.40-1.05) 0.081 1.07 (0.69-1.64) 0.78
rs1063857 C VWF 0.98 (0.60-1.61) 0.94 1.22 (0.78-1.91) 0.39
rs13146272 A CYP4V2 1.40 (0.86-2.29) 0.18 1.20 (0.77-1.86) 0.42
rs1613662 A GP6 1.02 (0.57-1.82) 0.95 1.79 (0.97-3.30) 0.063
rs2227589 T SERPINC1 1.59 (0.62-4.06) 0.33 1.98 (0.85-4.61) 0.11
Abbreviations: SNP, single nucleotide polymorphism; BCS, Budd-Chiari syndrome; PVT, portal vein throm-
bosis.
* Odds ratio with its 95% confidence interval and p-value are expressed per additional risk allele for compa-
rison of patients with PVT (n=77) with controls (n=81). All analyses were adjusted for age and sex.
† Odds ratio with its 95% confidence interval and p-value are expressed per additional risk allele for compa-
rison of patients with BCS (n=77) with controls (n=81). All analyses were adjusted for age and sex.
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8pared to controls (OR 1.9 (95% CI 1.1-3.2), p=0.02 per addition of an A allele, adjusted for 
age and sex). None of the SNPs was associated with an increased risk of BCS compared 
to controls. We tested the combined effect of the genetic variations by calculating the 
total number of risk-increasing alleles. The number of risk-increasing alleles per patient 
or control ranged from 1 to 9. The addition of one risk-increasing allele did not signifi-
cantly increase the risk of BCS or PVT compared to controls (OR 1.22 (95% CI 0.98-1.51), 
p=0.077 for BCS and OR 1.12 (95% CI 0.89-1.40), p=0.34 for PVT). 
Blood group type non-O in portal vein thrombosis and Budd-Chiari syndrome
In the EN-Vie study cohort, prevalence of blood group type non-O (non-GG at rs687289) 
was significantly higher in patients with PVT (81.6%) both in comparison with patients 
with BCS (57.1%, p=0.001) and in comparison with controls (58.8%, p=0.002). In univa-
riable regression analysis, presence of blood group type non-O was associated with a 
more than threefold increased risk of PVT compared to controls (OR 3.1 (95% CI 1.5-6.5), 
p=0.002). Patients with blood group type non-O did not have an increased risk of BCS 
compared to controls (OR 0.8 (95% CI 0.5-1.8), p=0.8). In multivariable regression ana-
lysis, additionally adjusting for age, sex, and other genetic risk factors for VTE, presence 
of blood group type non-O remained significantly associated with a threefold increased 
risk of PVT compared to controls (OR 3.1 (95% CI 1.4-6.9), p=0.005) (Table 8.4). Presence 
of other genetic risk factors for VTE, i.e. presence of the factor V Leiden mutation, pro-
thrombin G20210A variant, and/or deficiency for protein C, protein S and antithrombin, 
was independently associated with an increased risk of both PVT and BCS compared 
to controls (OR 5.4 (95% CI 1.7-16.9), p=0.004 and OR 4.3 (95% CI 1.5-12.5), p=0.008 
respectively), as described previously (3, 4).
Blood group type non-O was also significantly more prevalent in PVT as com-
pared to BCS (OR 3.3 (95% CI 1.6-6.9), p=0.001). In multivariable regression analysis, 
having blood group non-O remained independently associated with an increased risk 
Table 8.4 Association between blood group type non-O and PVT or BCS compared to healthy controls 
(n=81) in multivariable analysis in the EN-Vie study cohort 
EN-Vie study cohort
PVT (n=76) BCS (n=77)
OR (95%CI) p-value OR (95%CI) p-value
Age, year 1.08 (1.05-1.10) <0.001 1.02 (0.99-1.04) 0.16
Female sex 1.00 (0.48-2.08) 1.0 0.89 (0.46-1.73) 0.73
Inherited thrombophilia* 5.37 (1.71-16.9) 0.004 4.28 (1.47-12.5) 0.008
Blood group non-O 3.12 (1.41-6.90) 0.005 0.95 (0.50-1.83) 0.88
* Presence of other genetic risk factor for venous thrombosis, i.e. presence of the factor V Leiden mutation, 
prothrombin G20210A variant, protein C deficiency, protein S deficiency and/or antithrombin deficiency
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8of PVT compared to BCS (OR 3.0 (95% CI 1.4-6.5), p=0.006). Presence of other genetic 
risk factors for VTE was not associated with an increased risk of PVT compared to BCS in 
this model (OR 0.8 (95% CI 0.3-1.9), p=0.6). Additionally adjusting for presence of MPN 
did not alter the association between blood group type non-O and PVT compared to 
BCS (OR 2.8 (95% CI 1.3-6.3), p=0.01).
There was no interaction between blood group type and presence of other 
genetic risk factors for VTE for both the comparison of PVT with controls and PVT versus 
BCS. Also, we did not observe an interaction between blood group type and presence 
of MPN for patients with PVT compared to patients with BCS. 
Validation cohort
To validate our findings on the role of blood group type non-O in the pathogenesis of 
SVT, we enrolled a validation cohort of 351 patients diagnosed with BCS or PVT in the 
tertiary referral clinics of Clichy (France), Barcelona (Spain), and Rotterdam (The Nether-
lands) between November 2005, the end of inclusion in the EN-Vie study, and 2014. In 
this cohort, BCS was present in 108 (30.8%) and PVT in 243 (69.2%) patients (Table 8.5). 
Median age of this cohort was 41.7 (31.8-54.7) years and 46.4% was male. Inherited 
thrombophilia was observed in 30.3% (64 of 211 tested) of patients with PVT and in 
Table 8.5 Characteristics of the EN-Vie study cohort (n=154) and validation cohort (n=351) 
PVT (n=320) BCS  (n=185)
EN-Vie (n=77) Validation 
(n=243)
p-value EN-Vie (n=77) Validation
(n=108)
p-value
Age, years 50.1 (41.9-57.3) 44.7 (35.4-57.0) 0.04 37.1 (26.5-51.1) 37.6 (27.0-45.1) 0.5
Female sex 43 (55.8) 112 (46.1) 0.1 46 (59.7) 76 (70.4) 0.1
Protein C deficiency* 1 (1.5) 23 (10.6) 0.02 1 (1.4) 22 (23.4) <0.001
Protein S deficiency 4 (6.0) 34 (15.3) 0.05 0 15 (16.6) <0.001
Antithrombin 
deficiency
2 (3.0) 7 (3.1) 1.0 2 (2.7) 11 (11.3) 0.04
Factor V Leiden 
mutation
4 (5.3) 7 (3.0) 0.5 11 (14.3) 11 (10.5) 0.4
Prothrombin gene 
G20210A
8 (10.5) 15 (6.4) 0.2 2 (2.6) 3 (2.8) 1.0
Myeloproliferative 
neoplasms
20 (26.3) 46 (20.3) 0.4 29 (37.7) 35 (32.7) 0.5
Categorical variables are represented as counts (percentage). Continuous variables are expressed as median 
(interquartile range).
* Definitions of presence of pro-thrombotic risk factors were based on local criteria in the validation cohort. 
In the EN-Vie cohort, all patients were systematically evaluated for etiological factors using a standardized 
protocol.
Abbreviations: PVT, portal vein thrombosis; BCS, Budd-Chiari syndrome.
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838.9% (37 of 95 tested) of patients with BCS (p=0.14). MPN was diagnosed in 20.3% (46 
of 227 tested) and 32.7% (35 of 107 tested) of the patients with PVT and BCS, respecti-
vely (p=0.013). 
In this validation cohort, blood group type non-O was present in 59.3% of 
patients with BCS and 65.8% of patients with PVT. Compared to the controls, blood 
group type non-O was not associated with an increased risk of PVT or BCS in this co-
hort of patients seen during regular hospital care (OR 1.36 (95% CI 0.77-2.39), p=0.29 
and OR 1.01 (95% CI 0.54-1.90), p=0.98 respectively, adjusted for age, sex, and inherited 
thrombophilia). Presence of blood group type non-O was also not associated with an 
increased risk of PVT compared to BCS in this validation cohort (OR 1.18 (95% CI 0.69-
2.02), p=0.54).
DISCUSSION  
In summary, we studied the role of six recently identified SNPs, associated with the risk 
of common forms of VTE, in the largest prospective multinational cohort of patients 
with BCS and PVT to date. Interestingly, none of the investigated genetic variations can 
be considered a risk factor for SVT. Although we observed that presence of blood group 
type non-O was associated with an increased risk for the development of PVT, but not 
for BCS in the EN-Vie study cohort, we could not confirm these results in the valida-
tion cohort. Our findings support previous hypotheses that thrombosis development is 
site-specific and depends on a complex interplay between specific local and systemic 
factors (10).
There is a considerable overlap in etiology between common forms of VTE on 
one hand, and PVT and BCS on the other hand (10). However, it remains elusive why 
thrombosis develops in the splanchnic veins in some patients, while the majority of 
patients with similar risk factors develops a more common form of VTE, i.e. DVT and 
PE. Likewise, the etiology of BCS and PVT is comparable to a large extent, but there 
are also some clear differences (10). A hypothesis to explain this phenomenon is that 
thrombus formation is side-specific. One of the factors that may play a central role in 
this side-specificity is endothelial cell heterogeneity (26). Endothelial-derived antico-
agulants and procoagulants, like VWF, are not evenly expressed in the vasculature re-
sulting in a site-specific equilibrium to balance local hemostasis. This endothelial cell 
heterogeneity could explain how a systemic imbalance in clotting factors can result in 
local thrombus formation (26). Endothelial activation has been described previously in 
PVT and BCS (27). It has been hypothesized that exposure to gut-derived products and 
vulnerability of the splanchnic veins to activated platelets and high viscosity, character-
istic features of MPN, play an important role in the pathogenesis of SVT, while they are 
not important for thrombus formation at other, non-splanchnic, sites (26). Therefore, 
it is possible that some risk factors for VTE, including blood group type non-O, are not 
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MPN – are of more importance in the pathogenesis of SVT.
Blood group type non-O is an important genetic risk factor for common VTE 
(14-17). The effect of blood group type non-O on VTE risk can be explained by increased 
VWF and factor VIII levels. Patients with blood group type non-O are known to have 25 
percent higher VWF and factor VIII levels than patients with blood group type O, due to 
VWF glycosylation protecting it from proteolysis and/or clearance (28-31). The increase 
in VWF, which binds FVIII in the circulation and protects FVIII from degradation, results 
in higher FVIII levels. Elevated VWF and factor VIII levels on their turn are associated 
with an increased risk of VTE (11, 13, 32). In the EN-Vie study cohort, the SNP for blood 
group type non-O was associated with an independently increased risk of PVT. This 
was not observed in BCS. However, this observation could not be validated in a cohort 
of patients with BCS or PVT referred for tertiary care in the three largest centers of the 
original EN-Vie cohort.
The different outcomes in both cohorts may, in part, be due to differences in 
the studied patient populations. The EN-Vie cohort is a well-described multinational 
cohort in which all patients were systematically evaluated for etiological factors using 
a standardized protocol. In the patients in the validation cohort seen during regular 
hospital care, etiological factors were defined according to local criteria and not all eti-
ological factors have been evaluated, which might have resulted in a selection bias. This 
accounts in particular for blood group type, as this is not an established risk factor for 
PVT or BCS.
We did not observe an association between the VTE-associated genetic vari-
ations located in the STXBP5, VWF, CYP4V2, GP6, and SERPINC1 genes and presence of 
PVT or BCS. It is possible that the sample size of the EN-Vie study cohort (154 patients) 
was too small to detect an association between these candidate SNPs and PVT, despite 
the fact that this study was conducted in a large, multinational cohort. In particular, 
this could have been the case for the SNPs with a small minor allele frequency, like the 
SNPs in the GP6 and SERPINC1 gene, which have been discovered in a very large cohort 
of over 1,000 patients with VTE (20). Another explanation for the lack of association be-
tween the candidate SNPs and PVT and BCS could be that other factors, including local 
factors and MPN, are of more importance in the etiology of SVT, as discussed before. 
 The major strength of the current study is that this study was performed in a 
large, prospective, multinational cohort of newly diagnosed, well-described patients 
with BCS and PVT and controls. Furthermore, we tried to validate our findings in an ex-
tensive cohort of patients diagnosed with SVT in the three largest centers of the EN-Vie 
study cohort after the EN-Vie inclusion period. Our study also has some limitations that 
need to be addressed. First, we did not include all patients that were originally included 
in the EN-Vie study cohort, because DNA was not available anymore of all patients. As 
this was caused by the fact that DNA was randomly missing in some patients as no DNA 
was remaining after previous analyses, we believe that no selection bias has occurred 
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8as a result of this. Second, although this study was conducted in the largest multina-
tional cohort of patients with PVT and BCS to date, these diseases are very rare, and 
therefore absolute numbers of patients might have been too low to detect associations 
between the candidate VTE-associated SNPs with a small minor allele frequency and 
SVT. Finally, the control group of the EN-Vie study cohort was also used as reference 
group for the validation cohort. However, we do not believe this influenced our results, 
as the distribution of blood group type in this control group (blood group type non-O 
present in 58.8%) was comparable to that of the general French (58%), Dutch (53%), 
and Spanish (55%) population (33-35). 
In conclusion, none of the six VTE-associated genetic variations located in the 
ABO, STXBP5, VWF, CYP4V2, GP6, and SERPINC1 genes was associated with SVT in this 
large prospective study. Identification of these differences in etiology between SVT 
and more common forms of VTE may aid in understanding the pathogenesis of venous 
thrombosis at different sites.   
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8Supplementary table 8.1 Frequencies of genotypes and call rates for all single nucleotide polymorphisms in 
the EN-Vie study cohort (n=235 patients and controls)
SNP Genotypes Frequency, n(%) MAF (this cohort) Call rate (%)
rs687289 AA 29 (12.4) 0.39 99.1
AG 124 (53.2)
GG 80 (34.3)
rs1039084 AA 49 (21.4) 0.43 97.4
GA 100 (43.7)
GG 80 (34.9)
rs1063857 CC 33 (14.3) 0.36 98.3
TC 101 (43.7)
TT 97 (42.0)
rs13146272 CC 36 (15.7) 0.36 97.4
CA 93 (40.6)
AA 100 (43.7)
rs1613662 GG 9 (3.9) 0.19 98.7
GA 68 (29.3)
AA 155 (66.8)
rs2227589 TT 1 (0.4) 0.087 98.3
TC 38 (16.5)
CC 192 (83.1)
Call rates were calculated after exclusion of n=5 in whom all genotyping failed, resulting in a remaining 
cohort of 235 patients. In these 235 patients, in total 35 genotypes were missing in 12 patients.
Abbreviations: SNP, Single nucleotide polymorphism; MAF, minor allele frequency.
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9ABSTRACT
Background and aims
Gastrointestinal ischemia is a concerning complication of portal vein thrombosis (PVT). 
Minimally invasive techniques, such as visible light spectroscopy (VLS), have greatly 
improved the ability to diagnose gastrointestinal ischemia. The aim of this study was 
to assess the clinical presentation and characteristics of gastrointestinal ischemia in pa-
tients with PVT. 
Methods
Patients with non-cirrhotic, non-malignant PVT were included in this prospective co-
hort study. Clinical symptoms of gastrointestinal ischemia were assessed by a struc-
tured questionnaire, VLS, and radiological evaluation of the mesenteric vasculature. 
VLS measurements were compared to those in patients with cirrhosis and a reference 
population. 
Results
We included 15 patients with chronic PVT and one patient with acute PVT (age 46.1 [IQR 
30.9-53.7] years; 44% male). Decreased mucosal oxygenation in at least one location of 
the gastrointestinal tract was found in 12/16 (75%) patients. Compared to the refer-
ence population (median 60.0 [56.2-61.7]), VLS measurements were mostly decreased 
in the descending duodenum for patients with PVT (median 55.5 [52.3-58.8], p=0.02) 
and patients with cirrhosis (median 52.0 [46.5-54.0], p=0.003). Symptoms typical for 
gastrointestinal ischemia, such as postprandial pain and exercise-induced pain, were 
reported in 10/16 (63%) patients with PVT. In patients with extension of thrombosis 
into the superior mesenteric vein and splenic vein and/or presence of hypercoagulabil-
ity, decreased VLS measurements were observed compared to the historical controls. 
Conclusions
In patients with chronic PVT, gastrointestinal ischemia is frequent. VLS enables objec-
tive and quantitative determination of gastrointestinal mucosal ischemia. Onset of 
abdominal symptoms such as postprandial pain should prompt the physician to re-
evaluate extent, cause and treatment of PVT.
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9INTRODUCTION
Portal vein thrombosis (PVT) is an infrequent vascular disorder that often leads to por-
tal hypertension. Etiological factors include systemic and local prothrombotic factors.
[1] PVT can be classified as acute or chronic. The latter is characterized by the presence 
of portal cavernoma, which depends on the duration of existence of the thrombus in 
the portal vein (PV).[1-3]  
Gastrointestinal ischemia is a concerning complication of PVT. It can result in 
intestinal infarction, a life-threatening complication that often requires immediate sur-
gical intervention.[2] Treatment  of acute PVT therefore aims at vascular recanalization, 
preventing occurrence of gastrointestinal ischemia and portal hypertension.[1] The ac-
tual prevalence of gastrointestinal ischemia in patients with PVT is unknown. Studies, 
mainly conducted in patients with acute PVT, report prevalences of intestinal infarction 
of 2%-32%, with mortality rates of 0%-20%.[3-9] Regarding patients with chronic PVT, 
studies report conflicting results. As patients with chronic PVT often have an extensive 
venous collateral circulation, it is assumed  that  gastrointestinal ischemia is less likely 
to occur.[2] However, in a large prospective study in splanchnic vein thrombosis, 26% 
of patients presented with intestinal infarction. In nearly half of these patients a portal 
cavernoma was detected, suggesting gastrointestinal ischemia is also a frequent com-
plication in chronic PVT.[4] 
Typical complaints suggesting gastrointestinal ischemia are postprandial and/
or exercise related abdominal pain, weight loss, and diarrhea. However, some patients 
present with more atypical symptoms, which limits the diagnosis of gastrointestinal 
ischemia based on clinical symptoms alone.[10] In addition, clinical signs of gastroin-
testinal ischemia are often difficult to differentiate from symptoms due to PVT. Also, it 
has been suggested that signs of ischemia in patients with PVT depend largely on the 
extent of the occlusion, the size of the vein, and the involvement of the superior mes-
enteric vein (SMV) and/or splenic vein (SV).[2, 11] 
With the development of minimally invasive techniques, such as visible light 
spectroscopy (VLS), the ability to diagnose gastrointestinal ischemia has greatly im-
proved.[12] VLS enables direct measurement of the adequacy of mucosal perfusion in 
the gastrointestinal tract.[13] It is a new technique that non-invasively measures cap-
illary hemoglobin oxygen saturation using white light delivered by a fiberoptic probe 
during gastroscopy.[12, 13] The oxygen saturation reflects the adequacy of mucosal 
perfusion. Therefore, venous occlusion, hampering oxygenation of the gastrointesti-
nal mucosa, may result in lower mucosal hemoglobin oxygen saturations.[12] VLS is a 
validated diagnostic method to detect gastrointestinal ischemia with a sensitivity and 
specificity of 90% and 60%, respectively.[12, 13]
Due to the rarity of the disease and lack of adequate diagnostic tools in the 
past, most data on gastrointestinal ischemia in patients with PVT stem from retrospec-
tive studies in selected patient populations.[3-7] VLS enables us to directly quantify 
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9gastrointestinal ischemia in patients with PVT. Therefore, we performed a prospective 
cohort study in patients with PVT using VLS, radiological examination, and question-
naires. The objective of this study was to assess the presence, clinical presentation and 
characteristics of gastrointestinal ischemia in patients with PVT.
MATERIALS AND METHODS
Study population 
Patients with non-cirrhotic, non-malignant PVT were studied in this single-center pro-
spective cohort study in a tertiary care center. Patients aged 18 years and over with 
non-cirrhotic, non-malignant PVT were included in the study from 2009 until 2010. 
Acute and chronic PVT were defined according to Baveno V criteria as the presence of 
PVT with or without portal cavernoma and portal hypertension.[14] Patients with isolat-
ed SV or SMV thrombosis were excluded. All patients underwent radiological evaluation 
within two months of the VLS measurements. All patients with PVT received scheduled 
visits at the out-patient clinic. For this cohort study, we adhered to the Strengthening 
the Reporting of Observational studies in Epidemiology (STROBE) initiative.[15]
Patients with liver cirrhosis and portal hypertension with patent mesenteric 
vasculature were included as cirrhotic patient controls. Portal hypertension was de-
fined as: presence of varices and/or splenomegaly and/or ascites and/or hepatic hy-
drothorax and/or increased hepatic venous pressure gradient (>12mm Hg) AND in the 
absence of an intrahepatic shunting stent (i.e. TIPS). 
For further comparison, VLS measurements of a historical reference popula-
tion were used. These were participants in the original cohort of van Noord et al., of 
whom mucosal saturation measurements using VLS were obtained to establish the 
present cut-off values for gastrointestinal ischemia in the different locations in the gas-
trointestinal tract. These were consecutive patients referred for evaluation of possible 
chronic gastrointestinal ischemia who underwent the standard diagnostic work-up for 
gastrointestinal ischemia consisting of evaluation of symptoms, radiological imaging, 
and gastrointestinal tonometry in addition to VLS. In all these patients, more common 
causes of upper gastrointestinal symptoms had been previously excluded. A diagnosis 
of chronic gastrointestinal ischemia was established if a patient fulfilled two of the three 
following criteria: (a) distinct clinical presentation including presence of postprandial 
pain and otherwise unexplained weight loss of >5% of the normal body weight, (b) 
significant stenosis of >50% of at least one of the mesenteric arteries, and (c) functional 
signs of mucosal ischemia demonstrated by VLS. None of the historical controls fulfilled 
the required criteria. The VLS measurements were performed in identical fashion as in 
the previous study of the same group.[12]  
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9Informed consent was obtained from all patients. Approval for the study was 
obtained from the Institutional Review Board of the Erasmus MC University Medical 
Center Rotterdam, the Netherlands. The study was registered at the ISRCTN registry 
(study ID ISRCTN14235960). 
Diagnostic work-up and data collection
All patients with PVT received the standard work-up. This consisted of screening for 
etiologic factors, laboratory testing, abdominal ultrasound, and gastroscopy. 
Standardized abdominal ultrasound was performed to assess the liver paren-
chyma, PV, hepatic artery, hepatic veins, SV, SMV, and to exclude the presence of cirrho-
sis and assess features of portal hypertension. Gastroscopy was performed to deter-
mine the possible presence of varices.   
Use of antithrombotic medication was evaluated for all patients. Antithrom-
botic medication was initiated at the discretion of the treating physician and/or ac-
cording to standard care. Time of antithrombotic medication use was assessed from 
diagnosis of PVT to time of VLS measurements. For each patient, a covered time (in %) 
of antithrombotic use was calculated by dividing the time (in months) of antithrombot-
ic medication use by time (in months) since diagnosis of PVT. 
Assessment of gastrointestinal ischemia
Clinical symptoms of gastrointestinal ischemia were assessed by a structured question-
naire, VLS measurements and radiological evaluation of the mesenteric arteries. 
The questionnaire was specifically designed to collect relevant medical and 
family history, medication use, and gastrointestinal symptoms.[10, 16] To avoid missing 
data, medical history notes on gastrointestinal symptoms were also included. 
Radiological evaluation of the mesenteric vasculature was performed by CT- A, 
or MR-angiography (MR-A), with a maximum slice thickness of 3mm. Site and extension 
of the PVT, as well as involvement of the SMV and SV, were also evaluated. Stenosis of 
the mesenteric arteries of ≥70% of vessel lumen was considered significant.   
Mucosal saturation measurements 
Gastroscopy was performed in all patients. VLS measurements were performed during 
gastroscopy as described before.[12, 17] In short, cleansing of remnant bile, fluids or 
food remnants was done prior to measuring along with administration of butylsco-
polamine 20 mg intravenously to halt upper gastrointestinal motility. Measurements 
were performed at three specific locations: descending duodenum, duodenal bulb and 
gastric antrum. We averaged three repeated readings per location, with every measure-
ment within 5% variation of panel read-out once a stable reading was obtained. This 
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The sites of the VLS measurements per location were standardized in the way that in 
every patient the same anatomical regions were used. Peripheral oxygenation was 
kept above 94%. Mucosal ischemia was defined as: mucosal saturation <63%, <62% 
and < 58%, for measurements in the gastric antrum, duodenal bulb, and descending 
duodenum, respectively.[12] The physician performing the VLS measurements was not 
blinded to the patient characteristics. However, he was not the treating physician of the 
patient and was therefore not familiar with the specifics of the radiological findings of 
these patients. At time of inclusion, only two physicians in our center were specialized 
in performing the VLS measurements. The second physician was trained by the other 
physician, limiting a possible inter-observer variability.
Statistical analysis
Baseline characteristics were calculated using descriptive statistics. Data were ex-
pressed as mean and standard deviation (SD), median and interquartile range (IQR) or 
count and percentage (%), when appropriate. Differences in VLS measurements per 
location in the GI-tract between the different groups were assessed with linear regres-
sion analysis. Statistical analysis was performed using SPSS 21.0 program (SPSS Inc., 
Chicago, IL, USA). A two-sided p-value of <0.05 was considered statistically significant.
RESULTS
Study population
In this prospective cohort study, we included 16 patients with PVT (age 46.1 [30.9-53.7] 
years; seven patients were male). Baseline characteristics of these patients, at the mo-
ment of VLS measurement, are displayed in Table 9.1. At diagnosis, five patients had an 
acute PVT and in 11 patients a portal cavernoma was observed. At the moment of VLS 
measurement, 15 patients (94%) had chronic PVT. 
In 14 patients (87%), at least one prothrombotic risk factor was present, includ-
ing an inherited hypercoagulable risk factor in six patients of whom three with a factor 
V Leiden mutation. A local risk factor, such as inflammatory bowel disease or pancreati-
tis, was found in four patients. 
Treatment with heparin followed by oral anticoagulants (OAC) was adminis-
tered in 12 patients (75%). In nine of these patients (75%), anticoagulants were started 
at diagnosis and was continued at least until the moment of VLS measurement (cov-
ered time 99-100%). In two of these 12 patients, administration of OAC was delayed by 
6 and 9 months respectively, which resulted in treatment with anticoagulants with a 
covered time <99-100%. In the remaining patient, OAC was directly administered, but 
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ered time of 16.7%. The absolute length and percentage covered time of anticoagula-
tion use is further described in Table 9.1. In two patients, acetylsalicylic acid was started 
because of presence of a myeloproliferative neoplasm (MPN). Before administering oral 
anticoagulants, thrombolysis was unsuccessfully attempted in one patient. All patients 
who initially presented with an acute PVT were treated with OAC from diagnosis until 
at least the moment of VLS measurement. 
To determine whether the VLS measurements in patients with PVT are affected 
only by presence and extent of the portal and mesenteric venous thrombosis or also by 
portal hypertension, we included a cirrhotic patient control group consisting of five pa-
tients (age 61.0 [57.5-66.1] years (p=0.02 compared to patients with PVT), three patients 
were male (p=0.2)) with liver cirrhosis without PVT. All of these patients had Child-Pugh 
C cirrhosis and were screened for liver transplantation. In these five patients, liver cir-
rhosis was caused by hepatitis B virus infection (n=2), hepatitis C virus infection (n=2) or 
primary sclerosing cholangitis (n=1). All patients in the cirrhotic patient control group 
had oesophageal varices. There were no liver function abnormalities in all patients with 
PVT. 
Clinical features of gastrointestinal ischemia
Abdominal pain was reported by ten out of 16 (63%) patients with PVT (see Table 9.2). 
Postprandial pain, typical for gastrointestinal ischemia, was reported by nine out of 16 
(56%). Furthermore, exercise-induced pain and weight loss (median 5.0 [2.0-6.7] kg/
month) were reported in eight (50%) and seven (44%) patients with PVT. None of the 
cirrhotic patient controls reported any presence of postprandial abdominal or exercise-
induced pain. Of the 11 PVT patients with extension into the SMV and SV, eight repor-
ted postprandial or exercise-induced abdominal pain. None of the PVT patients wit-
hout involvement of the SMV and SV reported abdominal pain. 
Abdominal pain was the presenting symptom and reason for referral in the 
vast majority of the 29 historical controls (38% male (p=0.09 and p=0.09 compared to 
patients with PVT and cirrhotic patient controls respectively), age 56.5 [43.9-66.4] years 
(p=0.7 and p=0.4 respectively)). However, the occurrence of significant weight loss (me-
dian 0.6 [0-1.1] kg/month) and loose stools (28%) was significantly lower in this group 
compared to patients with PVT (p=0.001 and p=0.002, respectively). Mesenteric arte-
rial stenosis was ruled out in the patients with PVT and the cirrhotic patient controls. 
Four historical controls were referred because of a stenosis of the mesenteric arteries, 
however the diagnosis of gastrointestinal ischemia was excluded during the diagnostic 
work-up.
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9Table 9.1 Continued
Abbreviations: PVT, portal vein thrombosis; PS, platelets/spleen; MPN, myeloproliferative neoplasm; SMV, 
superior mesenteric vein; SV, splenic vein; FVL, factor V Leiden; APA, antiphospholipid antibodies; na, not 
available; FVIII, factor VIII; PC, protein C deficiency; NOS, not otherwise specified; PV, polycythemia vera; ET, 
essential thrombocytosis.
* Site of thrombotic involvement of the portal vein. Type 1=thrombosis of the trunk; type 2a=thrombosis of 
one branch; type 2b=both branches; type 3=thrombosis of both portal trunk and branches.
† Presentation at moment of VLS measurement, as diagnosed by radiological imaging (CT or abdominal 
ultrasound).
‡ One patient (ID 4) had elevated antiphospholipid (anti-cardiolipin) antibodies and ID 8 had elevated levels 
of factor VIII. Three patients had an FVL mutation.
§  MPN NOS: an MPN is present, but the type could not be classified into more detail by histological examina-
tion of bone marrow.
ǁ	 Amount of time on anticoagulants (oral anticoagulants and/or heparin) from diagnosis un-
til VLS measurement divided by total amount of time from diagnosis until VLS measurement. 
All patients had oesophageal varices, except for ID 2, who was diagnosed with duodenal varices. ID 1 had 
both gastric (GOV-1) and oesophageal varices. 
◊ PS ratio: platelet (n/mm3) divided by spleen size (mm); cut-off ≤ 909
Table 9.2 Clinical symptoms and risk factors for gastrointestinal ischemia at time of VLS measurements
Cases
n=16
Cirrhotic patient 
controls
n=5
Historical
controls
n=29
Abdominal pain 10 (63) 0 28 (97)
- Postprandial pain 9 (56) 0 15 (52)
- Exercise-induced pain 8 (50) 0 13 (45)
Weight loss 7 (44)  1(20) 19 (66)
Weight loss (kg/month)* 5 [2.0-6.7] - 0.6 [0-1.1]
Loose stools 12 (75) 3 (60) 8 (28)
BMI (kg/m2)* 25.4 [21.9-26.8] 28.4 [24.0-33.5] 20.9 [19.6-23.9]
Coronary and/or peripheral arterial disease 0 1 (20) 7 (24)
Family history of CVD† 4(27) 5 (100) 12 (44)
DM type II 1 (6) 2 (40) 3 (10)
Hypertension‡ 9 (56) 1 (20) 10 (35)
Hypercholesterolemia§ 4 (27) 1 (25) 6 (21)
Smoking 3 (19) 1 (20) 13 (46)
Mesenteric arterial stenosisǁ 0 0 4 (14)
Values represent number of patients (percentage %), unless otherwise specified.
Abbreviations: BMI, Body Mass Index; CVD, cardiovascular disease; DM, diabetes mellitus. 
* Median, interquartile range.
† Positive family history is defined as first-degree relatives with history of coronary and/or peripheral arterial 
disease. Family history of cardiovascular disease was missing in one patient with PVT.
‡ Hypertension is defined as systolic blood pressure of >140mm Hg and/or diastolic blood pressure of 
≥90mm Hg or use of anti-hypertensive medication.
§ Hypercholesterolemia is defined as serum LDL cholesterol ≥190 mg/dl or use of statins. Serum LDL-choles-
terol was missing in one cirrhotic patient control.
ǁ	 Mesenteric arterial stenosis is defined as a significant stenosis of ≥70% of the vessel lumen of the celiac 
trunk (CT), superior mesentery artery (SMA) or inferior mesentery artery (IMA) on CT-angiography with 
maximum slice thickness of 3mm.
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Figure 9.1 Visible light spectroscopy (VLS) measurements in patients with portal vein thrombosis (PVT), cirr-
hotic patient controls and in the reference population. VLS measurements performed at three locations in the 
gastrointestinal tract for all three groups of patients. VLS measurements were significantly decreased for pa-
tients with PVT compared to the reference population in the antrum and descending duodenum, but not in 
the duodenal bulb. Compared to the reference population, patients with portal hypertension had decreased 
VLS measurements in all locations, indicating mucosal ischemia. Boxes represent medians with interquartile 
range, whiskers extend to the most and least extreme scores respectively.
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Mucosal saturation measurements  
VLS measurements were performed in all patients with PVT and in the five patients 
with severe cirrhosis and portal hypertension. VLS measurements of the historical con-
trols were used as reference population. Decreased VLS measurements in at least one 
location of the gastrointestinal tract were found in 12 out of 16 (75%) patients with 
PVT. Compared to the reference population (median 60.0 [56.2-61.7]), mucosal satu-
ration measurements were mostly decreased in the descending duodenum for both 
patients with PVT (median 55.5 [52.3-58.8], p=0.02) and patients with cirrhosis (median 
52.0 [46.5-54.0], p=0.003) (see Figure 9.1). The median VLS measurement of patients 
with PVT (median 62.0 [60.0-65.8]) and cirrhosis (median 57.0 [55.0-60.0]) were also sig-
nificantly lower in the antrum compared to the historic reference population (median 
65.9 [64.2-69.3], p=0.01 and p<0.001 respectively). There was a significant difference in 
median VLS measurements in the duodenal bulb between patients with cirrhosis and 
portal hypertension (median 58.0 [50.5-61.0]) compared to the historic reference pop-
ulation (median 62.9 [59.2-66.9], p=0.02), but not between patients with PVT (median 
60.5 [59.3-64.0]) and the reference population (p=0.5)). There seemed to be an associ-
ation between presence of postprandial abdominal pain and/or exercise-induced ab-
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9dominal pain and decreased VLS measurements in the descending duodenum. Patients 
with abdominal pain tended to have lower VLS measurements than patients without 
abdominal pain (median 54.0 [48.8-57.3] vs median 58.5 [53.8-60.5], p=0.09). Of the ten 
patients with PVT with postprandial abdominal pain and/or exercise-induced abdom-
inal pain, nine (90%) had decreased VLS measurements, of which six at more than one 
location in the gastrointestinal tract.  
Characteristics of ischemic colitis
Colonoscopy was performed in three out of 16 patients with PVT at the moment of 
VLS measurements. Two patients had abnormal findings. In one patient, signs of ul-
ceration and colitis were seen in the descending colon attributed to ischemia, which 
was confirmed by histological tissue evaluation. This patient (ID 2) was diagnosed with 
a complete occlusion of a side branch of the PV, SMV, and SV. This patient also had de-
creased VLS measurements in the descending duodenum. In the second patient (ID 3), 
colonoscopy revealed mucosal edema and erythema in the distal colon and sigmoid, 
suggestive for colitis due to congestion. This patient had a complete occlusion of the 
PV and SMV, and decreased VLS measurements of the duodenum. None of the cirrhotic 
patients had signs of ischemic colitis during colonoscopy. 
Factors associated with VLS measurements 
Patients with an extension of the thrombus into the SMV and/or SV had significantly 
lower VLS measurements in the antrum and descending duodenum compared to the 
reference population, indicating mucosal ischemia (p=0.01 and p=0.009, respectively) 
(see Figure 9.2). There was no difference in VLS measurements between patients with 
PVT without extension compared to the historical controls. Furthermore, no difference 
in VLS measurements was observed in patients with extension of the PVT into the SMV 
and/or SV compared to patients without extension of thrombus outside the PV. 
Patients who were treated with OAC had higher VLS measurements compared 
to those who were not or partly (covered time <99%) treated, (median 58.0 [53.5-59.5] 
vs 53.0 [49.0-57.0], p=0.096 in the descending duodenum) (see Figure 9.3). Patients who 
were not or partly treated with OAC had significantly lower VLS measurements in the 
antrum and descending duodenum compared to the reference population, indicating 
mucosal ischemia (p=0.007 and p=0.003, respectively). The use of OAC in patients with 
PVT results in a relative risk difference of 19% in decrease of VLS measurements. Hence, 
the number needed to treat with anticoagulants to prevent decreased VLS measure-
ments in one patient is 5.3.  
Abdominal pain was reported in a lower proportion of patients using OAC 
compared to patients without anticoagulation, but this difference was not statistically 
significant (56% vs 71%, p=0.6). 
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Figure 9.2 VLS measurements and extent of venous thrombosis. Patients with PVT with an extension of 
the thrombus into the superior mesenteric vein (SMV) and/or splenic vein (SV) had significantly lower VLS 
measurements in the antrum and descending duodenum compared to the reference population, indicating 
mucosal ischemia. Boxes represent medians with interquartile range, whiskers extend to the most and least 
extreme scores respectively.
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Figure 9.3 VLS measurements in relation to use of antithrombotic therapy. Patients who were not or partly 
treated with oral anticoagulation (OAC) had significantly lower VLS measurements in the antrum and des-
cending duodenum compared to the reference population, indicating mucosal ischemia. Boxes represent 
medians with interquartile range, whiskers extent to the most and least extreme scores respectively.
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9Presence of an inherited hypercoagulable risk factor resulted in decreased VLS 
measurements at all locations in three out of six (50%) patients. In two of the three 
remaining patients with an inherited risk factor, decreased measurements in the de-
scending duodenum – and antrum in one patient – were observed. One patient with an 
inherited risk factor did not have decreased VLS measurements, however this patient 
had an incomplete occlusion of the PV. Patients with a known inherited hypercoagula-
ble risk factor more often reported abdominal pain typical for gastrointestinal ischemia 
compared to patients without an inherited hypercoagulable risk factor (83% vs 44%, 
p=0.3). 
Follow-up after VLS measurements
After a median follow-up time of 51 (11-59) months, 15 of the 16 patients with PVT were 
still alive. One patient developed multi-organ failure due to renal insufficiency and died 
of pneumonia and sepsis. 
Ischemic events occurred in two patients. One patient (ID 13) presented with 
an acute small bowel ileus at time of diagnosis of PVT, which was treated conservative-
ly. Four months after diagnosis, due to ongoing symptoms, an explorative laparotomy 
was performed which showed a complete stenosis of the jejunum as well as thrombo-
sis of the draining mesenteric veins. A side-to-side jejuno-jejunostomy was performed 
proximally of the stenosis. The second patient (ID 2) presented with melena one month 
after the VLS measurements. Distal enteroscopy showed signs of ischemic colitis for 
which the patient was treated conservatively. In both patients decreased VLS measure-
ments were observed in at least one location of the gastrointestinal tract. 
Gastrointestinal bleeding events occurred in three patients and were all relat-
ed to variceal bleeding (ID 1, 2, and 9). One patient did not use OAC at time of bleeding. 
However, in the fourth year of follow-up, the patient developed deep vein thrombosis 
(DVT), for which OAC treatment was initiated. Two patients were using OAC at time of 
bleeding. In one of these patients, OAC had to be discontinued, which resulted in a DVT 
five months later. 
DISCUSSION
Gastrointestinal ischemia is a concerning complication of PVT. The occurrence and 
risks of gastrointestinal ischemia have in particular been acknowledged in patients 
with acute PVT.[1-3, 5, 6] The clinical spectrum of gastrointestinal ischemia in patients 
with chronic PVT is hitherto unknown. Therefore, we performed a unique prospective 
study in a well-characterized cohort of PVT patients in which clinical symptoms for gas-
trointestinal ischemia were assessed using a structured questionnaire, imaging of the 
mesenteric vasculature and VLS measurements. The latter enabled us to objectively and 
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9quantitatively determine the presence and extent of gastrointestinal mucosal ischemia. 
Patients presenting with non-malignant, non-cirrhotic PVT are quite rare, but we were 
able to include 15 patients meeting our inclusion criteria during a period of 24 months. 
The rarity of the disease made it difficult to compose a homogenous group. Therefore, 
we included patients with both acute and chronic PVT, patients on anticoagulation ver-
sus no anticoagulation, and complete versus partial occlusion of PV. 
Nevertheless, this is one of the few studies with prospective data on the oc-
currence of gastrointestinal ischemia in a population of patients with PVT. In our study, 
15 out of 16 patients were known with chronic PVT at time of the VLS measurements. 
We found that postprandial abdominal pain and exercise-induced pain are common in 
patients with chronic PVT and that mucosal ischemia is often present in these patients, 
especially in the antrum and descending duodenum. We also found that patients with 
a thrombus extending into the SMV and/or SV more often report abdominal pain than 
patients without extension of the thrombus. Also, patients with extension of the throm-
bus into the SMV and/or SV had significantly lower VLS measurements in the antrum 
and descending duodenum compared to the reference population. 
The findings presented in this study warrant caution in the patient with PVT: 
onset of abdominal symptoms such as postprandial pain should prompt the physician 
to re-evaluate extent, cause and treatment of PVT. For instance, one should be vigi-
lant of a possible thrombus extension into the SMV, as this is associated with worse 
outcome.[18] The results of our study show that involvement of the SMV and/or SV in 
patients with PVT can be detected by VLS measurements, however this was not the 
case in patients with PVT without thrombus extension. This suggests that mucosal isch-
emia could be more prevalent in patients with PVT with thrombus extension. Also, one 
should be aware of presence of a systemic hypercoagulable state, as this is associated 
with thrombosis of the smaller venules. Hypercoagulability results in thrombosis begin-
ning in the intramural venules, venous arcades, and vasa recta, often without involve-
ment of the larger venous vessels. Occlusion of these small veins, easily missed on con-
ventional CT-A or MR-A,[19] results in compromised venous drainage and is associated 
with an increased risk of bowel infarction.[2, 11, 20] Indeed, we found decreased VLS 
measurements in five out of six patients with an inherited hypercoagulable risk factor. 
Finally, we observed that VLS measurements were higher in patients treated with OAC 
compared to patients who were not or only partly treated, although this difference was 
not statistically significant, suggesting that there might be a positive effect of OAC on 
gastrointestinal ischemia in patients with chronic PVT.  The reported NNT needs to be 
interpreted with caution given it is based on a very limited number of patients. Com-
bined with the demonstrated beneficial effects of anticoagulation in chronic PVT in 
previous studies, showing a reduction in thrombotic events and splanchnic venous 
infarction without increasing the risk of gastrointestinal bleeding, it is tempting to ad-
vocate for a more prominent role of OAC in the treatment of patients with chronic PVT.
[21, 22]
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9In order to extrapolate our findings into daily practice, it is important to ad-
dress a few issues. First, patients with chronic PVT by definition have portal hyperten-
sion leading to venous congestion, which may result in decreased VLS measurements. 
This might be attributed to the presence of portal hypertension, since decreased VLS 
measurements were also observed in patients with cirrhosis. Furthermore, patients 
with cirrhosis had even lower VLS measurements than patients with PVT. Gastrointesti-
nal ischemia in patients with portal hypertension might be attributed to the substantial 
circulatory imbalance between vasoactive mediators, such as endothelin and nitric ox-
ide synthetase, due to the affected liver parenchyma in cirrhosis that may lead to vas-
cular dysfunction in the gastric antrum.[23, 24] Nonetheless, intestinal infarction is not 
a common complication of cirrhotic portal hypertension. This suggests compensatory 
mechanisms in these patients, which are lacking in patients with non-cirrhotic portal 
hypertension such as PVT. However, an in-depth studiy of the differences between cir-
rhotic and non-cirrhotic portal hypertension was beyond the scope of this study. 
Second, we used historical controls as a reference group for VLS measure-
ments as concurrent controls were not available. These controls were derived from the 
study by van Noord et al.[12] The VLS measurements in this group were performed in 
the same fashion as in the patients with PVT and cirrhotic patient controls, using the 
same protocol of measuring, devices, and equipment. Nevertheless, we cannot exclude 
the possibility that the inclusion of historical controls, instead of concurrent controls, 
might have led to a selection bias. Therefore, caution is needed in the interpretation of 
these results. 
Finally, cardiovascular risk factors for atherosclerosis, especially DM type II and 
obesity, are associated with occurrence of PVT and intestinal infarction.[20, 25, 26] In 
our study, only one patient had diabetes. However, given the limited number of pa-
tients, we cannot exclude the possibility that cardiovascular risk profile is associated 
with PVT-related gastrointestinal ischemia.  
To our knowledge, this is the first study which quantitatively assessed the pres-
ence of gastrointestinal ischemia in patients with PVT. VLS measures capillary hemoglo-
bin oxygen saturation and is a validated diagnostic method with a high sensitivity to 
assess the presence of gastrointestinal ischemia. The established cut-off values for each 
of the specific sites of the mesenteric tract were previously calculated by van Noord 
et al. These cut-off values were based on a trainee data set obtained from patients di-
agnosed with gastrointestinal ischemia using gastric tonometry and the values were 
additionally validated in a confirmation cohort.[12] Events that decrease the delivery 
of oxygen to the mesenteric mucosa (i.e. concomitant cardiopulmonary diseases) will 
result in lower mucosal hemoglobin oxygen saturations. Therefore, peripheral oxygen 
saturation and heart rate are continuously monitored during VLS measurements. In or-
der to minimize the effect of modifying factors such as concomitant cardiopulmonary 
diseases, peripheral saturation is kept above 94% by administering oxygen (FiO2 21%), 
if necessary. Factors that may affect VLS measurements are luminal spasms and bile 
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9acid remnants. Therefore, butylscopolamine is administered intravenously prior to the 
start of VLS measurements and these measurements are performed after irrigation of 
the target area. There is no difference in VLS measurements between younger and older 
patients, as VLS measurements are known to be affected only by the above mentioned 
factors and by presence of a significant stenosis of the mesenteric vasculature. As VLS 
measurements were performed at one time point only, it would be interesting to study 
the time course of gastrointestinal ischemia in patients with PVT, for instance before 
and after initiation of anticoagulation. Nonetheless, we were able to collect follow-up 
data in all patients, enabling us to assess occurrence of bleeding events, recurrent 
thrombosis, ischemic complications, and mortality. 
In future studies, it would be interesting to perform colonoscopy in all patients 
with PVT to assess ischemic changes in the colonic mucosa. Because bloody diarrhoea 
is only rarely observed in gastrointestinal ischemic patients, colonoscopy is now only 
included in our standard work up of the patient in case of lower GI symptoms. Further-
more, we believe it would be interesting to quantify the potential presence of ischemia 
in the colon by colonoscopy and also by VLS in future studies. However, currently VLS 
measurements are only validated in the upper GI tract and have not yet been validated 
in the colon. 
In addition, future studies should look into interactions between the factors 
associated with VLS measurements. Unfortunately, we were not able to look into this 
further due to the limited number of patients included in our cohort. 
In conclusion, gastrointestinal ischemia in patients with chronic PVT is more 
frequently encountered than previously assumed. Albeit in a small cohort, mucosal 
ischemia was detected in 75% of patients with PVT. Furthermore, two patients experi-
enced an ischemic event. To increase generalizability, future studies assessing patients 
with PVT should put more focus on the diagnosis and treatment of gastrointestinal 
ischemia. 
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This thesis aimed to provide more insight in the role of thrombophilia and genetic va-
riations in the pathogenesis and outcome of liver disease. The first part of the thesis 
focused on the prevalence and factors associated with liver fibrosis in the general po-
pulation. In part two of this thesis, we addressed the association between thrombop-
hilia and liver fibrogenesis. Finally, in the third part, the role of new genetic risk factors 
in SVT and the occurrence of gastrointestinal ischemia in portal vein thrombosis were 
discussed.  In the current chapter, the main findings of our studies will be summarized 
and discussed. Furthermore, directions for future research will be presented.
PREVALENCE AND RISK FACTORS OF LIVER FIBROSIS IN THE 
GENERAL POPULATION
Worldwide, each year over 1.7 million persons die due to cirrhosis and/or liver cancer 
(1). It is estimated that approximately 29 million persons are currently suffering from 
chronic liver disease in the European Union (2). In the next years, the burden of chronic 
liver diseases is projected to increase due to an expected, ongoing, increment in the 
number of persons suffering from non-alcoholic fatty liver disease (NAFLD). This incre-
ase in prevalence of NAFLD will parallel the rise in the number of individuals affected 
by obesity and diabetes mellitus. As individuals with NAFLD, particularly those with 
concomitant diabetes mellitus, are at risk of progression to non-alcoholic steatohepati-
tis (NASH) and advanced fibrosis, the number of individuals with chronic liver injury will 
rise significantly in the years to come (3, 4). 
The exact number of individuals suffering from chronic liver disease is not well 
known. For decades, it was not feasible to study the presence of liver fibrosis in healthy 
individuals, due to the lack of non-invasive tools to detect liver fibrosis. As a result, the 
prevalence of liver fibrosis in the general population was unknown. The introduction of 
transient elastography (TE) (Fibroscan®, EchosensTM, France) enabled non-invasive, fast 
and reproducible assessment of fibrosis, paving the way for studies investigating fibro-
sis without the morbidity and mortality associated with liver biopsy (5-8). In chapter 2, 
we investigated the distribution of and risk factors associated with clinically relevant 
liver fibrosis, using TE, in a large population-based cohort of Caucasian individuals. This 
study, as well as the studies described in chapter 3, 5, and 6 of this thesis, were part of 
the Rotterdam Study, a large, ongoing, prospective population-based cohort study. The 
main objective of the Rotterdam Study is to investigate the prevalence and incidence of 
and risk factors for chronic diseases in the elderly (9). For this purpose, all individuals liv-
ing in Ommoord, a suburb of the city of Rotterdam, aged 55 years and older were asked 
to participate at the start of this study in 1990. Of all invitees, 78% (7,983/10,275) agreed 
to participate in the study. In 2000, a second cohort was added to the Rotterdam Study 
including participants who had turned 55 years of age or had moved into the study 
district. A third cohort consisting of participants of 45 years and over was added to the 
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study in 2006. Each participant visits the designated research center every 3-5 years. 
During each visit, a uniform and extensive evaluation is conducted in all participants, 
including a home interview and a range of physical examinations. As of the most recent 
research center visit of all three cohorts, abdominal ultrasonography and a liver stiff-
ness (LS) measurement were added to this evaluation for all participants. 
We found that clinically relevant liver fibrosis, defined by a LS measurement of 
≥8.0 kPa, was present in 5.6% of 3,041 consecutive participants that visited the research 
center between January 2011 and September 2013. Higher age, presence of diabetes 
mellitus and/or steatosis, higher ALT, larger spleen size, current or former smoking, 
and positive viral serology for hepatitis B and/or C were all independent risk factors of 
clinically relevant fibrosis. These results were comparable to the results of two smaller 
previously reported studies assessing liver fibrosis by means of TE in healthy volunteers 
attending a free medical check-up in France and in a community-based study in Hong 
Kong Chinese subjects (10, 11). Taking the identified risk factors of fibrosis into account, 
we calculated the predicted probability of fibrosis for all participants. This probability 
increased with age and with the presence of steatosis or diabetes mellitus. Participants 
with both steatosis and diabetes mellitus had the highest probability of fibrosis, irre-
spective of age. In this subgroup, the overall probability of clinically relevant fibrosis 
was 17.2% (12.5-23.4%). These findings highlight the impact of obesity and diabetes 
mellitus  – modifiable risk factors – on fibrogenesis in the general population. Next 
to that, the observation that probability of fibrosis did not increase with age in par-
ticipants with concurrent steatosis and diabetes mellitus implicates that the relative 
burden of these risk factors is the highest for the youngest participants in our cohort, 
aged 50-60 years. In the context of an ageing population with an increasing prevalence 
of obesity and diabetes mellitus, these findings suggest that liver fibrosis and its com-
plications will become a more prominent public health issue in the nearby future. Our 
results therefore advocate the importance of targeting obesity and insulin resistance in 
order to prevent liver fibrosis. 
Genetics in liver fibrosis
Recent technical advancements and the unravelling of the human genome have ena-
bled hypothesis-free testing of common variants or single nucleotide polymorphisms 
(SNPs) throughout the genome for an association with complex traits and diseases. 
Since then, several genome-wide association studies (GWAS) have been performed in 
at-risk populations, including patients with viral hepatitis, alcoholic liver disease, cho-
lestatic liver diseases, gallstones, and NAFLD (12-22). In addition, multiple candidate 
SNP studies have been performed in patients with chronic liver injury. Several of these 
studies identified SNPs predisposing to liver fibrosis in at-risk populations (13, 16, 17, 
20, 23-25). However, it is unknown whether these SNPs affect fibrogenesis by interac-
ting with the agents causing chronic liver injury, for instance alcohol or viral hepatitis, 
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or whether these SNPs inflict fibrogenesis independently of other factors. Therefore, 
we studied the association between these fibrosis-associated SNPs and LS in the Rot-
terdam Study in chapter 3. We found that two linked SNPs in the interferon gamma 
receptor 2 (IFNGR2) gene, rs9976971 and rs2284553, were independently associated 
with increasing LS in this otherwise healthy Caucasian population. Exclusion of par-
ticipants with positive serology for hepatitis B and/or C and those with an excessive 
alcohol intake did not alter these results, suggesting that the SNPs in the IFNGR2 gene 
affect fibrogenesis independently of presence of chronic liver injury. The association 
between IFNGR2 and LS was also observed in a subgroup of participants with NAFLD, 
as a third SNP in the IFNGR2 gene, rs9808753, was independently associated with LS in 
this subgroup. In addition, we discovered that the association between these three IF-
NGR2 SNPs and fibrosis was significantly modified by body mass index. The association 
between the IFNGR2 SNPs and fibrosis was stronger for overweight (for rs9808753) and 
obese (for rs9976971 and rs2284553) participants compared to the total cohort. This 
finding might be explained by the presence of a systemic, chronic, pro-inflammatory 
state in obesity, which on its turn could reinforce the effect of interferon gamma on 
liver fibrosis development (26, 27). Future studies should aim at exploring the mecha-
nism by which IFNGR2 influences fibrogenesis, as this mechanism may give clues for the 
development of interferon gamma-based antifibrotic therapy.
THROMBOPHILIA IN LIVER FIBROGENESIS
Liver fibrosis is a multifactorial disorder. Besides chronic liver injury and genetic sus-
ceptibility, other factors, including hypercoagulability, are considered important in its 
pathogenesis. The first evidence for a role of hypercoagulability in fibrogenesis came 
from the observation that patients with concurrent chronic hepatitis C and haemop-
hilia were slow progressors of liver disease (28, 29). Later, several studies showed that 
presence of prothrombotic mutations – including the factor V Leiden polymorphism, 
prothrombin G20210A variant, and blood group type non-O – increased development 
and/or progression of fibrosis in patients with chronic viral hepatitis and NAFLD (30-
36). In chapter 4, we summarized the available evidence on the effect of anticoagulant 
drugs on fibrogenesis. Overall, studies suggest that administration of anticoagulant 
drugs could prevent fibrogenesis and possibly also reverse already existing fibrosis (37-
43). In addition, we described the hypotheses postulated in literature regarding the 
mechanism by which hypercoagulability could influence liver fibrogenesis, in which 
thrombin is a key player. 
To further explore the role of thrombophilia in liver fibrogenesis, we studied the 
association between common prothrombotic genetic risk factors and liver fibrosis in par-
ticipants of the Rotterdam Study cohort in chapter 5. Presence of the factor V Leiden 
mutation or prothrombin G20210A gene variant was associated with a twofold-increased 
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risk of clinically relevant fibrosis in this Caucasian population-based study cohort. This 
association was independent of other risk factors for liver fibrosis, including presence 
of steatosis, diabetes mellitus, smoking, age, ALT level, and alcohol intake. Combined 
presence of blood group type non-O and the factor V Leiden mutation or prothrombin 
G20210A gene variant resulted in an even higher risk of fibrosis. Participants with both 
blood group type non-O and the factor V Leiden mutation or prothrombin G20210A gene 
variant had a predicted probability of 14.3% of having fibrosis, which was significantly 
higher than the probability for those with blood group type O and/or those without the 
factor V Leiden mutation or prothrombin G20210A gene variant. These results may be 
explained by the fact that both the factor V Leiden mutation and blood group type non-O 
reduce sensitivity for activated protein C, causing an additional increase in procoagulant 
capacity if both factors are present (44-46). We concluded that these findings suggest 
that thrombophilia is an important factor in liver fibrogenesis in the general population. 
Therefore, one may suggest screening for common prothrombotic genetic risk factors in 
individuals with liver fibrosis of unknown etiology, as these individuals could potentially 
benefit from anticoagulant therapy.
Von Willebrand factor (VWF) is a key player in hemostasis, as it is involved in plate-
let adhesion, thrombus formation and binding of clotting factor VIII, thereby preventing 
its clearance (47, 48).  Previous studies have shown that high levels of VWF are associated 
with an increased risk of both venous and arterial thrombosis (49-51). It is known that VWF 
levels are increased in patients with cirrhosis. In these patients, VWF levels correlate with 
the hepatic venous pressure gradient and can even predict clinical outcomes (52, 53). In 
chapter 6, we showed that increased VWF levels were associated with liver fibrosis after 10 
years in the general population and in a subgroup of individuals with steatosis. Recently, a 
study in patients with hepatitis C showed that VWF levels increase with increasing fibrosis 
stage (54). However, the nature of the relationship between VWF levels and fibrosis and 
cirrhosis remains to be elucidated. Future studies are therefore warranted unravelling the 
mechanism behind the association of VWF levels with fibrosis and cirrhosis. Next to that, 
as our study suggests that VWF might be used as marker of preclinical liver fibrosis in the 
general population, future studies should assess the role of VWF levels in the prediction 
of development and progression of fibrosis. Finally, it remains to be determined whether 
VWF levels can also be used as predictor of clinical outcomes in individuals with fibrosis.
ETIOLOGY AND ISCHEMIC COMPLICATIONS OF VASCULAR LIVER 
DISEASES
Budd-Chiari syndrome (BCS) and non-malignant, non-cirrhotic portal vein thrombosis 
(PVT), collectively called splanchnic vein thrombosis (SVT), are rare forms of venous 
thrombosis of the hepatic venous outflow tract and the portal vein respectively. SVT is 
associated with considerable morbidity and mortality (55, 56). However, due to the low 
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prevalence of these disorders, few prospective studies have been performed assessing 
their etiology, diagnosis, treatment and prognosis. In chapter 4, we describe the role 
of anticoagulant therapy in the treatment of vascular liver diseases, including BCS and 
PVT, based on currently available data. 
Like in common venous thrombosis, systemic prothrombotic risk factors are 
pivotal in the etiology of SVT. Within this group of risk factors, genetic and acquired 
conditions are distinguished. Myeloproliferative neoplasms (MPNs) are the most com-
mon acquired risk factor for SVT with a prevalence of 20-50% (57, 58). Diagnosing MPNs 
in patients with SVT is important, given the prognostic and therapeutic implications 
regarding anticoagulant therapy (59, 60). However, detecting presence of MPNs is of-
ten challenging in clinical practice as portal hypertension resulting from the obstruc-
tion of the hepatic veins and/or portal vein causes hypersplenism and hemodilution. 
These conditions may conceal the characteristic peripheral blood cell changes asso-
ciated with MPN, such as thrombocytosis or polycythemia (61). The discovery of the 
JAK2V617F mutation has greatly improved the ability to non-invasively detect MPNs in 
patients with SVT (62-64). However, diagnosing MPNs remains difficult in the absence 
of the JAK2V617F mutation (59, 65). Recently, exome sequencing resulted in the detec-
tion of somatic mutations in CALR in patients with MPN lacking JAK2V617F and MPL 
mutations (66, 67). We hypothesized therefore that identification of CALR mutations 
in patients with SVT could improve the ability to diagnose MPNs in these patients. In 
chapter 7, we evaluated the prevalence and role of CALR mutations in patients with 
SVT. This study was based on data from the European Network for Vascular Disorders of 
the Liver (EN-Vie). For the EN-Vie study cohort, patients with BCS and non-malignant, 
non-cirrhotic PVT were prospectively enrolled from nine European countries. Data on 
etiology, clinical presentation, diagnosis and follow-up was systematically collected for 
all patients. In addition, DNA and plasma was stored for future analyses (57, 58). Using 
these DNA-samples, we found that CALR mutations are rare in patients with SVT, as only 
one patient had a CALR mutation in our cohort. As a result, prevalence of CALR muta-
tions was 0.7% in the total cohort and 2.3% in patients with MPN. Our findings were 
confirmed by other studies, the reported prevalence of CALR mutations in patients with 
SVT ranged between 0 and 2% (68-72). This low prevalence might be attributable to the 
fact that patients with a CALR mutation have a lower risk of thrombosis compared to 
patients with a JAK2V617F mutation. This could be explained by the presence of lower 
hemoglobin and white blood cell counts in patients with a CALR mutation compared 
to MPN patients without a CALR mutation (66, 67). Nonetheless, we believe that testing 
for CALR mutations should be performed in patients with JAK2V617F negative SVT, as 
screening for somatic CALR mutations is an easy to perform diagnostic method that 
could aid in the challenging diagnosis of MPN with limited burden for the patient. The 
recently published consensus guidelines from the Baveno VI faculty also recommend 
screening for presence of CALR mutations in JAK2V617F negative SVT patients (73).
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Despite the fact that multiple genetic and acquired risk factors have been 
identified, in 15-25% of patients with SVT no etiologic factor can be detected (57, 58), 
underlining the need for studies investigating new risk factors. Given the fact that many 
risk factors of common venous thrombosis are also recognized as etiologic factors in 
SVT, we investigated the role of novel candidate SNPs, known to increase the risk of 
common venous thrombosis, as risk factors for SVT in chapter 8. We genotyped six 
SNPs – in the ABO, STXBP5, VWF, CYP4V2, GP6, and SERPINC1 gene – known to increase 
the risk of common venous thrombosis using DNA samples from patients and controls 
of the EN-Vie study cohort (74-77). In this cohort, the SNP determining blood group 
type was associated with an increased risk of PVT, but not BCS. However, this finding 
could not be confirmed in a validation cohort consisting of patients diagnosed with 
SVT in three large tertiary referral clinics in France, Spain and the Netherlands. The other 
five SNPs were not associated with an increased risk of either PVT or BCS in the EN-Vie 
cohort. Therefore, none of the six SNPs can be considered a risk factor for BCS or PVT. 
These findings suggest that other local and systemic risk factors are of more impor-
tance in the etiology of SVT. The identification of these differences in etiology between 
SVT and common venous thrombosis contributes to a better understanding of the 
pathogenesis of venous thrombosis at different sites and supports the site-specificity 
of venous thrombosis.
Gastrointestinal ischemia is considered a concerning adverse event of PVT, 
as it can result in intestinal infarction, a life-threatening condition (78). However, the 
prevalence and characteristics of gastrointestinal ischemia in PVT are not well known. 
The reported prevalence of gastrointestinal ischemia in patients with acute PVT ranges 
between 2% and 32%, with mortality rates of 0-20% (58, 79-84). In chronic PVT, studies 
are more scarce and report conflicting results. Some assume that ischemia is unlikely to 
occur in these patients due to presence of a collateral circulation, while others did find 
a portal cavernoma in nearly half of the SVT patients presenting with ischemia (78, 80). 
The paucity of data on the occurrence of ischemia in PVT results, at least in part, from 
a lack of diagnostic tools. As clinical symptoms of ischemia are often atypical and com-
parable to the clinical findings in patients with PVT, it is difficult to diagnose ischemia 
based on clinical symptoms solely. The introduction of visible light spectroscopy (VLS) 
offers a new minimally invasive tool in diagnosing gastrointestinal ischemia in PVT (85). 
VLS enables objective and direct quantification of ischemia in the gastrointestinal tract, 
by measuring the adequacy of mucosal perfusion during gastroscopy (85, 86). There-
fore, we prospectively determined the presence and characteristics of gastrointestinal 
ischemia in patients with PVT using VLS in chapter 9.  Gastrointestinal ischemia was 
frequent in these patients with mainly chronic PVT, as a decreased mucosal oxygen-
ation was found in 75% of patients in at least 1 location of the gastrointestinal tract. 
VLS measurements were mostly decreased in the descending duodenum. Symptoms 
typical for ischemia, such as postprandial pain and exercise-induced pain, were present 
in 63% of patients. We found that extension of thrombus into the superior mesenteric 
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vein and splenic vein and/or presence of hypercoagulability were associated with lower 
VLS measurements in patients with PVT compared to historical controls. Next to that, 
VLS measurements were higher in patients treated with oral anticoagulation than in 
those who were not or only partly treated, but this difference did not reach statistical 
significance. However, this finding suggests that there might be a positive effect of oral 
anticoagulation on the occurrence of ischemia in patients with chronic PVT. Confirma-
tion of these results in larger studies is warranted, but our findings suggest that onset 
of abdominal symptoms, such as postprandial pain, should prompt the physician to 
re-evaluate extent, cause, and treatment of PVT. 
DIRECTIONS FOR FUTURE RESEARCH
As described in this thesis, liver fibrosis affects approximately 1 in 18 older Caucasian 
adults in Rotterdam. In particular, individuals with steatosis and diabetes mellitus are 
at risk, as their probability of fibrosis is as high as 17%. Given the current increase in 
prevalence of steatosis and diabetes mellitus in the Western world, the prevalence of 
NAFLD-induced fibrosis is expected to increase and become a major public health pro-
blem (4). Wide implementation of prevention programs targeting obesity, insulin resis-
tance, and its complications is therefore urgently needed. Lifestyle interventions, most 
importantly diet and exercise, are the cornerstone of the management of NAFLD, but 
adherence to these lifestyle measures is often challenging (4). A recent trial in patients 
with coronary heart disease showed that frequent semipersonalized test messages im-
proved cardiovascular disease risk factors, including BMI, smoking and physical activity 
(87). Investigating the efficacy of such lifestyle-focused support programs might prove 
to be beneficial in improving the adherence to lifestyle interventions in patients with 
NAFLD. Despite multiple studies, no drug has yet been approved for treatment of these 
patients, limiting other therapeutic options. Studies evaluating mortality rates associa-
ted with fibrosis in the general population will aid in assessing the impact of this public 
health issue. 
During the last decade, there has been an exponential increase in the number 
of studies investigating the role of genetics in various complex diseases, including liver 
diseases. However, the currently available studies only represent the first steps in unravel-
ling the complex interplay between genetic variations and liver diseases. Therefore, many 
promising fields remain to be explored. With respect to liver fibrosis, several SNPs have 
currently been identified as risk factors of fibrosis (13, 16, 17, 20, 23-25). It would be very 
interesting to perform a GWAS within the Rotterdam Study to identify genetic variants 
contributing to the development of liver fibrosis in the general population. In addition, 
as techniques in mapping the human genome are rapidly evolving, it is now possible to 
sequence exomes and even whole genomes. Therefore, these new techniques will offer 
more possibilities to identify loci associated with various liver diseases in the years to come. 
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The observation that administration of low molecular weight heparin reduced 
the incidence of liver decompensation and improved survival in cirrhosis (43) warrants 
further investigation of the potential beneficial role of anticoagulant drugs in these 
patients in larger, double-blind trials. These studies should also include an objective 
assessment of portal hypertension. Additional research questions that remain to be 
answered include the effect of other anticoagulant drugs, including new oral anticoag-
ulants (NOACs), and the optimal treatment dose and duration. Furthermore, as studies 
also showed a potential beneficial effect of anticoagulant drugs on liver fibrosis (37-42), 
it would be desirable to study the effect of anticoagulant medication on fibrosis in larg-
er populations, including at-risk groups and population-based studies.
In patients with PVT, long-term anticoagulant therapy is currently recommend-
ed only in patients with a persistent prothrombotic condition, recurrent thrombosis or 
intestinal infarction (73). Prospective studies assessing risks and benefits of anticoagu-
lant therapy in patients with chronic non-malignant, non-cirrhotic PVT without these 
conditions are warranted, as the role of anticoagulant treatment in the management of 
these patients is not known. In recent years, two new types of direct acting oral antico-
agulants were introduced: direct thrombin inhibitors and factor Xa inhibitors. A major 
advantage of these new drugs is that they do not require laboratory monitoring, have 
fewer drug-drug and drug-food interactions, and have a wider therapeutic range. In 
a large meta-analysis in almost 28,000 participants, these NOACs were as effective as 
standard anticoagulation in the treatment of deep venous thrombosis (88). Although 
an increased risk of gastrointestinal bleeding has been described in patients treated 
with NOACs (89), studies in patients with venous thromboembolism reported a com-
parable or even decreased risk of bleeding associated with NOACs when compared to 
the standard treatment with vitamin K antagonists (88, 90, 91). Use of these NOACs in 
patients with common venous thrombosis is currently implemented in clinical practice. 
It is important to determine the place of these new oral anticoagulants in the treatment 
of patients with SVT. Therefore, trials assessing the efficacy and safety of these new 
oral anticoagulants in comparison to standard anticoagulation should be initiated in 
patients with SVT.
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Het doel van dit proefschrift was om meer inzicht te geven in de rol van trombofilie en 
genetische varianten in de pathogenese en uitkomst van leverziekten. Het eerste deel 
van het proefschrift focuste zich op de prevalentie en factoren geassocieerd met lever 
fibrose in de algemene bevolking. In deel twee van dit proefschrift hebben we de asso-
ciatie tussen trombofilie en lever fibrogenese behandeld. Tot slot werden in het derde 
deel de rol van nieuwe genetische risicofactoren in splanchnische veneuze trombose 
(SVT) en het voorkomen van gastro-intestinale ischemie bij vena portae trombose be-
sproken. In dit hoofdstuk zullen de belangrijkste bevindingen van onze studies worden 
samengevat en bediscussieerd. Verder zullen suggesties voor toekomstig onderzoek 
worden gepresenteerd.
PREVALENTIE EN RISICOFACTOREN VAN LEVER FIBROSE IN DE 
ALGEMENE BEVOLKING
Wereldwijd sterven jaarlijks 1.7 miljoen personen aan de gevolgen van cirrose en/of 
leverkanker (1). Naar schatting lijden ongeveer 29 miljoen personen in de Europese 
Unie aan een chronische leverziekte (2). De verwachting is dat de ziektelast ten gevolge 
van chronische leverziekten de komende jaren zal toenemen door een verdere stijging 
van het aantal personen met niet-alcoholische vetleverziekte (‘non-alcoholic fatty liver 
disease’, NAFLD). Deze stijging van de prevalentie van NAFLD zal parallel lopen aan de 
toename in het aantal personen met obesitas en diabetes mellitus. Het aantal personen 
met een chronische leverziekte zal significant toenemen in de komende jaren,  omdat 
personen met NAFLD, in het bijzonder degenen die tevens diabetes mellitus hebben, 
risico lopen op progressie naar niet-alcoholische steatohepatitis (NASH) en gevorderde 
fibrose (3, 4). 
Het is niet precies bekend hoeveel personen aan een chronische leverziekte 
lijden. Het was lange tijd niet mogelijk om gezonde personen te onderzoeken op de 
aanwezigheid van lever fibrose, vanwege het ontbreken van niet-invasieve methoden 
voor het opsporen van fibrose.  Daardoor was de prevalentie van lever fibrose in de 
algemene bevolking onbekend. De introductie van transiente elastografie  (‘transient 
elastography’ (TE) (Fibroscan®, EchosensTM, France) maakte het mogelijk om aanwezig-
heid van fibrose te onderzoeken op een niet-invasieve, snelle en reproduceerbare ma-
nier. Hierdoor ontstond de mogelijkheid om studies naar fibrose op te zetten zonder 
de morbiditeit en mortaliteit geassocieerd met lever biopsie (5-8). In hoofdstuk 2 on-
derzochten we de verdeling van- en risicofactoren geassocieerd met klinisch relevante 
lever fibrose, onderzocht met TE, in een groot bevolkingsonderzoek onder Kaukasische 
personen. Deze studie en de studies beschreven in hoofdstuk 3, 5 en 6 van dit proef-
schrift waren onderdeel van het Erasmus Rotterdam Gezondheid Onderzoek (ERGO), 
ook wel de ‘Rotterdam Study’ genoemd. Het ERGO is een groot, longitudinaal, nog 
steeds lopend bevolkingsonderzoek. Het belangrijkste doel van het ERGO is het onder-
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zoeken van de prevalentie, incidentie en risicofactoren van chronische ziekten bij ou-
deren (9). Met dit doel werd bij de start van het ERGO aan alle inwoners van Ommoord, 
een wijk in Rotterdam, van 55 jaar en ouder gevraagd om deel te nemen aan dit bevol-
kingsonderzoek. Van alle genodigden, besloot 78% (7,983/10,275) om deel te nemen. 
In 2000 werd een tweede cohort toegevoegd aan het ERGO. Dit tweede cohort bestond 
uit personen die 55 jaar of ouder waren geworden of waren verhuisd naar Ommoord 
sinds de start van het eerste ERGO-cohort. Een derde cohort, bestaande uit deelnemers 
van 45 jaar en ouder, werd toegevoegd aan het onderzoek in 2006.  Iedere deelnemer 
bezoekt het onderzoekscentrum van ERGO elke 3-5 jaar. Tijdens ieder bezoek wordt 
een uniform en uitgebreide evaluatie uitgevoerd bij alle deelnemers, bestaande uit een 
thuisinterview en een aantal onderzoeken. Sinds het meest recente bezoek aan het 
onderzoekscentrum wordt bij alle deelnemers van de drie cohorten ook een echo van 
de buik en een meting van de leverstijfheid (LS) verricht. 
Wij zagen dat klinisch relevante lever fibrose, gedefinieerd als een LS meting 
van ≥8.0 kPa, aanwezig was in 5.6% van 3041 opeenvolgende deelnemers die het onder-
zoekscentrum bezochten tussen januari 2011 en september 2013. Een hogere leeftijd, 
aanwezigheid van diabetes mellitus en/of steatose, hoger ALT, grotere miltdiameter, 
roken en aanwezigheid van virusserologie voor hepatitis B en/of C waren onafhanke-
lijke risicofactoren voor het hebben van klinisch relevante fibrose. Deze resultaten wa-
ren vergelijkbaar met de resultaten van twee kleinere, eerder gepubliceerde studies, 
waarin lever fibrose werd onderzocht door middel van TE in gezonde vrijwilligers die 
meededen aan en gratis medische controle in Frankrijk en in een studie met personen 
uit de Hong Kong Chinese bevolking (10, 11). Voor alle deelnemers in onze studie heb-
ben we de voorspelde waarschijnlijkheid van het hebben van fibrose berekend met 
inachtneming van de risicofactoren voor fibrose. Deze waarschijnlijkheid nam toe met 
de leeftijd en met de aanwezigheid van steatose of diabetes mellitus. Deelnemers met 
zowel steatose als diabetes mellitus hadden de hoogste kans om fibrose te hebben, on-
geacht hun leeftijd. De waarschijnlijkheid van het hebben van klinisch relevante fibrose 
was 17.2% (12.5-23.4%) in deze subgroep van ons cohort. Deze bevindingen onderstre-
pen de impact van obesitas en diabetes mellitus op fibrogenese in de algemene bevol-
king. De observatie dat de waarschijnlijkheid van fibrose niet toenam met de leeftijd 
in deelnemers met zowel steatose als diabetes mellitus impliceert bovendien dat de 
gevolgen van deze risicofactoren relatief het grootst zijn voor de jongste deelnemers in 
ons cohort, dat wil zeggen de deelnemers tussen 50 en 60 jaar oud. In het licht van de 
huidige vergrijzing van de samenleving met daarnaast een stijgende prevalentie van 
obesitas en diabetes mellitus suggereren deze bevindingen dat lever fibrose en de bij-
behorende complicaties een prominenter gezondheidsprobleem voor de samenleving 
zullen worden in de nabije toekomst. Onze resultaten pleiten daarom voor de aanpak 
van obesitas en insuline resistentie met het doel lever fibrose te voorkomen. 
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Genetica in lever fibrose
Recente technologische ontwikkelingen en de ontrafeling van het menselijk genoom 
hebben het mogelijk gemaakt om zonder hypothese te testen of veelvoorkomende 
veranderingen van een enkele nucleotide (‘single nucleotide polymorphism’ (SNP)) in 
het genoom geassocieerd zijn met het voorkomen van complexe aandoeningen en 
ziektes. Sindsdien zijn verschillende genoom-brede associatie studies (‘genome-wide 
association studies’ (GWAS) verricht in risicopopulaties, zoals patiënten met virale he-
patitis, alcoholische leverziekte, cholestatische leverziekten, galstenen en NAFLD (12-
22). Daarnaast zijn er verscheidene kandidaat SNP studies uitgevoerd in patiënten met 
chronische leverschade. In verschillende van deze studies werden SNPs geïdentificeerd 
die zorgden voor een genetische aanleg voor lever fibrose in risicopopulaties (13, 16, 
17, 20, 23-25). Het is echter niet bekend of deze SNPs het ontwikkelen van fibrose beïn-
vloeden door een interactie met de factoren die chronische leverschade veroorzaken, 
zoals alcohol en virale hepatitis, of dat deze SNPs de ontwikkeling van fibrose onafhan-
kelijk van andere factoren stimuleren. Daarom hebben wij de associatie tussen deze 
fibrose-gerelateerde SNPs en LS onderzocht in het ERGO in hoofdstuk 3. We vonden 
dat 2 gelinkte SNPs in het interferon gamma receptor 2 (IFNGR2) gen, rs9976971 en 
rs2284553, onafhankelijk waren geassocieerd met een stijgende LS in deze verder ge-
zonde Kaukasische bevolking. Exclusie van deelnemers met positieve virusserologie 
voor hepatitis B en/of C en van deelnemers met excessief alcoholgebruik veranderde 
de resultaten niet. Dit suggereert dat de SNPs in het IFNGR2 gen fibrogenese onafhan-
kelijk van de aanwezigheid van chronische leverschade beïnvloeden. De associatie 
tussen IFNGR2 en LS werd ook gezien in een subgroep van deelnemers met NAFLD. 
In deze subgroep was namelijk een derde SNP in het IFNGR2 gen, rs9808753, onafhan-
kelijk geassocieerd met LS. We ontdekten ook dat de associatie tussen deze drie IFNGR2 
SNPs en fibrose significant werd veranderd door de body mass index (BMI). De associ-
atie tussen de IFNGR2 SNPs en fibrose was sterker voor deelnemers met overgewicht 
(voor rs9808753) en deelnemers met obesitas (voor rs9976971 en rs2284553) vergeleken 
met het totale cohort. Deze bevinding zou verklaard kunnen worden door de aanwe-
zigheid van een systemische, chronische, pro-inflammatoire status in obesitas, die op 
haar beurt het effect van interferon gamma op de ontwikkeling van lever fibrose zou 
kunnen versterken (26, 27). Toekomstige studies zouden zich moeten richten op het 
ontdekken van het mechanisme waarmee IFNGR2 fibrogenese beïnvloedt, aangezien 
dit mechanisme aangrijpingspunten voor de ontwikkeling van interferon gamma-ge-
baseerde antifibrotische therapie zou kunnen geven. 
TROMBOFILIE IN LEVER FIBROGENESE
Lever fibrose is een multifactoriële aandoening. Naast chronische leverschade en gene-
tische aanleg spelen andere factoren, zoals hypercoagulabiliteit, een belangrijke rol in 
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de pathogenese. De eerste aanwijzing dat hypercoagulabiliteit een rol speelt in fibro-
genese was de observatie dat patiënten die zowel chronische hepatitis C als hemofilie 
hadden een trage progressie hadden van hun leverziekte (28, 29). Verschillende studies 
toonden later dat aanwezigheid van protrombotische mutaties – waaronder het factor 
V Leiden polymorfisme, protrombine G20210A variant en bloed groep type non-O – 
de ontwikkeling en/of progressie van fibrose versnelden in patiënten met chronische 
virale hepatitis en NAFLD (30-36). In hoofdstuk 4 hebben we een overzicht gegeven 
van het beschikbare bewijs over het effect van anticoagulantia op fibrogenese. Samen-
vattend suggereren studies dat het geven van anticoagulantia fibrogenese zou kunnen 
voorkomen en reeds gevormde fibrose zou kunnen verminderen (37-43). Daarnaast 
hebben we in dit hoofdstuk de in de literatuur gepostuleerde hypothese over het 
mechanisme waarmee hypercoagulabiliteit lever fibrogenese beïnvloedt beschreven. 
Trombine speelt een essentiële rol in deze hypothese. 
Om de invloed van trombofilie op lever fibrogenese verder te bestuderen, 
hebben we de associatie tussen veelvoorkomende protrombotische genetische risico-
factoren en lever fibrose in deelnemers van het ERGO cohort onderzocht in hoofdstuk 
5. Het hebben van een factor V Leiden mutatie or protrombine G20210A gen variant 
was geassocieerd met een twee keer verhoogd risico op klinisch relevante lever fibro-
se in dit Kaukasische cohort bestaande uit personen uit de algemene bevolking. Deze 
associatie was onafhankelijk van andere risicofactoren voor lever fibrose, waaronder 
aanwezigheid van steatose, diabetes mellitus, roken, leeftijd, ALT waarde en alcoho-
linname. Gecombineerde aanwezigheid van bloed groep type non-O en het factor V 
Leiden polymorfisme of protrombine G20210A gen variant leidde tot een nog hoger 
risico op fibrose. Deelnemers met zowel bloed groep type non-O als het factor V Leiden 
polymorfisme of de protrombine G20210A gen variant hadden een voorspelde waar-
schijnlijkheid van 14.3% op het hebben van fibrose. Deze kans was significant hoger 
dan de kans voor deelnemers met bloed groep type O en/of deelnemers zonder het 
factor V Leiden polymorfisme of de protrombine G20210A gen variant. Deze resultaten 
zouden mogelijk kunnen worden verklaard door het feit dat zowel het factor V Leiden 
polymorfisme als bloed groep type non-O de gevoeligheid voor geactiveerd proteïne 
C verminderen. Hierdoor ontstaat een extra verhoogde procoagulante capaciteit wan-
neer beide factoren aanwezig zijn (44-46). 
Wij concludeerden dat deze resultaten suggereren dat trombofilie een belang-
rijke factor is in lever fibrogenese in de algemene bevolking. Screening op aanwezig-
heid van veelvoorkomende protrombotische genetische risicofactoren zou daarom 
aangeraden kunnen worden in personen met lever fibrose van onbekende origine, 
aangezien deze personen potentieel voordeel zouden kunnen hebben van behande-
ling met anticoagulantia. 
Von Willebrand factor (VWF) is een essentiële factor in hemostase, aangezien 
het betrokken is bij de adhesie van trombocyten, trombusvorming en binding van stol-
lingsfactor VIII, waarmee het zijn klaring voorkomt (47, 48). Voorgaande studies hebben 
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laten zien dat hoge VWF waarden geassocieerd zijn met een verhoogd risico op zowel 
veneuze als arteriële trombose (49-51). Het is bekend dat VWF waarden verhoogd zijn 
in patiënten met cirrose. In deze patiënten correleren VWF waarden met de hepati-
sche veneuze drukgradiënt en kunnen ze zelfs klinische uitkomsten voorspellen (52, 
53). In hoofdstuk 6 toonden we dat verhoogde VWF waarden geassocieerd zijn met 
de aanwezigheid van lever fibrose na 10 jaar in de algemene bevolking en in een sub-
groep van personen met steatose. Een recente studie in patiënten met hepatitis C liet 
zien dat VWF waarden stegen met een toenemend fibrosestadium (54). De aard van de 
relatie tussen VWF en fibrose en cirrose is echter nog onbekend. Daarom zijn toekom-
stige studies nodig die het mechanisme achter deze associatie onderzoeken. Omdat 
onze studie suggereert dat VWF gebruikt zou kunnen worden als mogelijke marker van 
preklinische lever fibrose in de algemene bevolking zijn er ook studies nodig die zich 
richten op de rol van VWF waarden in de predictie van ontwikkeling en progressie van 
fibrose. Tot slot blijft het onopgehelderd of VWF waarden ook gebruikt kunnen worden 
om klinische uitkomsten in personen met fibrose te voorspellen.
ETIOLOGIE EN ISCHEMISCHE COMPLICATIES VAN VASCULAIRE 
LEVERZIEKTEN
Budd-Chiari syndroom (BCS) en niet-maligne, niet-cirrotische vena portae trombose 
(PVT), samen SVT genoemd, zijn zeldzame vormen van veneuze trombose van respec-
tievelijk de afvoerende bloedvaten van de lever en de vena portae. SVT is geassoci-
eerd met een aanzienlijke morbiditeit en mortaliteit (55, 56). Door de lage prevalentie 
zijn er echter weinig prospectieve studies naar de etiologie, diagnose, behandeling en 
prognose van deze aandoeningen gedaan. In hoofdstuk 4 hebben we op basis van de 
beschikbare literatuur een overzicht gegeven van de rol van anticoagulantia in de be-
handeling van vasculaire leverziekten, waaronder BCS en PVT.  
Systemische protrombotische risicofactoren zijn cruciaal in de etiologie van 
SVT, net zoals bij de meer gebruikelijke vormen van veneuze trombose. Binnen deze 
groep risicofactoren worden genetische en verworven aandoeningen onderscheiden. 
Myeloproliferatieve neoplasieën (MPNs) zijn de meest voorkomende verworven risi-
cofactor voor SVT, met een prevalentie van 20-50% (57, 58). Het diagnosticeren van 
MPNs in patiënten met SVT is belangrijk, gezien de prognose en de implicaties voor 
de behandeling met anticoagulantia (59, 60). Het is echter lastig om aanwezigheid van 
MPNs vast te stellen in de klinische praktijk, aangezien portale hypertensie veroorzaakt 
door obstructie van de hepatische venen en/of vena portae leidt tot hypersplenisme 
en hemodilutie. Deze omstandigheden kunnen de karakteristieke veranderingen van 
MPNs in het perifere bloed, zoals trombocytose en polycytemie, verhullen (61). De ont-
dekking van de JAK2V617F mutatie heeft tot een grote verbetering geleid in het niet-in-
vasief diagnosticeren van MPNs in patiënten met SVT (62-64). Het blijft echter lastig om 
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MPNs te diagnosticeren in de afwezigheid van de JAK2V617F mutatie (59, 65). Exome 
sequencing heeft recent geresulteerd in de ontdekking van somatische mutaties in 
CALR in patiënten met MPN zonder de JAK2V617F en MPL mutaties (66, 67). Wij heb-
ben daarop de hypothese opgesteld dat identificatie van CALR mutaties in patiënten 
met SVT het diagnosticeren van MPNs in deze patiënten zou verbeteren. In hoofdstuk 
7 hebben we de prevalentie en rol van CALR mutaties in patiënten met SVT geëvalu-
eerd. Deze studie was gebaseerd op data van een uniek patiëntencohort dat het re-
sultaat is van een Europees samenwerkingsverband (European Network for Vascular 
Disorders of the Liver (EN-Vie)). Voor het EN-Vie studiecohort werden patiënten met 
BCS en niet-maligne, niet-cirrotische PVT geïncludeerd afkomstig uit negen Europese 
landen. Van alle patiënten werd systemisch data verzameld over de etiologie, klinische 
presentatie, diagnose en follow-up. Daarnaast werd DNA en plasma opgeslagen voor 
toekomstige analyses (57, 58). Gebruikmakend van deze DNA-monsters vonden we dat 
CALR mutaties zeldzaam zijn in patiënten met SVT, aangezien slechts één patiënt in ons 
cohort een CALR mutatie had. Als gevolg hiervan was de prevalentie van CALR mutaties 
0.7% in het totale cohort en 2.3% in de patiënten met MPN. Onze bevindingen werden 
bevestigd door andere studies, de beschreven prevalentie van CALR mutaties in pa-
tiënten met SVT varieert tussen 0 en 2% (68-72). Deze lage prevalentie zou verklaard 
kunnen worden door het feit dat patiënten met een CALR mutatie een lager risico op 
trombose hebben dan patiënten met een JAK2V617F mutatie. Dit zou kunnen komen 
door de aanwezigheid van een lager hemoglobine gehalte en een kleiner aantal witte 
bloedcellen in patiënten met een CALR mutatie vergeleken met MPN patiënten zonder 
een CALR mutatie (66, 67). Desalniettemin geloven we dat men zou moeten testen op 
de aanwezigheid van CALR mutaties in patiënten met SVT zonder de JAK2V617F muta-
tie, aangezien screening naar somatische CALR mutaties een eenvoudig diagnosticum 
is dat zou kunnen helpen in de lastige diagnose van MPN met een beperkte belasting 
voor de patiënt. Ook de recent gepubliceerde richtlijnen van de Baveno VI expert groep 
adviseren om te screenen op aanwezigheid van CALR mutaties in JAK2V617F negatieve 
SVT patiënten (73).
Ondanks het feit dat meerdere genetische en verworven risicofactoren voor 
SVT bekend zijn, kan in 15-25% van de patiënten met SVT geen etiologische factor wor-
den ontdekt (57, 58). Daarom zijn studies nodig gericht op het ontdekken van nieuwe 
risicofactoren. Gezien het feit dat veel risicofactoren voor de meer gebruikelijke vor-
men van veneuze trombose ook een rol spelen bij de etiologie van SVT, hebben we 
onderzocht of nieuwe kandidaat SNPs, waarvan we weten dat ze het risico op de meer 
gebruikelijke vormen van veneuze trombose verhogen, een risicofactor zijn voor SVT in 
hoofdstuk 8. We hebben zes SNPs – in het ABO, STXBP5, VWF, CYP4V2, GP6 en SERPINC1 
gen – onderzocht waarvan we weten dat ze het risico op de meer gebruikelijke vormen 
van veneuze trombose verhogen. Hiervoor hebben we DNA monsters gebruikt van pa-
tiënten en controles van het EN-Vie studie cohort (74-77). In dit cohort was de SNP die 
het bloed groep type bepaalt geassocieerd met een verhoogd risico op PVT, maar niet 
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op BCS. Deze bevinding kon echter niet worden gevalideerd in een cohort bestaan-
de uit patiënten gediagnosticeerd met SVT in drie grote tertiaire verwijzingscentra in 
Frankrijk, Spanje en Nederland. De andere vijf SNPs waren niet geassocieerd met een 
verhoogd risico op PVT of BCS in het EN-Vie cohort. Geen van de zes SNPs kan daarom 
worden beschouwd als een risicofactor voor BCS of PVT.  Deze resultaten suggereren 
dat andere lokale en systemische risicofactoren een grotere rol spelen in de etiologie 
van SVT. Het ontdekken van deze verschillen in de etiologie van SVT en de meer gebrui-
kelijke vormen van veneuze trombose zorgt voor meer inzicht in de pathogenese van 
veneuze trombose op verschillende plaatsen in het lichaam en ondersteunt de locatie-
afhankelijkheid van veneuze trombose. 
Gastro-intestinale ischemie wordt beschouwd als een ernstig gevolg van PVT, 
omdat het kan resulteren in intestinale infarcering, een levensbedreigende aandoe-
ning (78). De prevalentie en karakteristieken van gastro-intestinale ischemie in PVT zijn 
echter niet goed bekend. De beschreven prevalentie van gastro-intestinale ischemie 
in patiënten met acute PVT varieert tussen 2% en 32% met een mortaliteit van 0-20% 
(58, 79-84). Er zijn nauwelijks studies naar ischemie in patiënten met chronische PVT 
en de studies die beschikbaar zijn, rapporteren conflicterende resultaten. Sommige 
stellen dat het optreden van ischemie onwaarschijnlijk is bij deze patiënten vanwege 
de aanwezigheid van een collaterale circulatie, terwijl anderen een portaal cavernoom 
vonden in bijna de helft van de patiënten met SVT die zich presenteerden met ischemie 
(78, 80). Het gebrek aan data over het voorkomen van ischemie in PVT komt, in ieder 
geval deels, door de afwezigheid van goede diagnostische methodes. Het is lastig om 
de diagnose ischemie te stellen gebaseerd op alleen klinische symptomen, aangezien 
deze vaak atypisch zijn en vergelijkbaar met de klinische bevindingen bij patiënten met 
PVT. De introductie van zichtbaar licht spectroscopie (‘visible light spectroscopy’, VLS) 
biedt een nieuwe, minimaal invasieve methode om gastro-intestinale ischemie te diag-
nosticeren in PVT (85). Met behulp van VLS kan een objectieve en directe kwantificatie 
van ischemie in het maagdarmkanaal worden verkregen, door de mucosale perfusie 
te meten tijdens gastroscopie (85, 86). Daarom hebben wij prospectief de aanwezig-
heid en karakteristieken van gastro-intestinale ischemie in patiënten met PVT bepaald 
met behulp van VLS in hoofdstuk 9. Gastro-intestinale ischemie kwam frequent voor 
in deze patiënten met voornamelijk chronische PVT. In 75% van de patiënten werd een 
verlaagde mucosale oxygenatie gemeten op minimaal 1 plaats in het maagdarmka-
naal. VLS metingen waren voornamelijk verlaagd in het pars descendens van het duo-
denum. Typische symptomen van ischemie, zoals postprandiale pijn en inspanningsge-
relateerde pijn waren aanwezig in 63% van de patiënten. Uitbreiding van de trombose 
naar de vena mesenterica superior en de vena lienalis en/of aanwezigheid van hyper-
coagulabiliteit waren geassocieerd met lagere VLS metingen in patiënten met PVT 
vergeleken met historische controles. Daarnaast zagen we dat VLS metingen hoger 
waren in patiënten die behandeld werden met orale anticoagulantia vergeleken met 
patiënten die niet of slechts gedeeltelijk behandeld werden, dit verschil was echter niet 
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statistisch significant. Deze bevinding suggereert echter wel dat het gebruik van orale 
anticoagulantia een positief effect zou kunnen hebben op het optreden van ischemie 
in patiënten met chronische PVT. Bevestiging van deze resultaten in grotere studies is 
noodzakelijk, maar onze bevindingen suggereren dat het optreden van abdominale 
symptomen, zoals postprandiale pijn, zouden moeten leiden tot herbeoordeling van 
de uitbreiding, oorzaak en behandeling van PVT.
AANBEVELINGEN VOOR TOEKOMSTIG ONDERZOEK
Lever fibrose komt voor bij ongeveer 1 op de 18 oudere Kaukasische volwassenen in 
Rotterdam, zoals beschreven in dit proefschrift. Voornamelijk personen met steatose 
en diabetes mellitus lopen een verhoogd risico, hun kans op fibrose is zelfs 17%. Gezien 
de huidige stijging van de prevalentie van steatose en diabetes mellitus in de Westerse 
wereld, is de verwachting dat het aantal personen met fibrose op basis van NAFLD zal 
toenemen en belangrijke gevolgen voor de volksgezondheid zal hebben (4). Brede im-
plementatie van programma’s gericht op de preventie van obesitas, insulineresistentie 
en hun complicaties is daarom hard nodig. Leefstijlinterventies, waarvan afvallen en 
lichamelijke inspanning het meest belangrijk zijn, zijn de hoeksteen van de behande-
ling van NAFLD, maar het volhouden van deze leefstijlmaatregelen blijkt in de praktijk 
vaak lastig (4). Een recente trial in patiënten met hart- en vaatziekten liet zien dat het 
regelmatig sturen van semi-gepersonaliseerde tekstberichten cardiovasculaire risico-
factoren, zoals BMI, roken en de hoeveelheid lichamelijke inspanning, kan verbeteren 
(87). Dergelijke ondersteunende programma’s zouden ook gunstige effecten kunnen 
hebben op het volhouden van leefstijlveranderingen in patiënten met NAFLD. Onder-
zoek naar het effect van deze programma’s in patiënten met NAFLD is daarom gewenst. 
Op dit moment is er nog geen medicament goedgekeurd voor de behandeling van 
deze groep patiënten, ondanks verschillende studies naar mogelijke medicamenten, 
waardoor andere behandelopties beperkt zijn. Studies gericht op het bepalen van de 
mortaliteit veroorzaakt door fibrose in de algemene bevolking zullen helpen in het be-
palen van de impact van dit volksgezondheidsprobleem. 
Gedurende het laatste decennium was er een exponentiele toename van 
het aantal studies gericht op de rol van genetica in verschillende complexe ziekten, 
waaronder leverziekten. Het huidige aanbod aan studies vormt echter slechts de eer-
ste stap in de ontrafeling van de complexe samenhang tussen genetische varianten 
en leverziekten. Verschillende veelbelovende onderzoeksrichtingen zijn daarom nog 
onontgonnen. Op dit moment zijn verschillende SNPs geïdentificeerd als risicofactor 
voor fibrose (13, 16, 17, 20, 23-25). Het zou erg interessant zijn om een GWAS in het 
ERGO te verrichten om genetische varianten die bijdragen aan de ontwikkeling van 
lever fibrose in de algemene bevolking te identificeren. Bovendien is het door de snel-
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le ontwikkeling van technieken nu mogelijk om sequenties van exomen en zelfs hele 
menselijke genomen te bepalen. Deze nieuwe technieken zullen de komende jaren 
nog meer mogelijkheden bieden om loci te identificeren die geassocieerd zijn met di-
verse leverziekten.
De observatie dat het geven van laag moleculair gewicht heparine de inci-
dentie van lever decompensatie en de overleving in patiënten met cirrose verbetert 
(43) behoeft verder onderzoek in grote, dubbelblinde trials gericht op de potentieel 
gunstige rol van anticoagulantia in deze patiënten. In deze studies zou ook een objec-
tieve bepaling van portale hypertensie verricht moeten worden. Aanvullende onder-
zoeksvragen die nog beantwoord zouden moeten worden, omvatten onder andere het 
effect van andere anticoagulantia, waaronder nieuwe orale anticoagulantia (NOACs) 
en de optimale behandeldosis en –duur. Bovendien zou het ook wenselijk zijn om het 
effect van anticoagulantia op lever fibrose in verschillende populaties – waaronder ri-
sicogroepen en de algemene bevolking – te onderzoeken, omdat eerdere studies ook 
een potentieel gunstig effect van anticoagulantia op fibrose hebben laten zien (37-42).
In patiënten met PVT wordt op dit moment alleen langdurige behandeling 
met anticoagulantia aangeraden indien er sprake is van een persisterende protrombo-
tische aandoening, terugkerende trombose of een intestinaal infarct (73). Prospectieve 
studies naar de risico’s en voordelen van behandeling met anticoagulantia in patiënten 
met chronische niet-maligne, niet-cirrotische PVT zonder deze aandoeningen zijn no-
dig, aangezien de rol van anticoagulantia in de behandeling van deze patiënten on-
bekend is. In de laatste jaren zijn er twee types direct werkende orale anticoagulantia 
geïntroduceerd: directe trombineremmers en factor Xa-remmers. Een groot voordeel 
van deze medicijnen is dat laboratoriumcontrole niet nodig is. Daarnaast hebben ze 
minder interacties met andere medicijnen en voeding en hebben ze een grotere thera-
peutische breedte. In een grote meta-analyse van bijna 28.000 deelnemers waren NO-
ACs net zo effectief als standaard anticoagulantia in de behandeling van diep veneuze 
trombose (88). Ondanks het feit dat een verhoogd risico op gastro-intestinale bloedin-
gen is beschreven in patiënten die behandeld worden met NOACs (89), laten studies 
in patiënten met veneuze trombo-embolieën een vergelijkbaar of zelfs verlaagd risico 
op bloedingen geassocieerd met NOACs zien vergeleken met de standaardbehande-
ling met vitamine K antagonisten (88, 90, 91). Het gebruik van NOACs in patiënten met 
veelvoorkomende vormen van veneuze trombose wordt op dit moment geïmplemen-
teerd in de klinische praktijk. Het is belangrijk om de plaats van deze nieuwe orale anti-
coagulantia in de behandeling van patiënten met SVT te bepalen. Trials gericht op het 
vergelijken van de effectiviteit en veiligheid van deze nieuwe orale anticoagulantia met 
de standaard anticoagulantia zouden daarom moeten worden geïnitieerd in patiënten 
met SVT.
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ABBREVIATIONS
ALP alkaline phosphatise
ALT alanine aminotransferase
APA antiphospholipid antibody
APC activated protein C
APTT activated partial thromboplastin time
AST aspartate aminotransferase
BCS Budd-Chiari syndrome
BMI body mass index
BP blood pressure
CT-A CT-angiography
DM diabetes mellitus
DVT deep venous thrombosis
EN-Vie European network for vascular disease of the liver
ET essential thrombocythemia
FPG fasting plasma glucose
FVL factor V Leiden
FVIII factor VIII
GGT gamma glutamyl transferase
GWAS genome-wide association studies
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HDL-C high-density lipoprotein cholesterol
HIV human immunodeficiency virus
HSC hepatic stellate cells
HWE Hardy-Weinberg equilibrium 
HOMA-IR homeostasis model assessment of insulin resistance
IFNGR2 interferon gamma receptor 2 
IL28B interleukin 28B
INCPH idiopathic noncirrhotic portal hypertension
INR international normalized ratio
IQR interquartile range
IU international units
LMWH low molecular weight heparin
LS(M) liver stiffness (measurement) 
MPN myeloproliferative neoplasm
MR-A MR-angiography
NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatitis
NOAC new oral anticoagulant
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OAC oral anticoagulation
PE pulmonary embolism
PAR protease activated receptor
PMF primary myelofibrosis
PNPLA3 patatin-like phospholipase domain-containing protein 3 
PT prothrombin time
PV polycythemia vera
PVT portal vein thrombosis
SD standard deviation 
SECF spontaneous erythroid colony formation
SNP single nucleotide polymorphism
SOS sinusoidal obstruction syndrome
SMV superior mesenteric vein
SV splenic vein
SVT splanchnic vein thrombosis
ULN upper limit of normal
TE transient elastography.
TIPS transjugular intrahepatic portosystemic shunt
VKA vitamin K antagonists
VLS visible light spectroscopy
VTE venous thromboembolism
VWF von Willebrand factor
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Lieve collega-onderzoekers, jullie hebben ervoor gezorgd dat mijn promotie naast leer-
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sanne, Jorie, Vivian, Atija, Sophie, Anne, Mitchell, Shannon, Els, Maren, Floor, Marjolein, 
Anniek, Joany, Louisa, Wouter, Elmer, Wesley, Rik, Vincent, bedankt voor de leuke tijd! 
Lieve Pauline, Daphne, Edith, Ludi en Michelle, aka de ‘hepa-chicks’, dank voor de gezel-
ligheid op de congressen, met name onze tijd in NYC was top! Lieve Loes, m’n ERGO-
opvolger, heel veel succes. Je gaat er ongetwijfeld iets moois van maken. Lieve Sil, ik 
heb weinig hoeven doen als je buddy, er zijn maar weinig mensen met zo’n discipline 
als jij. Je mag heel trots zijn op de grote, internationale studies die je hebt opgezet. 
Snel maar weer eens koffie doen? Lieve Margo, al snel na je komst op het dak werden 
we vaste roomies op de congressen. Wat hebben we veel lol gehad samen, maar ik 
kon ook altijd bij je terecht als ik even stoom af wilde blazen. De badjassenfotoshoot 
was legendarisch! Het eerste half jaar op het beruchte ‘dak’ heb ik een kamer gedeeld 
met Roeland en Femme, dank voor het me wegwijs maken in de do’s en don’ts als on-
derzoeker. Daarna heb ik bijna 3 jaar met Jihan en Heng kamer Ca-411 gedeeld. Lieve 
Jihan en Heng, in het begin was het even wennen, maar uiteindelijk bleken we een 
geweldige combinatie! Er ging bijna geen dag voorbij waarop we niet hardop lachend 
kamers verder in de gang te horen waren. Lieve Heng, wat was het fijn om af en toe 
ook wat mannelijke inbreng (en relativering) in de kamer te hebben, dank nog voor 
al je hulp bij mijn Graphpad, Excel en tabellenstress, maak je het imago van een ware 
Chinees toch waar;) Heel veel succes met je coschappen en het afronden van je eigen 
promotie! Lieve Jihan, vele ups en downs werden in onze kamer gedeeld. Je bent een 
pittige dame, maar stiekem ook heel lief en zorgzaam. Heb vertrouwen in jezelf, het is 
ontzettend knap hoe je je promotie hebt weten af te ronden in je tijd op het dak. Lieve 
Esmée, wat ben ik blij dat jij vandaag naast mij staat. Ik waarder je nuchtere, onomwon-
den aanpak enorm. Het was altijd fijn om even met je te sparren en jouw kijk op iets te 
horen. Daarnaast hebben we vooral ook heel veel lol gehad, you know how to party! 
Ik vind het dan ook heel gezellig dat we komend jaar weer collega’s worden in Delft. 
Lieve Lidewij, ons vaste koffiemomentje op woensdag was mijn rustpunt in de week. In 
de afgelopen 3 jaar hebben we zo elkaars promotietraject van dichtbij meegemaakt. Ik 
vind het heel fijn dat je mijn paranimf wilt zijn op deze speciale dag. 
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heel erg bedankt voor alle leuke afleiding in de vorm van etentjes, borrels, feestjes en 
weekendjes weg. Lieve Gianta, jou wil ik graag even apart noemen, ik vind het heel bij-
zonder dat we al 17 jaar vriendinnen zijn. Het is ontzettend stoer dat je in je eentje naar 
Canada bent gegaan, ik kom je snel een keertje opzoeken!
Lieve ooms, tantes, neven en nichten, dank voor jullie interesse en de gezellige familie-
etentjes, verjaardagen en familiedagen. Lieve oma, wat ben ik blij dat je er bij bent 
vandaag! Dank voor je interesse en betrokkenheid bij alles wat ik doe. Ik vind het heel 
bijzonder dat we zo’n hechte band hebben.
Lieve Ward, ik voel me een geluksvogel met jou als broer. Jouw rust en scherpe denk-
vermogen hebben mij al vaak geholpen. Verhuizen, klussen, helpen met computerpro-
blemen, koken, niets is je te gek. Dank je voor alle keren dat ik een beroep op je mocht 
doen. Ik ben erg trots op je.
Lieve papa en mama, het is een heerlijk gevoel te weten dat ik altijd bij jullie terecht 
kan. Ik vind het heel fijn dat jullie zo geïnteresseerd zijn in wat ik doe, ook al zijn de 
medische termen af en toe wat lastig bij te benen. Jullie onvoorwaardelijke steun en 
vertrouwen stimuleren me om het beste in mezelf naar boven te halen. Bedankt voor 
jullie liefde en het feit dat jullie altijd voor me klaar staan.
Lisanne
Rotterdam, december 2015
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